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I SUMMARY 
Summary 
 
In higher vertebrates, the development of a functional circulatory system based on 
blood and lymphatic vessels is a basic step in order to generate a full organism. The 
formation of the vasculature involves the generation of mesodermal-derived 
angioblasts and their subsequent differentiation into blood endothelial or lymphatic 
endothelial cell lineages. The switch between the undifferentiated and cell-specific 
genetic programs during cell differentiation requires an orchestrated spatiotemporal 
coordination of gene expression. 
JUNB, a member of the AP-1 family, is a context-dependent transcription factor that 
exerts both positive and negative functions. Loss of function studies in mice revealed 
that JUNB is a key regulator of vascular development in embryos. Hence, JUNB 
transactivates pro-angiogenic molecules such as Vegfa, Cbfβ and Hmox1. Recently, Junb 
was described to regulate the development of lymphatic vessels in zebrafish via its 
target miR182. However, it remained unclear whether activator functions of JUNB are 
relevant for lymphangiogenesis. Therefore, I aimed to investigate whether JUNB is 
necessary for the formation of lymphatics and if so, to unravel in which specific step of 
the lymphatic vascular development JUNB is implicated. For this purpose, I used a dual 
approach of in vitro differentiation of mouse embryonic stem cells into lymphatic 
endothelial cells and an in vivo approach by generating junb mutant zebrafish in the 
background of the transgenic reporter line Tg(fli:EGFP)y1 to evaluate the development 
of the vasculature. 
The study of the JUNB kinetics during the LEC differentiation process revealed that JUNB 
is strongly induced at the RNA and protein level during the angioblast formation until 
the formation of the LEC-like cells. Strikingly, Junb-/- mESCs failed to form proper LECs 
due to considerable cell death during the angioblast formation. This increased apoptosis 
could be associated to a failure to initiate the induction of VEGFR1 and VEGFR2 
expression. In the parallel in vivo approach, novel zebrafish mutants with ablated junba 
and junbb expression were generated using CRISPR-Cas9 technology. Successful 
mutations resulted in a premature end of the reading frame. Homozygous junba-/-  
embryos could not be identified and the Mendelian ration of wildtype and heterozygous 
offspring suggests a recessive lethal phenotype. By contrast, junbb mutants were 
detected according to expected Mendelian ratio, reached adulthood and were fertile. 
Albeit the mutant embryos exhibited an allele-dependent decrease in the number of 
parachordal cells present at 3 days post fertilization; almost all the analyzed embryos 
displayed a complete thoracic duct at 5 dpf. Surprisingly, the mutants developed ectopic 
sprouts at the dorsal side of the trunk from 3 dpf until 5 dpf recapitulating the phenotype 
previously observed upon neuronal loss of soluble vegfr1 in zebrafish. In summary, these 
data underscore the role of JUNB not only in lymphangiogenesis but also at an earlier 
developmental stage, namely the angioblast formation and suggest a JUNB-dependent 
regulation of vascular endothelial growth factor receptors during development. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
III ZUSAMMENFASSUNG 
Zusammenfassung 
 
In höheren Wirbeltieren ist die Entwicklung eines funktionellen Kreislaufsystems, 
bestehend aus Blut- und Lymphgefäßsystem, ein grundlegender Schritt um einen 
vollständigen Organismus zu bilden. Für die Ausbildung der Blutgefäße ist die 
Entstehung von Angioblasten aus dem Mesoderm und deren anschließender 
Differenzierung in Blut- oder Lymphendothelzellen notwendig. Das Umschalten 
zwischen den undifferenzierten und zell-spezifischen genetischen Programmen 
während der Differenzierung erfordert eine abgestimmte räumliche und zeitliche 
Koordination der Genexpression. 
JUNB, ein Mitglied der AP-1 Familie, ist ein Kontext-abhängiger Transkriptionsfaktor, der 
positive und negative Funktionen ausübt. Studien an Mäusen mit einem Junb 
Funktionsverlust zeigten dass JUNB ein Schlüsselregulator der vaskulären Entwicklung 
ist, indem JUNB pro-angiogene Moleküle wie Vegfa, Cbfβ und Hmox1 transaktiviert. Vor 
kurzem wurde beschrieben, dass Junb die Entwicklung lymphatischer Gefäße in 
Zebrafischen über das Zielgen miR182 reguliert. Jedoch ist noch unklar, ob zusätzlich 
auch aktivierende Funktionen von JUNB relevant für die Lymphangiogenese sind. Ziel 
der Disseration war daher zu untersuchen, ob JUNB für die Entstehung der Lymphgefäße 
notwendig ist, und aufzuklären in welche spezifischen Schritte der 
Lmyphgefäßentwicklung JunB involviert ist. Aus diesem Grund habe ich einen dualen 
Ansatz gewählt  bei dem in vitro die Differenzierung von murinen embryonalen 
Stammzellen (mESC) zu lymphatischen Endothelzellen untersucht wurde und in vivo 
Zebrafische mit mutiertem Junb im Hintergrund der Reporterlinie Tg(fli:EGFP)y1 
generiert wurden um die Gefäßbildung zu erforschen. 
Die Untersuchung der Expressionskinetik von JUNB während Differenzierungsprozesses 
zu Lymphendothelzellen (LEC) hat gezeigt, dass JUNB auf RNA und Protein Ebene 
während der Angioblast Entstehung bis hin zur Bildung der LEC-ähnlichen Zellen 
induziert wird. Interessanterweise können Junb-/- mESC aufgrund von erheblichem 
Zelltod während der Angioblast Entstehung keine richtigen LEC ausbilden. Diese erhöhte 
Apoptose war mit einem Defekt in der Induktion von VEGFR1 und VEGFR2 verbunden. 
In einem parallelen in vivo Ansatz wurden mit Hilfe der CRISPR-Cas9 Technologie 
neuartige Zebrafischmutanten mit defekter junba und junbb Expression generiert. 
Gelungene Mutationen resultierten in einem frühzeitigen Ende des Leserasters. 
Homozygote junba-/-  Embryonen konnten nicht detektiert werden, wobei die 
Mendelsche Rate der Wildtyp und Hetreozygoten Nachkommen auf eine rezessive letale 
Phänotyp hinweist. Im Gegensatz traten junbb Mutanten im erwarteten Mendelschen 
Verhältnis auf erreichten das Erwachsenenalter und waren fertil. Obwohl, die Mutanten 
eine Allel-abhängige Verringerung der Anzahl an parachordalen Gefäßen zum Zeitpunkt 
3 dpf aufwiesen, zeigten fast alle untersuchten Embryonen einen kompletten Ductus 
thoracicus zum Zeitpunkt 5 dpf. Interessanterweise, entwickelten die Mutanten 
 ektopische Gefäßaussprossungen  an der dorsalen Seite des Gefäßstrangs zwischen dem 
Zeitpunkten 3 dpf und 5 dpf und rekapitulieren damit einem Phäenotyp, der nach 
neuronalem Verlust von löslichem Vegfr1 im Zebrafisch beobachtet wurde. 
Zusammenfassend unterstreichen diese Daten die Rolle von JUNB nicht nur während 
der Lymphangiogenese sondern auch bei vorausgehenden Entwicklungsschritten, wie 
der Angioblast Entstehung, und deuten darauf hin, dass die Regulierung der Rezeptoren 
für vaskuläre endotheliale Wachstumsfaktoren, 1 und 2 während der Entwicklung vom 
JUNB abhängig ist. 
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V Volts 
VEGF-A Vascular Endothelial Growth Factor A 
VEGF-C Vascular Endothelial Growth Factor C 
VEGFR1 Vascular Endothelial Growth Factor Receptor 1 
VEGFR2 Vascular Endothelial Growth Factor Receptor 2 
VEGFR3 Vascular Endothelial Growth Receptor 3 
vISVs venous Intersegmental Vessel 
WISH Wholemount In Situ Hybridization 
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1.Introduction 
An orchestrated spatiotemporal coordination of gene expression is necessary for proper 
embryo development as well as for the maintenance of tissue homeostasis. 
Dysregulation of these signals can lead to the development of pathologies. 
Gene regulation occurs at different levels: i) transcriptionally at the DNA level, ii)  post-
transcriptionally at the mRNA level or iii) at the protein level during translation and the 
post-translational modifications. 
At the DNA level, the transcription factors are the first regulators that activate or repress 
gene transcription becoming key players in development and differentiation processes. 
 
1.1 JUNB, an AP-1 transcription factor 
1.1.1 AP-1 signaling 
The Activating Protein-1 (AP-1) transcription factors are considered “immediate-early” 
products that mediate gene expression in response of a plethora of extracellular stimuli 
including growth factors, cytokines, carcinogens, tumor promoters and physical stress 
such us UV irradiation and mechanical strain (Angel and Karin, 1991). 
The AP-1 family comprises homo- and heterodimers of the JUN family (JUN, JUNB and 
JUND), FOS family (FOS, FOSB, FRA1 and FRA2), ATF family (ATF, ATF2,ATF3) and JDP 
subfamily (JDP1 and JDP2) and its members share structural and functional similarities. 
All AP-1 members harbor conserved features like the bZip domain, a basic DNA-binding 
domain with a leucine zipper region. The leucine zipper enables and determines the 
dimer formation of the partners prior the DNA binding to the basic DNA motif. While 
some members of the family like FOS can only form heterodimers, JUN proteins can 
additionally form homodimers. The composition of the dimers ultimately affects their 
stability and transactivation potential. While JUN, c-FOS and FOSB are strong activators, 
JUNB, FRA1 and FRA2 are considered rather weak transactivators (Hess et al., 2004).  
The DNA binding specifically occurs at some palindromic DNA recognition sites known 
as TRE (TPA Responsive Element) and dependent on the dimer composition, certain 
dimers are also able to recognize and bind the CRE (cAMP Response Element) sites. 
AP-1 members have been described in many biological processes such as cell 
proliferation, differentiation and transformation (Angel and Karin, 1991). 
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1.1.2 Context-dependent JUNB function 
JUNB is a transcription factor that is induced upon stress signals such as hypoglycemia 
(Textor et al., 2006), hypoxia (Schmidt et al., 2007) and growth factors among others. 
Due to its weak transactivation potential, JUNB was once only considered as a 
transcriptional repressor of the JUN:FOS signaling. However, loss-of function 
approaches revealed that JUNB acts in a context-dependent manner holding both 
positive and negative functions required for physiological processes (Hess et al., 2004). 
A clear example of its dual function is the regulation of the cell cycle: depending on the 
specific cell cycle phase, JUNB either promotes or blocks the cell cycle progression. 
During G0/G1 and G2/M transitions, JUNB levels are very low but they increase upon 
mitogenic stimulations in G1 and S phases (Piechaczyk and Farràs, 2008). At the G1/S 
transition, JUNB prevents cell cycle entry via i) transactivation of cyclin-dependent 
kinase inhibitor p16INK4a (Passegué and Wagner, 2000) and ii) repression of Cyclin D1, 
the key regulator of the G1/S transition (Bakiri et al., 2000). Later on, during the G2/M 
transition, JUNB promotes cell cycle progression by direct transactivation of Cyclin A 
(Andrecht et al., 2002). At G2 phase, an accelerated JUNB decay by proteasomal 
degradation is required to reduce Cyclin A levels in transition towards mitosis (Farràs et 
al., 2008).  
Apart from the cell cycle, the repressor functions of JUNB have been associated with 
inflammation and immune response. JUNB has been described to be required for the i) 
hematopoietic progenitor cells production, preventing myeloid malignancies (Passegué 
et al., 2001, 2004; Santaguida et al., 2009). ii) control of cytokines during wound healing 
(Florin et al., 2006), iii) suppression of IL-6 signaling in systemic lupus erythematosus 
phenotype (Pflegerl et al., 2009) and iv) regulation of chemokine expression in psoriasis 
via repression of SQSTM1/p62 (Zhang et al., 2015). 
On the other side, the activator functions of JUNB have been associated with a variety 
of physiological functions such as i) T helper differentiation (Li et al., 1999; Hartenstein 
et al., 2002), ii) osteoclast differentiation (Hess et al., 2003; Kenner et al., 2004), iii) mast 
cell cytokine secretion and mast cell-endothelial cell cross-talk (Textor et al., 2007) and 
iv) vascular development which are described in detail in the section 1.1.3. 
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1.1.3 Role of JUNB in vascular biology  
In mice, total loss of Junb led to embryonic lethality at midgestation (E8.5-E10.0) due to 
severe vascular defects. The Junb-/- embryos were grossly retarded in development and 
their premature death was associated to the insufficient exchange of nutrients through 
a defective feto-maternal communication. Several defects on the formation of the extra-
embryonic tissues were observed during placentation: i) abnormal distribution of the 
trophoblast giants cells and subsequent decidua vascularization, ii) disorganized 
vascular network in the yolk sac and iii) absent vascularization in the labyrinth (Schorpp-
Kistner et al., 1999). 
Endothelial-specific deletion of Junb (Tie2-Cre) resulted in a similar outcome with 
embryonic lethality around E10. Again, the Junb-deficient embryos exhibited growth 
retardation and aberrant vasculature with abnormal branching and dilated vessels (Licht 
et al., 2006). In addition, using a mesenchymal-specific Junb-ablated mouse model 
(Coll1α2-Cre), a better characterization of adult endothelial cells was performed. Junb-
deficient endothelial cells were described to display reduced sprouting capability in 
aortic explants and reduced tube formation in matrigel. JUNB direct target  Core-Binding 
Factor beta (Cbfβ) and CBFβ targets Mmp2 and Mmp13 were found to be required for 
endothelial cell morphogenesis (Licht et al., 2006). 
Besides, several pro-angiogenic molecules have been described to be JUNB-regulated 
like Vascular Endothelial Growth Factor A (Vegf-A) and Heme Oxygenase (Hmox) (Hock 
et al., 2007). JUNB transactivates Vegf-A upon hypoglycemic (Textor et al., 2006) and 
hypoxic conditions via NF-κB (Schmidt et al., 2007).This hypoxia-induced Vegf regulation 
was proposed to be the cause for the reduced angiogenesis observed in Junb-/- 
teratocarcinomas. 
Not only JUNB has been linked to developmental angiogenesis but also to the control of 
tissue homeostasis via transactivation of Myosin Regulatory Light Chain 9 (Myl9), a key 
player in the actomyosin contraction. Mesenchymal-specific ablated Junb mice 
displayed defects on arterial contractility making them unresponsive the 
deoxycorticosterone acetate DOCA-salt hypertension model. In addition, vascular 
smooth muscle cells isolated form these mice exhibited reduced stress fiber formation 
and motility (Licht et al., 2010). 
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Figure 1-1. Vascular processes affected upon Junb loss.                         
Developmental angiogenesis (left panel): JUNB is required for proper vascularization in mouse embryos. 
Both total (Schorpp-Kistner et al., 1999) and endothelial cell specific loss of Junb (Licht et al., 2006) lead 
to embryonic death due to defects in vascularization. Sprouting and tube formation (middle panel): Junb-
deficient cells display impaired cell sprouting in the aortic ring assay and impaired endothelial cell tube 
formation on matrigel (Licht et al., 2006). Cell contractility and tissue homeostasis (Right panel): Junb-
defective cells are devoid of p-MYL9 expression, leading to a defect on arterial contractility upon DOCA-
salt treatment (Licht et al., 2010). 
 
Although, most of the known JUNB regulatory functions are based on direct regulation 
of its target genes (Figure 1-1), JUNB has also been described to regulate gene 
expression indirectly via regulation of microRNAs.  
MicroRNAs comprise small non-coding RNAs that negatively regulate gene expression 
at the post-transcriptional level. MicroRNA expression profiling comparing Junb and 
Junb-deficient endothelial cells revealed that about 18% of the miRnome was altered 
upon Junb loss. MiR182 was found to be JUNB-regulated in endothelial cells, mouse 
embryonic fibroblasts and vascular smooth muscle cells. In addition, miR182 was 
described to be a lymphangiomiR required for proper lymphatic zebrafish development 
via attenuation of foxo1 levels. Transient downregulation of zebrafish paralogues −junba 
and junbb– and their target miR-182 and foxo1 in zebrafish  embryos resulted in a failure 
in the formation of the first lymphatic structures so called parachordal cells (PACs) and 
the main lymphatic vessel, the thoracic duct (TD). Ectopic expression of miR-182 could 
successfully revert this effect. The axis Junb-miR182-Foxo1 was the first connection 
between JUNB and the development of lymphatic vessels ever described (Kiesow et al., 
2015). 
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1.2 Lymphatic vascular system 
1.2.1 Functions and network structure 
The vascular network comprises two major circulatory systems: the circulatory blood 
and the linear lymphatic system. Although they resemble in some anatomical features, 
they harbor different functions and structures. 
The lymphatic vasculature plays a role in several physiological functions: i) tissue 
homeostasis by collecting and transporting the interstitial fluid from the tissue back to 
the bloodstream, ii) fat absorption by the lacteal lymphatics in the intestinal villi (Tso 
and Balint, 1986; Harvey et al., 2005) and the iii ) immune trafficking of antigens and 
activated antigen-presenting cells to the lymph nodes (Alitalo and Carmeliet, 2002). 
The lymphatic vasculature includes lymphatic capillaries and collective lymphatic 
vessels. While the capillaries are blind-ended vessels formed by a thin single layer of 
endothelial cells (Leak and Burke, 1966, 1968); the collective lymphatics additionally 
contain a perivascular muscle cell layer, a basement membrane and valves that 
guarantee the unidirectional flow of the lymph (Kampmeier, 1928; Smith, 1949). 
Malfunction of the lymphatic vasculature leads to the onset of several pathologies 
associated with inflammation and fibrosis. The most severe diseases are the 
lymphedema and the lymphatic tumor-metastasis (Alitalo et al., 2005). Lymphedema is 
a condition characterized by the excessive accumulation of water and proteins in the 
tissues. Primary lymphedema is congenital and is associated with an abnormal vessel 
development. Secondary lymphedema is more common and occurs as a result of a 
physical damage in the lymphatics upon trauma, surgery or infection by filariasis (Szuba 
and Rockson, 1998). In addition, the formation of tumor-related lymphatic vessels is 
used by metastatic tumor cells to disseminate toward distant organs and lymph nodes 
(Cueni and Detmar, 2008). The presence of lymphatic metastasis in the patients is 
normally correlated with poor prognosis (Achen et al., 2005; Stacker et al., 2002; Tobler 
and Detmar, 2006). 
Hence, a strong understanding of the signaling pathways involved in the proper 
formation and function of the lymphatic vasculature might shed some light in the 
development of novel targets or therapies for lymphatic-related diseases. 
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1.2.2 Lymphangiogenesis 
Since the first observations of the existence of the lymphatic system by Hippocrates, it 
was not until the 20th century when two different theories for the origin of the lymphatic 
system were postulated. The anatomist Florin Sabin performed ink injections in pig 
embryos and suggested that the first lymphatic structures were stemming from the 
cardinal vein. These results led to the so-called “centrifugal model” in which lymphatics 
originate from venous structures (Sabin, 1902, 1904). Contrary to this theory, the 
anatomists George S. Huntington and Charles F.W McClure performed cat embryo wax 
reconstructions and proposed that the lymphatic sacs were formed from a cluster of 
mesenchymal cells. This study led to the “centripetal” model (Huntington and McClure, 
1910).  
Recent cell tracing experiments finally revealed that the lymphatics have a dual origin: 
while the first lymphatics arise from a special cluster of cells located within a venous 
structure; non-venous origins have been described for organ-specific lymphatics. 
Stanczuk et al., (2015) described that in mice, mesenteric lymphatic vessels derive from 
cKit+ hemogenic-endothelium cells and Martinez-Corral et al., (2015) proposed that 
murine dermal lymphatics form de novo during a lymphvasculogenesis process in which 
lymphatic endothelial cells (LECs) cluster together prior assembling the lymphatic 
networks. Klotz et al., (2015) also described a heterogeneous origin of heart lymphatics 
in which part of the lymphatic structures were formed independently of a venous 
source. 
In general, lymphangiogenesis is the process of growth of lymphatic vessels from pre-
existing lymphatics. It mostly takes place during embryonic development and during 
some pathological situations in adults such as wound healing or tumor metastasis. 
In mammalian embryonic development and vasculogenesis, some mesodermal 
progenitors become “hemangioblasts”, the common precursor cells of blood and 
vascular lineages. These precursors are characterized by VEGFR2 expression and they 
give rise to the endothelial cells that form the first vascular structures. Subsequently, a 
small population of venous endothelial cells acquire several molecular signatures and 
assume the lymphatic identity. Loss-of function studies in mice led to the identification 
of specific lymphatic markers like Vascular Endothelial Growth Factor 3 VEGFR3 
(Kaipainen et al., 1995), Lymphatic Vessel Endothelial Hyaluronan Receptor 1 LYVE1 
(Banerji et al., 1999), Prospero-related homeobox domain 1 PROX1 (Wigle and Oliver, 
1999) and PODOPLANIN (Breiteneder-Geleff et al., 1999).   
The first lymphatic structures are formed only when the blood vascular system has been 
previously established through two main processes: i) lymphatic endothelial 
specification of the vascular precursors and ii) formation of lymphatic structures.  
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LEC specification 
In mouse embryos (E9.5-E10.5), a subpopulation of blood endothelial cells within the 
dorsolateral wall of the anterior cardinal vein acquires the competence to be lymphatic 
endothelial cell precursors by the expression of transcriptional regulators of the 
lymphatic endothelial fate: Sox 18, Nr2fr (Coup-TFII) and Prox1. SRY-related HMG-box 
18 (Sox18) is a known marker required for arteriovenous specification and Chicken 
Ovalbumin Upstream Transcription Factor II (Coup-TFII) is a known as a vein marker. 
Both SOX18-dependent and COUP-TFII-dependent Prox1 induction in the polarized 
venous compartment is observed during the lymphatic specification of the precursor 
cells (François et al., 2008; You et al., 2005; Srinivasan et al., 2010). Prospero-related 
homeobox domain 1 (Prox1) expression is necessary and sufficient to trigger lymphatic 
endothelial specification in these polarized cells (Srinivasan and Oliver, 2011; Wigle and 
Oliver, 1999; Wigle et al., 2002). Once the cells are committed to the lymphatic fate, 
they upregulate markers characteristic of lymphatic endothelial cells and downregulate 
blood endothelial markers. 
Formation of lymphatic sacs 
Around E10.5, PROX1-expressing  progenitor cells are determined to the lymphatic 
lineage and start to express lymphatic markers like PODOPLANIN, VEGFR3 and NRP2. 
Then, the lymphatic cells sprout laterally from the vein and migrate in stream to form 
the primordial lymphatic structures called lymph sacs (Wigle and Oliver, 1999; Wigle et 
al., 2002). This process is mainly regulated by the signaling of VEGFR3 receptor 
expressed in the Prox1-specified cells and its ligand VEGF-C expressed by the 
mesenchymal cells (Makinen, 2001; Karkkainen et al., 2004; Tammela et al., 2005). A 
small cluster of PROX1-expressing cells remain in the veins to form the so called lymph-
venous valves preventing the backflow of fluids (Srinivasan and Oliver, 2011). 
Subsequent sprouting from the lymphatic sacs and remodeling and maturation of the 
vessels generate more defined structures, the lymphatic plexus. 
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Figure 1-2. Lymphangiogenenesis in mammals 
Schematic illustration depicting the key steps that take place during mammalian lymphatic endothelial 
cell differentiation. Angioblasts give rise to the blood endothelial cells and first vascular structures. A 
cluster of cells from the cardinal vein acquire competence and commit to the lymphatic fate by expressing 
a subset of lymphatic-specific genes. Upon mesenchymal stimulation, the LEC-specified cells bud off the 
vein and migrate to form the first lymphatic structures, the lymphatic sacs. Subsequent growth of the cells 
and lymphatic sacs leads to mature lymphatic vessels. The key genes have been included below each 
process. Adapted from (Oliver and Srinivasan, 2010). 
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1.3 Experimental models 
The full understanding of the complex processes involved in the development of vessels 
requires experimentation with both in vitro and in vivo systems. While the in vivo study 
of animal models offers the possibility of visualizing processes as cell migration and tube 
formation; the in vitro systems are necessary to test conditions or treatments in a more 
controlled environment. 
1.3.1 Stem cells 
Stem cells are pluripotent cells that can give rise to cells of the three germ layers:  
endoderm-derived cells (inner organs), ectoderm-derived cells (skin and neural lineages) 
and mesoderm-derived cells (hematopoietic, cardiac, skeletal muscle and vascular 
lineages). They divide asymmetrically, renewing themselves in each division while 
generating another cell capable to respond to the environmental stimulus and undergo 
a differentiation lineage. Depending on the organ they belong to, they divide regularly 
to maintain the worn-out tissue or they divide only under special circumstances such as 
stress or tissue damage. 
The stem cells can be found during embryonic development and adulthood but the main 
difference is their ability to differentiate into other cell types. The adult "somatic" stem 
cells are multipotent and can give rise only to a limited set of cells within their niche. 
They are difficult to isolate and they have a low division rate. On the contrary, the 
embryonic stem cells (ESCs) are pluripotent and can give rise to all the embryonic cells 
except the extra-embryonic tissues. They are isolated from the inner cell mass of the 
mammalian blastocyst and divide fast. Due the multiple differentiation possibilities, 
embryonic stem cells have been widely used for biomedical research. 
Embryonic stem cells and the maintenance of pluripotency 
The maintenance of the pluripotent state in embryonic stem cells is controlled by the 
expression of three main transcription factors: OCT 3/4 (Nichols et al., 1998; Niwa et al., 
2000), SOX 2 (Avilion et al., 2003; Masui et al., 2007) and NANOG (Chambers et al., 2003; 
Mitsui et al., 2003). The collaboration between these three genes regulates gene 
expression in ESCs. In fact, a positive feedback in the activation of these genes is needed 
for stemness control. In addition, together they bind and recruit activators activating 
gene transcription in ESCs and repress lineage-specific regulators (Young, 2011). 
In addition, Leukemia Inhibitory Factor (LIF) is an essential compound for the 
maintenance of the stemness properties and its role on LIF-gp130-STAT3 survival 
signaling has been described in murine stem cells (Boeuf et al., 2001; Niwa et al., 1998). 
LIF has to be supplemented in an in vitro system to guarantee that the ESCs remain in 
an undifferentiated state. Upon LIF withdrawal, the cells spontaneously differentiate 
(Smith et al., 1988; Williams et al., 1988). 
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Embryonic stem cells differentiation 
The potential of the ESCs to give rise to cells of different lineages is used to study the 
development of cells from their progenitors. The differentiation protocols recapitulate 
the developmental key steps that occur in embryo development and allow the 
generation of differentiated cell populations (Murry and Keller, 2008). 
During the step of gastrulation, the specification of the cells into these specific 
populations is timely and spatially controlled. Since the scope of the study is the 
development of the vascular system, my in vitro system is based on the generation of 
mesoderm-derived cells. The early steps of mesoderm induction are controlled by the 
expression of VEGFR2 in the hemangioblasts, precursors with hematopoietic and 
vascular potential (Choi et al., 1998; Ema et al., 2006). 
Three basic methods for ESC differentiation have been mostly used: i) 3D aggregation of 
cells referred as embryoid bodies, ii) co- culture of cells in contact with supportive feeder 
cells and iii) monolayer culture in the presence of a matrix. 
Although all of methods have been described to succesfuly differentiate the plutipotent 
cells into endothelial cells; the differentiation method is selected according to the 
conditions and suitability of each experimental setting.  
 
Table 1-1.Summary of the published endothelial cell differentiation methods 
Targeted differentiation Differentiation model Origin Reference 
Lymphatic endothelial cells Embryid bodies Mouse (Kreuger et al., 2006) 
Lymphatic endothelial cells Embryid bodies Mouse (Liersch et al., 2006) 
Hematopietic cells Embryoid bodies Mouse (Obier et al., 2016) 
Endothelial cells Embryoid bodies Human (Costa et al., 2013) 
Endothelial cells Feeder cells human (Kusuma et al., 2013) 
Lymphatic endothelial cells Feeder cells Human (Nicenboim et al., 2015) 
Endothelial cells Feeder-cell Mouse (Blancas et al., 2008) 
Endothelial cells Matrix Human (Nguyen et al., 2016) 
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1.3.2 Danio rerio 
Danio rerio is a freshwater fish commonly known as zebrafish and has been widely used 
in the recent years as a vertebrate model for vessel formation.  
Zebrafish harbor a closed circulatory system and the main processes related to vessel 
formation as well as some of the regulatory cell signaling resemble to those described  
in mice and humans (Isogai et al., 2001, 2003; Ellertsdóttir et al., 2010). In addition, they 
display a separate lymphatic network similar to the one found in higher vertebrates with 
which they share functional and molecular features (Yaniv et al., 2006; Küchler et al., 
2006). 
Zebrafish present some unique advantages for in vivo experiments: i) easy husbandry 
and external fertilization, giving access to egg manipulation, ii) rapid development, iii) 
embryo transparency at early developmental stages allowing the imaging of internal 
anatomical structures and iv) availability of specific transgenic reporter lines to track 
vascular development in detail. One of the most used tools is the transgenic zebrafish 
line Tg(fli:EGFP)y1, a pan-endothelial reporter that expresses Enhanced Green 
Fluorescence Protein (EGFP) in all the endothelial cells and some neural cells (Lawson 
and Weinstein, 2002). 
In addition, contrary to mammals, the small size of the embryos in the first steps of 
development allows them to uptake oxygen by passive diffusion and even develop for 
some days without a functional cardiovascular system (Stainier et al., 1996) or blood 
(Isogai et al., 2001). 
 
1.3.2.1 Vascular development in zebrafish 
In the first step of vascular development, mesoderm-derived angioblasts aggregate to 
form de novo the two axial vascular structures: the dorsal aorta (DA) and the posterior 
cardinal vein (PCV) within the first 24 hours post fertilization (hpf). During their 
assembly, the cells express distinct genetic programs and concomitantly acquire venous 
and arterial identity (Herbert et al., 2009; Swift and Weinstein, 2009). Subsequently, a 
process of sprouting and lumen formation starts, commonly referred as angiogenesis. 
Following the generation of the first vessels, a two-step process takes place to generate 
the intersegmental vessels (ISVs). Around 22 hpf, a primary sprouting phase starts from 
the dorsal aorta (DA) to generate arterial intersegmental vessels (aISVs). The aISVs 
sprouts migrate rapidly dorsally until they reach the surface of the neural tube, where 
they migrate rostrally and caudally to form the dorsal longitudinal anastomotic vessel 
(DLAV). Around 32 hpf, a secondary sprouting takes place to form venous 
intersegmental vessels (vISVs) from the posterior cardinal vein (PCV) in a similar fashion 
(Isogai et al., 2003). One half of the vISVs will connect to aISVs and turn them into vISVs. 
The other half of the formed vISVs will contribute to the formation of the lymphatic 
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system (Yaniv et al., 2006; Bussmann et al., 2010). These cells will migrate towards the 
horizontal myoseptum, a tissue partition of the dorsal and ventral muscle wall at the 
midline,  and migrate rostrally and caudally to assemble the transient lymphatic 
structure of parachordal cells (PACs), which are the build-in blocks of the lymphatic 
system. Around 60 hpf, the intersegmental lymphatic vessels sprout from the PACs and 
migrate dorsally to form the dorsal lateral lymphatic vessel (DLLV) and ventrally to build 
the main lymphatic vessel, the thoracic duct (TD). These two vessels are complete by 5 
days post fertilization (dpf) (Yaniv et al., 2006). 
A novel model for lymphangiogenesis suggests that the lymphatic specification process 
starts as early as 24 hpf (Nicenboim et al., 2015). It was thought that the lymphatics cells 
derive from veins, but cell tracing experiments revealed that the lymphatics come from 
a cluster of precursor cells or angioblasts that locate anatomically within the plate of the 
ventral posterior cardinal vein (PCV). These precursors can give rise to cells of the 
venous, arterial and lymphatic fate (Nicenboim et al., 2015). The precursors divide 
asymmetrically and the Prox1+ specified cells migrate towards the dorsal part of the PCV 
prior budding off the vein towards the horizontal myoseptum (Koltowska et al., 2015) . 
A summary of the vascular development steps can be found in Figure 1-3. 
 
Figure 1-3. Vascular development in zebrafish.  
Schematic illustration of the formation of the major blood and lymphatic vessels. DA:Dorsal Aorta, PCV: 
Posterior Cardinal Vein, DLAV: Dorsal Longitudinal Anastomotic Vessel; aISVs: arterial Intersegmental 
Vessel; vISVs: venous Intersegmental Vessel; PACs: Parachordal cells; DLLV: Dorsal Longitudinal Lymphatic 
Vessel; TD: Thoracic duct. Henceforth, red marks arterial identity, blue marks venous identity and green 
marks the lymphatic identity of the vessels. Yellow cells marked in panel A and B refer to the angioblasts. 
A) Around 24hpf the major vessels DA and PCV have been formed and aISVs sprout from the DA to form 
the DLAV. B) Around 32 hpf, the secondary sprouting generates vISVs. C) At 72hpf the PACs have been 
formed and aligned. D) By 5dpf two new lymphatic structures have been completed: the DLLV in the dorsal 
side and the TD in the ventral side. Adapted from (Padberg et al., 2017) 
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1.4 Objectives  
The specification of cells into the vascular lineage and subsequent lymphatic fate is a 
very complex process in which many cell-specific differentiation programs as well as 
developmental signaling pathways are under strict control. The expression of specific 
genes is activated in a spatial and temporal manner and requires the appropriate 
expression of different gene regulators. 
The AP-1 member JUNB, is a context-dependent transcription factor that has been 
demonstrated to play an essential role in vascular development in mouse embryos 
acting as an activator of pro-angiogenic molecules. Recently, a new role of JUNB in the 
regulation of lymphatic vasculature development in zebrafish via its target miR-182 was 
unraveled. This study also uncovered  that transient loss of junba and junbb in zebrafish 
provoked a failure in lymphatic formation (Kiesow et al., 2015). Yet, the underlying 
mechanism still remains to be clarified. 
According to the latest lymphangiogenesis model (Nicenboim et al., 2015; Koltowska et 
al., 2015), the defect on the development of lymphatics could be due to an impairment 
of any of the following biological processes: i) angioblast formation and proliferation, ii) 
lymphatic endothelial cell specification and differentiation, iii) sprouting of the 
lymphatic precursors from the posterior cardinal vein (PCV) and iv) lymphatic cell 
migration. 
Thus, I aimed to investigate whether JUNB regulatory functions are needed during 
lymphatic vessel development and identify which developmental steps are altered upon 
Junb loss. 
In order to answer these questions I will use a dual approach: i) an in vitro differentiation 
of murine embryonic stem cells (mESCs) into lymphatic endothelial cells (LECs) to 
investigate the angioblast formation and the early lymphatic endothelial cell 
differentiation steps and ii) in vivo generation and characterization of junb-ablated 
zebrafish mutants using imaging techniques to investigate the sprouting and migration 
of lymphatic cells. 
For each of the approaches, the following specific questions will be addressed: 
In vitro study of the JUNB regulatory functions in mammalian lymphangiogenesis: 
1. Is JUNB implicated in mammalian lymphangiogenesis? 
2. Which specific steps of LEC differentiation are altered upon Junb loss? 
3. Is any lymphatic fate regulator deregulated upon Junb loss? 
 
In vivo study of lymphangiogenesis in junb-ablated zebrafish mutants: 
4. Can junb-ablated zebrafishes be generated? 
5. Do junb mutant fishes exhibit lymphatic defects? 
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2. Materials 
2.1 Equipment 
Bacteria Incubator Kelvitron©t Heraeus Instruments, Hanau 
Bacteria shaker HT Infors AG CH-4103 Infors, Bottmingen 
Binocular M10  Leica, Wetzlar 
Cell counter Z2 Coulter Particle Counter Belckman Coulter, USA 
Cell culture sterile hood SterilGard Hood The Baker Company, USA 
Cell incubator Binder Incubator 9140-0013 CB210 Binder, Tuttlingen 
Cell incubator Heracell 240i CO2 incubator Thermo Scientific, USA 
Centrifuge Heraeus Megafuge 16 Thermo Scientific, USA 
Centrifuge Heraeus Pico 17 Thermo Scientific, USA 
Centrifuge J2-HS Beckman, USA 
Centrifuge Varifuge 3.OR Sephatech Heraeus Instruments, Hanau 
Chemical hood Airflow Controller RVC 90.1 Waldner, USA 
Confocal microscope LSM 710 Zeiss, Oberkochen 
Confocal microscope LSM 780  Zeiss, Oberkochen 
Cooling centrifuge 5403, 5415R Eppendorf, Hamburg 
Cryo freezing container Nalgene Thermo Fisher Scientific, USA 
Developer Classic E.O.S.  Agfa, USA 
Electrophoresis chamber for agarose gels Serva, Heidelberg 
Electrophoresis chamber for agarose gels  PeqLab, Erlangen 
Electrophoresis chamber for SDS-PAGE  Bio-Rad Laboratories, Munich 
Electrophoresis Power supply Power Pac 300/Pac 3000 Bio-Rad Laboratories, Munich 
FACS CaliburTM  Becton Dickinson Biosciences, Heidelberg 
FACS Canto Becton Dickinson Biosciences, Heidelberg 
Magnetic stirrer/Heater Heidolph MR2000  Heideloph, Schwabach 
Micromanipulator/Injectior World precision instruments 
Microscope Nikon Eclipse Ti Nikon, Düsseldorf 
Microscope Olympus 1x51 Olympus,UK 
Multiplate reader Clariostar BMG Labtech, Ortenberg  
NanoDrop 1000 Spectrophotometer UV-Vis          Thermo Fischer Scientific, USA 
PCR Cycler PTC-200 MJ Research, USA 
pH-meter  Knick, Berlin 
Pipets Gilson, USA 
Pipettor Pipetboy  Integra Biosciences, Switzerland 
Platform shaker Polymax 2040  Heidolph, Schwabach 
Scale Model L2200S Sartorius, Göttingen 
Scale Model XS205 Mettler-Toledo, Giessen 
Scales  Sartorius, Göttingen 
Shaker mini Ika® Model MS1  Sigma-Aldrich, Munich 
Shaker Multitron Infors Bottmingen, Schweiz 
Shaker Roto-shake Genie Scientific Industries, USA 
Shaker Thermomixer Confort Eppendorf, Hamburg 
StepOne Plus real time PCR System Applied Biosciences,UK 
Thermal Cycler MJMini Personal  Bio-Rad Laboratories, Munich 
Thermocycler MJ Mini  Bio-Rad Laboratories, Munich 
Thermomixer 5437  Eppendorf, Hamburg 
UV-Stratalinker 2400 Stratagene, Heidelberg 
Vortex  Bender+Hobein, Ismaning 
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Water baths GFL, Burgwedel 
Wet blot transfer system Sigma, Deisenhofen 
Zebrafish aqua culture system  Tecniplast, USA 
Zebrafish breeding tanks  Tecniplast, USA 
 
2.2 Consumables 
Cell culture dishes 100mm Sigma Aldrich, USA 
Cell culture dishes 6-well, 12-well, 24-well, 96-well Sigma Aldrich, USA 
Cell scraper Corning Incorporated, Mexico 
Conical centrifuge tubes 15ml, 50ml  Corning, USA 
Cover glasses  Menzel-Gläser, Braunschweig 
Cryo vials  Thermo Fisher Scientific, USA 
Elisa plate Microlon Greiner Bio-One, Austria 
Filter flask 0.22μm 200ml, 500ml Sigma Aldrich, USA 
Filter pipet tips 10 μl, 20 μl, 200 μl, 1000 μl  Neptune, USA 
Luminac-200, flat bottom 96-well plates Sigma Aldrich, USA 
MicroAmp 96-Well Optical Adhesive Film  Applied Biosystems, UK 
MicroAmp® fast optical 96-well reaction plate  Applied Biosystems, UK 
Microflex powder-free nitrile examination Gloves Microflex, USA 
Mister Frosty TM Freezing Container Thermo Fisher Scientific, USA 
Object slides SuperFrost Plus  Thermo Fisher Scientific, USA 
Opitran BA-S83 Nitrocellulose membrane  GE Helthcare, Munich 
Parafilm PM996  Bemis flexible packaging, USA 
Pasteur pipets  WU, Mainz 
PCR reaction tubes (8-well stripes)  Nerbe plus, Winsen/Luhe 
Pipet tips  10μl, 20μl, 200μl, 1000μl Nerbe plus, Winsen/Luhe 
Pipet tips (filtered)10μl, 20μl, 200μl, 1000μl Neptune Rapton, USA 
Pipets plastic 5 ml, 1 ml, Sigma Aldrich, USA 
Plastic container for cell counter Nerbe plus, Winsen/Luhe 
Polystyrene Round-Bottom Tube/ cell-Strainer cap 5ml Falcon, Corining, USA 
Reaction tubes 1.5 ml, 2 ml  Eppendorf, Hamburg 
Serological pipette plastic 5ml,10ml,25ml,50ml Costar Incorporation, USA 
Syringe 10ml Dispomed, Gelnhausen 
Syringe filters 0.22 μm  Renner, Darmstadt 
Western blot membrane Optitran BA-S83 Schleicher & Schüll, Dassel 
Whatman 3 MM paper  Whatman, Dassel 
X-ray films  Fuji, Düsseldorf 
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2.3 Chemicals 
1-phenyl-2-thiourea (PTU) Sigma-Aldrich, USA 
3-amino benzoic acidethylester (Tricaine) Sigma-Aldrich, USA 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) Sigma-Adrich, Taufkirchen 
5-Bromo-4-Chloro-3-Indolyl β-D-Galactopyranoside    (X-Gal) Thermo Fisher Scientific, USA 
Acetic acid Merck, Darmstadt 
Acrylamid/Bisacrylamid Rotiphorese® (37,5:1) Roth, Karlsruhe 
Agar  Roth, Kalsruhe 
Agarose Roth, Karlsruhe 
Ammonium peroxodisulfate (APS) Sigma Aldrich, Taufkirchen 
Ampicillin Sodium Salt Sigma Aldrich, USA 
ATX Ponceau S red staining Solution Fluka Analytical, Munich 
Boric acid Sigma Aldrich,USA 
Bovine serum albumine, fraction V (BSA) PAA, Pasching, Austria 
Calcium chloride (CaCl2) Merck, Darmstadt 
Chloroform Sigma Aldrich, Munich 
Coulter Isoton II Diluent Belckmann Coulter, Krefeld 
Dimethylsulfoxide (DMSO)  Sigma-Aldrich, Munich 
Dithiothreitol (DTT) AppliChem, Darmstadt 
Enhanced chemoluminescence solution (ECL) Perkin Elmer, USA 
Ethanol (EtOH)  Fisher Scientific, UK 
Ethanolamine Merck, Darmstadt 
Ethidiumbromide  AppliChem, Darmstadt 
Ethylenediamine-tetraacetatic acid (EDTA) Roth, Karlsruhe 
FACS Clean/Flow/Rinse Solutions BD Biosciences, USA 
Formaldehyde Roth, Karlsruhe 
Formamide  Sigma-Aldrich, Munich 
Gelatine  Merck, Darmstadt 
Glycerol  Roth, Karlsruhe 
Glycine AppliChem, Darmstadt 
Isopropanol (2-Propanol)  Sigma-Aldrich, Munich 
Isopropyl-β-D-thiogalactoside (IPTG) Sigma Aldrich, Munich 
Kanamycin Sigma-Aldrich, Munich 
Litium Cloride Roth, Karlsruhe 
Magnesium sulfate (MgSO4) Sigma-Aldrich, Munich 
Magnesiumchloride (MgCl2) Sigma-Aldrich, Munich 
Manganchloride (MnCl2) Sigma-Aldrich, Taufkirchen 
Methanol  Merck, Darmstadt 
Methylcelllulose Sigma-Aldrich, Munich 
Milk poder Roth, Karlsruhe 
Monosodium phosphate (NaH2PO4)  Sigma-Aldrich, Munich 
Monosodium phosphate (NaH2PO4xH2O) Merck, Darmstadt 
N, N, N’, N’, Tetramethylethylenediamine (TEMED) Roth, Karlsruhe 
Paraformaldehyde  Roth, Karlsruhe 
Phenol Roth, Karlsruhe 
Phenol Chloroform pH 4.0 Sigma-Aldrich, Munich 
Phenol Chloroform pH 8.0 Sigma-Aldrich, Munich 
Phenol red Sigma-Aldrich, USA 
Potassium chloride (KCl)  Roth, Karlsruhe 
Potassium dihydrogen phosphate  Roth, Karlsruhe 
 
22 MATERIALS 
Sodium chloride (NaCl) Fluka Chemicals, Switzerland 
Sodium deoxycholate Sigma-Aldrich, Munich 
Sodium dodecylsulfate (SDS)  Gerbu Biotechnik, Gaiberg 
Sodium hydroxyde (NaOH) VWR, Leuven, Belgium 
Sodium phosphate dibasic dihydrate (Na2HPO4x2H2O) Roth, Karlsruhe 
Sodiumacetate-trihydrate (NaOAc) Roth, Karlsruhe 
Tergitol-type NP-40 Sigma-Aldrich, Munich 
Tris-base  Roth, Karlsruhe 
Tris-hydrochloride (Tris-HCl)  Roth, Karlsruhe 
Triton-X-100 AppliChem, Darmstadt 
Trypan blue  Sigma-Aldrich, Munich 
Tryptone Roth, Karlsruhe 
Tween-20 AppliChem, Darmstadt 
Xylol AppliChem, Darmstadt 
Yeast extract Roth, Karlsruhe 
β-Mercaptoethanol Sigma-Adrich, Taufkirchen 
 
 
 
2.4 Softwares 
Adobe Illustrator  Adobe Systems,USA  
Alibaba 2.1 
http://gene-regulation.com/pub/programs/alibaba2/ 
open source, designed by Niels Grabe 
ApE- A plasmid Editor 
http:// www.biology.utah.edu/jorgensen/wayned/ape/ 
open source, designed by M. Wayne Davis   
BD CellQuest ProTM  Becton Dickinson Biosciences, Heidelberg 
BD FACSDiva™ Software  Becton Dickinson Biosciences, Heidelberg 
Cell A v.3.3 Olympus Soft Imaging Solutions 
Chop-Chop(Labun et al., 2016) 
http://chopchop.cbu.uib.no 
non-profit, Harvard University 
Clustal Omega alignment(Sievers et al., 2011) 
https://www.ebi.ac.uk/Tools/msa/clustalo/ 
non-profit, EMBL-EBI, UK 
CRISPR design tool (Hsu et al., 2013)  
http://crispr.mit.edu/Feng 
non profit, Zhang group, MIT, USA 
Zotero v5.0  open source, RRCHNM.org  
FlowJo v.10  Tree Star, Inc., Ashland, USA  
Graphpad Prism  GraphPad Software, Inc., La Jolla, USA 
ImageJ  open source NIH, USA 
In Silico PCR(Kent et al., 2002) 
http://genome.ucsc.edu/cgi-bin/hgPcr 
open source, UCSC, USA 
MARS Data-Analysis Software V3.00.R3   BMG Labtech, Ortenberg  
Microplate Reader CLARIOstar  V5.00.R4 BMG Labtech, Ortenberg  
NIS Elements AR 4.13.04  Nikon, Darmstadt   
Office 2010  Microsoft, USA   
Primer blast (Ye et al., 2012) 
https://www.ncbi.nlm.nih. gov/tools/primer-blast/ 
open source NIH, USA 
Snap Gene and Sanp Gene Viewer 4.1 Life Technologies, Darmstadt  
StepOne Software v.2.2.2  Life Technologies, Darmstadt  
Tm calculator Thermo Scientific , USA  
ZEN Carl Zeiss AG, Oberkochen  
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2.5 Molecular reagents 
4-Nitro Blue Tetrazolium (NBT) Sigma-Aldrich, USA 
7-AAD Viability Staining Solution eBioscience, Frankfurt 
Acc65I Fast Digest Thermo Fisher Scientific, USA 
Accutase® Cell Detachment Solution Sigma Aldrich,USA 
alpha-Digoxigenin Alkaline Phosphatase-conjugated Fab   Sigma-Aldrich, USA 
BamHI Fast digest Thermo Fisher Scientific, USA 
Benzonase© Nuclease HC (90% purity) Novagen, Darmstadt 
Bradford MX Protein Assay Expedeon, Cambridge, UK 
Brdu Flow Kit BD Biosciences, USA 
Cas9 protein Thermo Fisher Scientific, USA 
Dako Fluorescence Mounting Medium Dako North America Inc,USA 
DH5α Competent Cells Thermo Fisher Scientific, USA 
DIG RNA Labelling Kit  Sigma-Aldrich, USA 
DMEM/F12 medium Gibco, USA 
DNA ladders (50bp, 100bp, 1kb) New England Biolabs, USA 
DNA loading Dye (6x) Thermo Fisher Scientific, USA 
DNAseI (4000U/mg) AppliChem, Darmstadt 
dNTP mix (25 mM each) Thermo Fisher Scientific, USA 
Dual Glo® Luciferase Assay System Promega, Mannheim 
Dulbecco´s Modified Eagle´s Medium (high glucose) Sigma-Aldrich, USA 
Dulbecco´s Phosphate Buffered Saline (PBS) Sigma-Aldrich, USA 
eBioscience™ Annexin V Apoptosis Detection Kit APC Invitrogen, USA 
Endothelial Cell Growth Medium Kit C-22110  Promocell, Heidelberg 
Endothelial Cell Growth Supplement (ECGS) Promocell, Heidelberg 
ESGRO (LIF) , 1 million units Merck, Darmstadt 
Fast Digest Buffer (10x) Thermo Fisher Scientific, USA 
Fetal Bovine Serum Sigma-Aldrich, USA 
Fetal Bovine Serum, embryonic stem cell-qualified Life Technologies, USA 
Forskolin Sigma-Aldrich, Taufkirchen 
FuGENE© HD Transfection Reagent Promega, Mannheim 
Gateway BP Clonase© Enzyme Mix Invitrogen, USA 
Gateway LR Clonase©II Plus Enzyme Mix (multi) Invitrogen, USA 
Gateway LR Clonase©II single Invitrogen, USA 
GENEART® Site Directed Mutagenesis System Invitrogen, USA 
GlutaMAX® Supplement Life Technologies, USA 
Goat serum Sigma-Aldrich, USA 
GoTaq® Green Master Mix Promega, Mannheim 
High Capacity cDNA Reverse Transcription Applied Bioscience, USA 
Hind III Fast Digest  Thermo Fisher Scientific, USA 
Hoechst 33342  Biomol, Hamburg 
Knockout® DMEM stem cell medium Life Technologies, USA 
L- Glutamine Gibco, USA 
LDS Sample Buffer (4x) Thermo Fisher Scientific, USA 
Ligation Buffer (2x) Promega, Mannheim 
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MEGAshortscript T7 kit AM1354 Ambion, USA 
Metaphor © Agarose Lonza, Switzerland 
Minimum essential medium - MEM Alpha Eagle Biozol Diagnostica, Eching 
miRNeasy Micro Kit  Qiagen, Hilden 
miRNeasy Mini Kit  Qiagen, Hilden 
Mycoplasma PCR Kit  Minerva Biolabs, Berlin 
Non-essential Amino Acids (100x) Gibco, USA 
NotI  Thermo Fisher Scientific, USA 
NucleoSpin® Gel and PCR Clean-up  Macherey Nagel, Düren 
Oligo(dT)-Primer (0,5 µg/µL)  Thermo Fisher Scientific, USA 
Opti-MEM Reduced Serum Medium  Thermo Fisher Scientific, USA 
PageRuler™ Prestained Protein Ladder (10 to 180 kDa)  Thermo Fisher Scientific, USA 
Penicillin/Streptomycin Solution Sigma Aldrich,USA 
Phosphatase Inhibitor Mix II Solution Serva, Heidelberg 
Plasmid Kit Nucleospin© Macherey Nagel, Düren 
Polyethylenimine (PEI) Sigma-Aldrich,USA 
Power SYBR® Green PCR Master Mix Life Technologies, USA 
Pre-Diluted protein assay standard: BSA Set  Thermo Fisher Scientific, USA 
Protease Inhibitors Cocktail Sigma Aldrich,USA 
Proteinase K Sigma Aldrich,USA 
PureLink© HiPure Plasmid Maxiprep Kit  Invitrogen, USA 
Q5 High-Fidelity Master Mix (2x) New England Biolabs, USA 
Qiazol Lysis Reagent Qiagen, Hilden 
Random Hexamer Primer (100 µM) Thermo Fisher Scientific, USA 
Rapid Ligation Buffer (2x) Promega, Mannheim 
Red Load Taq Master (5x) Jena Bioscience, Jena 
Reverse Transcription Buffer (5x) Thermo Fisher Scientific, USA 
RevertAid Reverse Transcriptase (200 u/µL) Thermo Fisher Scientific, USA 
RiboLock RNase Inhibitor (40 u/µL)  Thermo Fisher Scientific, USA 
RNAse Zap Ambion, Applera 
RNase-free DNase-Set Qiagen, Hilden 
SB431542 TGF-β inhibitor Merck, Darmstadt 
Sodium Pyruvate Solution (100x) Gibco, USA 
T4 DNA Ligase (3U/µl) Promega, Mannheim 
TRI Reagent © Sigma Aldrich,USA 
Trypsin-EDTA (0.25%) phenol red Life Technologies, USA 
VEGF-C murine recombinant Sigma Aldrich,USA 
Whatman paper (extra thick) Thermo Fisher Scientific, USA 
Wizard® SV Gel and PCR Clean-Up System Promega, Mannheim 
XL1Blue Competent Cells Chem.Agilent, USA 
X-Phosphate/5-Bromo-4-Chloro-3-indolyl-phosphate (BCIP) Sigma-Aldrich, USA 
β-Mercaptoethanol (100x) Gibco, USA 
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2.6 Buffers  
Table 2-1. Buffers and buffer composition. 
Buffer Buffer composition 
Acrilamide gel/ running gel 12% 
  10-15 % acrylamide/bisacrylamide, 375 mM Tris- HCl  
  pH 8.8, 0.1 % SDS, 0.1 % APS and 0.1 % TEMED 
Acrilamide gel/ running gel 4% 
4 % acrylamide/bisacrylamide solution, 125 mM Tris-HCl 
pH 6.8, 0.1 % SDS, 0.1 % APS and 0.1 % TEMED 
Blue water  
0.3g/l Instant ocean, 0.075 g/l calcium sulfate in distilled 
water 
Danieau's solution 1x (pH 7.1) 
58mM NaCl, 0,7mM KCl, 0,4mM MgSO4, 0,6mM Ca(NO3)2, 
HEPES 5mM in distilled water 
DNA Lysis Buffer for cells and tail biopsies 
50mM Tris pH 8,0; 100mM NaCl, 100mM EDTA, 1% SDS 
and fresh 0,5 µg/µl proteinase k 
DNA lysis: Extraction alkaline Buffer (pH 12) 25mM NaOH, 0.2mM EDTA  
DNA lysis: Neutralizing Buffer (pH 5) 40mM Tris-HCl  
Egg water 
0,6 g/l aquarium salt in reverse osmosis water and 0,01 
mg/l methylene blue 
FACS Buffer 1% BSA in 1x PBS 
LB-agar 
20 g/l, Agar, 10 g/l, 10 g/l NaCl,Tryptone, 5 g/l Yeast 
extract  pH 7.0 
Methylcellulose mounting medium 3% methylcellulose in egg water 
PBS 10x (pH 7.4) 
1.37 M NaCl, 27 mM KCl, 80 mM Na2HPO4 x 2 H2O Sodium 
phosphate dibasic dihydrate 20 mM KH2PO4 Potassium 
phosphate monobasic.  
PBS-T 1X PBS in distilled water and 0.2% Triton  
PFA 4% (pH 7.4) 4% PFA  in distilled water 
PTU 50x 1.5 mg/ml PTU in blue water 
Ringer solution 
55 mM NaCl, 1.8 mM KCl, 1.25 mM NaHCO3 in distilled 
water 
RIPA buffer 
10 mM Tris-Cl (pH 8.0),150mM NaCl,1% NP-40, 0.5% 
sodium deoxycholate,0.1% SDS,140 mM NaCl. 
SOC medium 
2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM 
KCl, 10 mM MgCl2, 10 mM MgSO4, and 20 mM glucose. 
SSC 20x (pH 7.0) 
3M sodium chloride, 300mM tri-sodium citrate dihydrate 
in distilled water 
TAE Tris-acetate-EDTA Buffer 1x 400mM Tris, 200mM acetic acid, 10mM EDTA 
TBE Tris/Borate/EDTA 10x 1 M Tris base ,1 M Boric acid ,20 mM EDTA 
TBS 10x (pH 8.1) 0.25 M Tris base, 1.37 M sodium chloride in distilled water 
TBS-T 1x TBS in distilled water, 0,1% Tween-20 
TE Buffer  10 mM Tris, 1 mM EDTA pH 8.0 in distilled water 
Time lapse solution 
250ml/l Danieau's solution, 50ml/l Tricaine 20x, 20ml/l 
PTU 50x in egg water 
Tricaine 20x (pH 7.0) 400 mg/ml tricaine and 2,1ml/l 1M Tris in egg water  
Western Blot Blocking Buffer 5% BSA in PBS-T or 5% milk powder in PBS-T 
Western Blot Running Buffer 10x 250 mM Tris-base, 1.92 M glycine, 1% SDS 
Western Blot Transfer Buffer 1x 
25% methanol, 25mM glycine, 0,15% ethanolamine in 
distilled water 
YT medium 16 g/L Tryptone, 10 g/L Yeast Extract 
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2.7 Oligonucleotides 
Table 2-2. Primers used for genotyping. 
Primers Sequence 5'-3' Size Reference 
mmu-Junb B2 for GGGAACTGAGGGAAGCCACGCCGAG 685 bp (Schorpp-Kistner et al., 1999) 
mmu-Junb B10 rev AAACATACAAAATACGCTGG   
dre-junba_for TTTGTACGGTCGGAGCATCACAG 211 bp  
dre-junba_rev TTGCAGCTGTTCAGGGTGGTGTA   
dre-junbb_for CCAGCTGAACCACCGGTTTT 222 bp  
dre-junbb-rev GGCCAGTTTGAGTGAGCCCA    
Kalt4 baitR1 CACTGTCCTCCTCCTGGATAT 208 bp  
 
Table 2-3. Primers used for qRT-PCR. 
Primers Sequence 5'-3' Size Reference 
dre-bactin2_for TGACAGGATGCAGAAGGAGA 101 bp (Avraham-Davidi et al., 2012) 
dre-bactin2_rev GCCTCCGATCCAGACAGAGT   
dre-junba_for TACACAGCGGCGACCGGAGA- 214 bp (Kiesow et al., 2015) 
dre-junba_rev TCGGCGGGGGCATTTGGTTC   
dre-junbb_for CGTGCTGACGACCCCCACAC 206 bp (Kiesow et al., 2015) 
dre-junbb_rev CCGACTGCAGGGAGGAGCC   
mmu-Junb_Q1for ACGCCGCCTGTGTCCCCCATCAA 175 bp  
mmu-Junb_Q2rev CACTCGACAGCCCCGCGTTCTCAG   
mmu-Lyve1_for GCCAACGAGGCCTGTAAGAT 106 bp  
mmu-Lyve1_rev TCCAACCCATCCATAGCTGC   
mmu-Nanog_for CAGGTGTTTGAGGGTAGCTC 223 bp  
mmu-Nanog_for CGGTTCATCATGGTACAGTC  (Takahashi and Yamanaka, 2006) 
mmu-Oct3/4_for TCTTTCCACCAGGCCCCCGGCTC 224 bp  
mmu-Oct3/4_rev TGCGGGCGGACATGGGGAGATCC  (Takahashi and Yamanaka, 2006) 
mmu-Pdpn_for AGAGAACACGAGAGTACAACC 203 bp (Durchdewald et al., 2008) 
mmu-Pdpn_rev CAACAATGAAGATCCCTCCGAC   
mmu-Prox1_for TCGCAGCTCATCAAGTGGTT 185 bp  
mmu-Prox1_rev TCTGGAACCTCAAAGTCATTTGC   
mmu-Rplp0_for CCCTGCACTCTCGCTTTCTGGAG 192 bp  
mmu-Rplp0_rev CAGATGGATCAGCCAGGAAGG   
mmu-Sox2_for TAGAGCTAGACTCCGGGCGATGA 297 bp (Takahashi and Yamanaka, 2006) 
mmu-Sox2_rev TTGCCTTAAACAAGACCACGAAA   
mmu-Vegf-C_for TGTGCTTCTTGTCTCTGGCG 148 bp  
mmu-Vegf-C_for CCTTCAAAAGCCTTGACCTCG   
mmu-Vegfr1_for TGCTAAGAGCCTGGACAGTG 190 bp  
mmu-Vegfr1_rev GCAACAGGCTTTGAACAGCA   
mmu-Vegfr2_for GACCCGGCCAAACAAGCCCG 208 bp  
mmu-Vegfr2_for ACCCTCTCTCCTCGTCCCGC   
mmu-Vegfr3_for AGATGCAGCCGGGCGCTGCGCT 143 bp (Hamada et al., 2000) 
mmu-Vegfr3_for TAGGCTGTCCCCGGTGTCAATC   
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Table 2-4. Primers used for zebrafish line generation. 
Primers Sequence 5'-3' 
dre-junba crispr 
gRNA_for TAGGACGGATTCGTCAAAGCGC 
dre-junba crispr 
gRNA_rev AAACGCGCTTTGACGAATCCGT 
dre-junbb gRNA for  TAGGGTTACGGTCACAACGACG 
dre-junbb gRNA rev AAACCGTCGTTGTGACCGTAA 
stop cassette junba 
GAAATCGACTTCTACACAGCGGCGTCATGGCGTTTAAACCTTAATTAAGC
TGTTGTAGACCGGAGACGTGGGCTCGCTGA 
stop cassette junbb 
TTGGGTTACGGTCACAACGAGTCATGGCGTTTAAACCTTAATTAAGCTGT
TGTAGCGCGGCTCTACACGACTACA 
junba 1A RF Kalt4_for CACTAGTAACGGCCGCCAGTGTTGCTTATGGTCATCCAGACGCT 
junba 1A RF Kalt4_rev GGATATCTGCAGAATTCGCCCTTTTTCAGCGAGCCCACGTCTT 
junbb 1b RF Kalt4_for CACTAGTAACGGCCGCCAGTGTCCAGCTGAACCACCGGTTTTCAA 
junbb 1b RF Kalt4_rev GGATATCTGCAGAATTCGCCCTTGGCCAGTTTGAGTGAGCCCA 
attb1 junba_for 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGTCAACAAAAATG
GAGCAACCG  
attb2 junba_rev 
GGGGACCACTTTGTACAAGAAAGCTGGGTAAAACGACTTGATCTTGGGC
GTCAG 
attb1 junbB_for 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACC 
ATGAGTACAAAAATGGAGCAGCCG  
attb2 junbB_rev 
GGGGACCACTTTGTACAAGAAAGCTGGGTAAAACGCCTCCATCTTACTG
GTCAG 
 
Table 2-5. Primers used for promoter cloning. 
Primers Sequence 5'-3' 
dre-flt1-prom_rev ATGTCATTGGTACCTCCGCCATTGTTACAGATATACAAG 
dre-flt1-prom_rev ATGTCATTAAGCTTCAAACTCCTGAAACCCTGCG 
dre-flt1-CRE1 mut_for CAAAGGGGGCTAATAATTCAGGGCTCCACTGTACACCAGTAAACAG 
dre-flt1-CRE1 mut_rev CTGTTTACTGGTGTACAGTGGAGCCCTGAATTATTAGCCCCCTTTG 
dre-flt1-CRE2 mut_for CATCGGGCTCGTGTAGGAGGGCTCCGTTGCGGGATGGGTGTGTC 
dre-flt1-CRE2 mut_rev  GACACACCCATCCCGCAACGGAGCCCTCCTACACGAGCCCGATG 
dre-flt1-CRE3 mut_for GATGGGTGTGTCGATGAGGCTCCCGGAAGCTCCGGTGGCGG 
dre-flt1-CRE3 mut_for CCGCCACCGGAGCTTCCGGGAGCCTCATCGACACACCCATC 
dre-flt1-TRE1 mut_for CTCCGGTGGCGGTGGGAAAATGTTCCATCCCAGCCCGCGGTCATG 
dre-flt1-TRE1 mut_rev CATGACCGCGGGCTGGGATGGAACATTTTCCCACCGCCACCGGAG 
 
Table 2-6. Primers used for sequencing. 
Primers Sequence 5'-3' 
M13 uni (-21) TGTAAAACGACGGCCAGT 
pGL3 for  CTAGCAAAATAGGCTGTCCC 
SP6 CATTTAGGTGACACTATAG 
T7 TAATACGACTCACTATAGGG 
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2.8 Plasmids 
Table 2-7. Plasmids used for cloning. 
Plasmid name Origin 
5' E2A tag RFP Gil Levkowitz Lab 
5x mutated TRE-pGL3 Peter Angel Lab 
5x TRE-pGL3 Peter Angel Lab 
800bp dre-Flt1-pGL3 This work 
800bp dre-Flt1-pGL3 CRE1 mutated This work 
800bp dre-Flt1-pGL3 CRE2 mutated This work 
800bp dre-Flt1-pGL3 CRE3 mutated This work 
800bp dre-Flt1-pGL3 TRE3 mutated This work 
DONR221 Invitrogen 
DONR221-junba-no stop This work 
DONR221-junbb-no stop This work  
eGFPbait-E2A-KalTA4-pA (addgene #61069) Filippo del Bene Lab (Auer et al., 2014) 
p5E-UAS- 10x UAS element and basal promoter for 
Gal4  #327 Tol2kit Doug Campbell, Chien lab 
pBSK junbA T7 antisense Bettina Füssel, Peter Angel Lab 
pBSK junbB T7 antisense Bettina Füssel, Peter Angel Lab 
pBSK junbB T7 sense Bettina Füssel, Peter Angel Lab 
pCR4 TOPO Zf‐Junba IS Atsushi Kawakami, TIT, Japan 
pCR4 TOPO Zf‐Junbb IS Atsushi Kawakami, TIT, Japan 
pDestTol2pAa destination vector  #392 Tol2kit Clemens Grabher, Look lab 
Pgemt Promega 
pGEMT junbA T7 sense Bettina Füssel, Peter Angel Lab 
pGL3 Promega 
PmaxGFP Amaxa/Lonza 
pT7-gRNA (addgene #46759) Wenbiao Chen (Jao et al., 2013) 
pU18 control plasmid Thermo Scientific 
TK renilla Peter Angel Lab 
UAS:junba-E2A-RFP This work 
UAS:junbb-E2A-RFP This work 
 
2.9 Antibodies 
Table 2-8. Antibodies used for Western Blot. 
Antibody Source Concentration Company 
CyclophilinA  rabbit polyclonal 1:1000 Cell signalling, #2175 
Junb (210)  rabbit polyclonal 1:1000 
Santa Cruz Biotechnology, sc-
73 
RFP mouse monoclonal 1:10000 Sigma,SAB2702214 
VEGFR1 (Y103)  rabbit monoclonal 1:2000 Abcam, ab32152 
VEGFR2 (55b11)  rabbit monoclonal 1:1000 Cell signalling,#2478 
anti-mouse HRP-conjugated Horse 1:2500 Cell Signaling; #7076S  
anti-rabbit HRP-conjugated Goat 1:2500 Cell Signaling; #7074S  
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Table 2-9. Antibodies used for Flow cytometry. 
Antibody Source Concentration Company 
anti-CD105-APC MJ7/18 Rat 1:100 Miltenyi Biotec 130-092-930 
anti-CD31-APC Mouse 1:100 
Affymetrix eBioscience 17-
0311 
anti-rabbit APC IgG (H+L)   Goat 1:250 Thermo Fisher, A10931 
APC-rat IG2a k isotype control Rat 1:20 eBioscience 17-4321-71 
VEGFR1 (Y103)  rabbit monoclonal 1:2000 Abcam, ab32152 
VEGFR2 (55b11)  rabbit monoclonal 1:1000 Cell signalling,#2478 
 
2.10 Cell lines and cell culture media 
Table 2-10. Cell lines used for experiments. 
Cell type  Species Reference 
MEFs immortalized Mouse (Licht et al., 2006; Schorpp-Kistner et al., 1999) 
Endothelioma immortalized Mouse (Licht et al., 2006) 
mESCs primary Mouse (Schorpp-Kistner et al., 1999; Licht et al., 2006) 
 
Table 2-11. Culture media for the different cell types. 
 
Medium Medium composition 
Freezing medium 10% DMSO, 20% FCS, 70% medium  
Frezing medium mESCs 
10% DMSO, stem cell-qualified 25% FCS, 70% 
KNOCKOUT DMEM medium  
Medium Endothelioma 
DMEM (high glucose), 10% FBS, 1% 
Penicillin/Streptomycin, 2% L-Glutamine, 2nM 
Endothelial Cell Growth Supplement (ECGS), 1% Sodium 
Pyruvate, 1 % Non-essential amino acids 
Medium F9 cells 
F12/DMEM medium, 10% FBS, 1 % 
Penicillin/Streptomycin, 1% L-Glutamine, 1% Sodium 
Pyruvate, 1 % Non-essential amino acids and 0,1mM β-
mercaptoethanol 
Medium MEFs DMEM (high glucose), 10% FBS, 1% L-Glutamine,  
Medium mESC LEC-directed 
differentiation 
Endothelial Cell Medium kit (0,02 ml/ml FBS, 0,004ml/ml 
endothelial cell growth supplement, 0,1 ng/ml epidermal 
growth factor, 1ng/ml basic fibroblast growth factor, 90 
µg/ml heparine, 1µg/ml hydrocortisone, 100ng/µl of 
VEGF-C to and 10 µM SB431542 
Medium mESC spontaneous 
differentiation 
alpha-modified Minimum Essential Medium Eagle 
(alphaMEM), stem cell qualified 10% FBS, 1% Penicillin/ 
Streptomycin, 2mM Glutamax and 0,1mM β-
mercaptoethanol   
Medium mESC stem cells 
KNOCKOUT DMEM, stem cell qualified 10% FBS, 1% 
Penicillin/ Streptomycin, 2mM Glutamax, 0,1mM β-
mercaptoethanol and 1000 U/ml of murine Leukemia 
Inhibitory Factor (LIF) 
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2.11 Zebrafish lines 
 
Table 2-12. Transgenic lines used for experiments. 
Zebrafish line Reporter tissue Reference 
Tg(fli1:EGFP)yl Pan-endothelial GFP expression (Lawson and Weinstein, 2002) 
Tg(fli1:gal4ubs3;uas:Kaedek8) Endothelial expression of Gal4 (Herwig et al., 2011) 
Tg(HuC/D:Gal4) Neuronal expression of Gal4 (Faucherre and López-Schier, 2011) 
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3.1 Molecular methods 
3.1.1 DNA extraction 
The genomic DNA was extracted from cells and tail biopsies of mice. Samples were 
digested on fresh lysis buffer containing 0,5 µg/µl proteinase K at 56°C for two hours 
(cells) or overnight (tail biopsies) with gentle shaking. Proteins and SDS complexes were 
separated by adding 1/3 of the volume of saturated 6M sodium chloride, vigorous 
shaking and maximum speed centrifugation for 15 minutes. The DNA-containing 
supernatant was then precipitated by mixing it with 1 volume of propanol-2 and 
centrifuged at maximum speed for 20 minutes. The pellet was further washed with 70% 
ethanol. The final pellet was air dried to remove any residual alcohol and re-suspended 
in water according to pellet size. 
The genomic DNA from zebrafish embryos and fin biopsies were isolated using the hot 
sodium hydroxide and Tris (HotSHOT) method (Truett et al., 2000) . In short, the tissue 
was digested in one volume of alkaline extraction buffer (pH 12) at 95°C for 1 hour. 
Subsequently, one volume of the neutralizing buffer (pH 5) was added. 
 
3.1.2 RNA isolation  
Cell samples were washed twice with cold 1x PBS to remove residual proteins from the 
medium supplements before starting the isolation protocol. For the zebrafish samples, 
around 30 embryos at different stages were manually dechorionated. They were 
anaesthetized and kept on ice for at least 10 min before proceeding to the lysis step. 
Total RNA isolation from cells, tissues and zebrafish embryos was isolated using Trizol© 
reagent and TRI Reagent© respectively prior to mRNeasy minikit and microKit (< 500000 
cells) according to manufacturer´s instructions. DNAse on-column treatment was 
included in all cases. Isolated RNA was stored at -80°C. 
 
3.1.3 DNA/RNA quantification 
DNA and RNA concentrations were measured by the Nanodrop ND-1000 UV VIS 
spectrophotometer. The concentration of the nucleic acids was calculated based on 
their absorbance readings at 260 nm considering that one optical unit at 260 nm ~ 
corresponds to 50µg/ml of DNA and ~40µg/ml of RNA. 
The quality of the nucleic acids was controlled by the A260/A230 and A260/A280 ratios. 
A260/A280 ratio was used to assess the presence of proteins and A260/A230 for the 
presence of salts or organic contaminants.  Pure DNA and pure RNA preparations were 
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considered when their A260/A280 ratio was equal or greater than 1.8 and 2.0 
respectively and their A260/A230 ratio close to 1.8 (Green et al., 2012) 
 
3.1.4 Reverse transcription  
500ng to 1µg of RNA isolated from cells was reverse transcribed into cDNA using 
RevertAid M-MuLV Kit according to instructions of the manufacturer. 
Reagent Volume 
RNA 500-1000ng 
Oligo dT (0,5 µg/µL) 0,25µl 
Random hexamers (10 µM) 0,25µl 
Nuclease-free water Up to 10µl 
5x RT Buffer 4µl 
25mM dNTPs 0,5µl 
Ribolock (40 u/µL) 0,5µl 
Reverse transcriptase (200 u/µL) 1µl 
The RT reaction was performed using the following parameters: 
Initial Denaturation  65°C 5 minutes 
Reverse Transcription 42°C 1 hour 
Final elongation 72°C 10 minutes 
End 10°C ∞ 
 
For the zebrafish samples, 1µg of RNA was transcribed using the cDNA Kit: High Capacity 
cDNA Reverse Transcription, Applied Biosciences according to manufacturer´s 
instructions. Transcribed cDNA was stored at -20°C. 
 
3.1.5 Polymerase Chain Reaction  
PCR was performed routinely to genotype cells using the protocol below 
Reagent Volume 
5x Red Load Taq 4µl 
Forward primer (10µM) 0,3µl 
Reverse primer (10µM) 0,3µl 
DNA cells (25ng/µl) 1µl 
Nuclease-free water 14,7µl 
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and the following parameters: 
Initial Denaturation  95°C 2minutes 
 25-30 cycles 
-Denaturation 95°C 30 seconds 
-Annealing (according to 
each primer set) 
57°C 1 minute 
-Elongation 72°C 30 seconds 
Final elongation 72°C 5 minutes 
End 10°C ∞ 
 
Go Taq Master Mix was used to genotype the zebrafish fin biopsies and embryos. 
PCR amplicons were further analyzed by agarose gel electrophoresis. All primers 
sequences and corresponding melting temperatures are listed on Table 2-2. 
 
3.1.6 Design and validation of quantitative Real Time PCR primers 
All qRT-PCR primers were designed using Primer blast (Ye et al., 2012), a primer 
designing tool from the NCBI, and selected for their specificity, the exon-exon spanning 
location and efficiency. The efficiency of the qRT-PCR primers was determined by 
analyzing serial ten-fold dilutions of cDNA ranging from 100ng to 0,001ng. Only primers 
with efficiency in the range of 1.8-2.1 were used in this study. Primer specificity was 
assessed by the analysis of the melting curve and the verification of the amplicon size 
by gel agarose electrophoresis. 
The efficiency of the primers was calculated according to equation 1: 
 
Equation 1. Calculation of real time PCR primers efficiency. 
𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (𝐸) = 10
(
−1
 𝑠𝑙𝑜𝑝𝑒 
)  
The slope value is taken from the linear standard curve of the graph log cDNA input vs 
Ct mean. 
All primer information can be found in Table 2-3. 
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3.1.7 Quantitative Real Time-PCR  
The quantitative Real Time PCR was performed using the StepOne Plus real time PCR 
System (Applied Biosciences). All samples were measured in technical duplicates 
containing 2,5ng of cDNA as template in a PowerSYBR© PCR Master Green mix as it 
follows: 
Reagent Volume 
Power SYBR Green PCR Mix (2x) 6.25 µl 
Forward Primer (50 µM) 0.075 µl 
Reverse Primer (50 µM) 0.075 µl 
Nuclease-free water 2.25 µl 
cDNA template (1 ng/µl) 2.50 µl 
Since the RT-PCRs were designed to work at 60°C using the following parameters: 
Initial Denaturation  95°C 10 minutes 
40 cycles 
-Denaturation 95°C 15 seconds 
-Annealing  60°C 30 seconds 
Melt Curve (Temperature increment 0,3°C) 
 95°C 15 seconds 
 60°C 1 minute 
 95°C 15 seconds 
 
All data was analyzed using StepOne software v2.3 The relative expression was 
calculated applying the ΔΔCt method (Pfaffl, 2001).In short, variations on the initial 
sample were corrected by normalizing the cycle of threshold (Ct) of the gene of interest 
(GOI) to the cycle of threshold of the reference gene (REF) according to equation 2: 
 
Equation 2. Mathematical model used for relative quantification. 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 =  
𝐸𝐺𝑂𝐼
𝛥𝐶𝑡𝐺𝑂𝐼( 𝑚𝑒𝑎𝑛𝑐𝑜𝑛𝑡𝑟𝑜𝑙−𝑚𝑒𝑎𝑛𝑠𝑎𝑚𝑝𝑙𝑒) 
𝐸𝑅𝐸𝐹
𝛥𝐶𝑡𝑅𝐸𝐹( 𝑚𝑒𝑎𝑛𝑐𝑜𝑛𝑡𝑟𝑜𝑙−𝑚𝑒𝑎𝑛𝑠𝑎𝑚𝑝𝑙𝑒) 
  
EGOI = Real time efficiency of the Gene of interest transcript 
EREF = Real time efficiency of the Reference transcript 
ΔCtGOI = Ct - deviation of Gene of interest transcript between control and sample 
ΔCtREF = Ct - deviation of Reference transcript between control and sample 
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3.1.8 Gel agarose electrophoresis 
DNA fragments were separated according to the size in 0.8% agarose gels (for restricted 
plasmids), 1,5% agarose gels (for PCR amplicons) or 3% (zebrafish mutant genotyping) 
stained with 5% Ethidium Bromide solution at constant voltage of 100V. Depending on 
the amplicon size, DNA ladders of certain range were used as reference of molecular 
weight. 
 
3.1.9 Nucleic acids purification  
DNA purification for further downstream application such as cloning was purified with 
the kit NucleoSpin® Gel and PCR Clean-up (amplicons after PCR) or with Wizard® SV Gel 
and PCR Clean-Up System (from gel) according to manufacturer´s instruction. 
DNA used for injections in zebrafish embryos needed to go through an extra step of 
purification by phenol/chloroform/isoamylalcohol 25:24:1 (Chomczynski and Sacchi, 
1987). In short, DNA solution was mixed with 1 volume of phenol/chloroform and 
vigorously mixed. The upper aqueous phase was then mixed with one volume of 
chloroform and finally the upper phase was mixed with 1 volume of propanol-2 to 
precipitate the nucleic acids. Since the pH of the phenol-chloroform determines the 
presence of certain nucleic acids on the aqueous phase, acidic phenol/chloroform pH 
4.0 was used for RNA purification and pH 8.0 for plasmid purification. 
 
3.1.10 Sequencing 
15µl of  0,7-1 µg DNA solution containing 10pmol/µl of primer was sequenced using  the 
Sanger method (Sanger et al., 1977) by Eurofins or the Sequencing Unit from the 
Weizmann Institute. More information about the sequencing primers can be found in 
Table 2-6.  
 
3.2 Protein analyses 
3.2.1 Whole cell protein isolation 
The cultured cells were washed several times with cold 1x PBS prior harvesting to reduce 
contamination from proteins present in the medium and its supplements. The cell 
lysates were incubated on ice in freshly prepared RIPA lysis buffer containing 1mM DTT, 
1% of protease inhibitors, 1% phosphatase inhibitors plus 250U benzonase© for 20 
minutes. After three freeze-thaw cycles and maximum centrifugation of the lysates for 
15 minutes, the protein-containing supernatant was collected and stored at -80°C until 
further applications. 
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3.2.2 Protein quantification 
The Bradford method was used to determine the protein concentration of the lysates 
(Bradford, 1976). For this purpose, a dilution of the lysates was mixed with Bradford 
MX© solution. A BSA set containing Pre-Diluted BSA standard concentrations within a 
range of 125 to 2000µg/ml were analyzed in parallel to create the standard curve. The 
absorbance of the samples was measured at 595nm using the Clariostar microplate 
reader and the Clariostar software V5.00.R4 and the final protein concentrations were 
calculated using the MARS Data Analysis Software V3.00.R3.  
 
3.2.3 SDS-PAGE electrophoresis 
The proteins were separated according to their molecular weight by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE). In short, 20 µg of the protein 
lysates were mixed with 4x Laemmli Buffer and boiled for 5 minutes to denature 
proteins (Laemmli, 1970). The lysates were then loaded into a 12% poly-acrylamide gel 
in 1x SDS running buffer at 120V for 90 minutes. Protein ladder was used as reference 
for protein size verification. 
 
3.2.4 Western Blot (Towbin et al., 1979) 
Proteins were transferred from the acrylamide gel onto a nitrocellulose membrane using 
a wet blotting system in transfer buffer at 175A for 2h at 4°C. After disassembling the 
transfer cassette, the membrane was stained with Ponceau S for rapid and reversible 
staining of the proteins to check for proper and equal amount of protein for each lane. 
After that, the membrane was quickly rinsed in 1x PBST buffer until the Ponceau staining 
was no longer perceptible. Then, the membrane was incubated in blocking buffer 
containing 5% BSA or 5% dry milk (depending on the primary antibody) for 1h at room 
temperature. Primary antibody was diluted accordingly in blocking buffer and the 
membrane was kept in rotation overnight at 4°C. Next, it was washed 3 times for 15 
minutes each to remove the traces and the unspecific binding of the antibody. 
Thereafter, the membranes were incubated in the diluted Horseradish peroxidase 
(HRP)-linked antibodies. Further on, the membrane was washed again 3 times for 15 
minutes and subsequently incubated for 1 minute with a chemiluminiscence agent. 
Finally, the signal was detected using X-ray films and developer Classic E.O.S (Agfa). All 
the primary and secondary antibodies are listed in Table 2-8. 
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3.2.5 Western blot quantification 
In order to quantify the amount of proteins, original X-Ray films exposed at similar time 
points were scanned and transferred into an image file. Using the gel plugging from 
ImageJ, equal areas of the bands were measured for intensity and corrected with a 
background control. For the calculations, the pixel density values were inverted. The 
inverted value was expressed as 255-X being X the pixel density by the gel plugin. The 
final calculation was the ratio between the net value of the band and the net value of 
the loading control (Equation 3). 
Equation 3. Quantification of western blot signals. 
((255 − 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡 𝑝𝑖𝑥𝑒𝑙 𝑑𝑒𝑛𝑠𝑖𝑡𝑦) − (255 − 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝑝𝑖𝑥𝑒𝑙 𝑑𝑒𝑛𝑠𝑖𝑡𝑦))
((255 − 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑝𝑖𝑥𝑒𝑙 𝑑𝑒𝑛𝑠𝑖𝑡𝑦) − (255 − 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝑝𝑖𝑥𝑒𝑙 𝑑𝑒𝑛𝑠𝑖𝑡𝑦))
 
 
3.3 Flow Cytometry 
Prior to the staining, cells were washed twice with 1x PBS, harvested using 0,25% 
accutase solution and re-suspended until they were a homogeneous one cell 
suspension. Cells were quantified using the cell counter Z2 (Beckmann Coulter) and 
around 250000 cells were used per staining condition. 
For direct staining, the fluorophore-coupled antibody was incubated in FACS buffer for 
20-30 minutes on ice, light protected and with gentle shaking. For indirect staining, the 
first antibody was incubated as previously described. After the incubation period, the 
cells were centrifuged, and the pellet was washed to get rid of the unbound antibody. 
Secondary fluorophore-coupled antibody was then incubated 1:200 as previously 
described. 
Most of the used antibodies in this study were membrane proteins but some of the 
epitopes recognized by the antibodies were in the cytoplasm. For those cases, prior the 
staining procedure, a fixing and permeabilization step was added to allow the antibody 
to penetrate the cells. The antibodies were diluted in permeabilization buffer to 
maintain the permeability. In all cases, unstained control and isotype control were 
analyzed in parallel to assess the specificity of the antibodies and the gating. The 
samples were analyzed using the FACS CaliburTM. All the antibodies and their working 
concentrations can be found in Table 2-9. 
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3.4 Cloning methods 
3.4.1 pGEM®-T cloning 
pGEM®-T easy vector was used to clone PCR amplicons prior to sequencing. pGEM®-T 
plasmids are linearized plasmids containing 3´T-overhangs which facilitate the ligation 
of PCR products which avoid re-circularization of the vector. In addition, the vector 
contains the enzyme β-galactosidase (LacZ operon) which allows blue-white screening 
for recombinant colonies. For that purpose, IPTG (Isopropyl β-D-1-
thiogalactopyranoside), a non-metabolizable inducer of β-galactosidase, and X-Gal, a 
chromogenic substrate, were added to the agar plates. 
β-galactosidase is an enzyme that cleaves lactose into glucose and galactose. In the 
presence of an analogue of galactose such as IPTG, the β-galactosidase is induced. If β-
galactosidase is produced, X-Gal produces a blue pigment called 5,5’-dibromo-4,4’-
dichloro-indigo. Therefore, colonies formed by non-recombinant cells will appear blue 
while the recombinant cells will appear white. Only white colonies were selected for 
further analysis.  
For the ligation, the following mixture was prepared and incubated 1h at room 
temperature according to manufacturer´s instructions. 
Reagent Volume 
pGEM®-T easy (50ng/µl) 1 µl 
2x Ligation Buffer 5 µl 
T4 DNA Ligase (3U/µl) 1 µl 
PCR clean product 0,3 µl 
Nuclease-free water 9,7 µl 
The volume of the PCR clean product was adjusted for each experiment according to the 
insert size and concentration (Equation 4). 
Equation 4. Calculation of the insertion volume for pGEM-T ligation 
 𝑖𝑛𝑠𝑒𝑟𝑡 (𝑛𝑔)
𝑃𝐶𝑅 𝑝𝑟𝑜𝑑𝑢𝑐𝑡 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑛𝑔/µ𝑙)
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3.4.2 Generation of dre-flt1 800bp-pGL3 construct 
The resulting vector containing 800bp of the promoter region of the zebrafish Flt1 in a 
pGL3 backbone was obtained by restriction enzyme cloning. pGL3 Luciferase Reporter 
Vector® is a reporter construct designed for quantitative analysis of gene expression in 
mammalian cells and contains a region coding for firefly (Photinus pyralis) luciferase.  
In order to clone the promoter region of interest into the pGL3 vector, the promoter 
fragment and the vector were treated with the same restriction enzymes to create 
compatible ends. For this case, the plasmid was linearized with two enzymes of the 
Multiple Clonal Site (MCS) (Acc65I (+1) and HindIII (+53)). In addition, specific primers 
amplifying the targeted 800bp region were designed using ApE software. Flanking 
sequences recognized by Acc65I and HindIII were included to the primers. 
The zebrafish promoter region was amplified using a proofreading Taq polymerase and 
zebrafish gDNA as it follows: 
Reagent Volume 
2x Q5 High-Fidelity Master Mix 
Zebrafish genomic DNA (1ng/µl) 
12,5µl 
2µl 
Primer F (10µM) 1,25µl 
Primer R (10µM) 1,25µl 
Nuclease  free water 8µl 
 
Initial Denaturation  98°C 2minutes 
 25-30 cycles 
-Denaturation 98°C 30 seconds 
-Annealing  65°C 30 seconds 
-Elongation 72°C 1 minute 
Final elongation 72°C 2 minutes 
End 10°C ∞ 
PCR amplicons were resolved in a 2% agarose gel and purified as described before. PCR 
amplicon and plasmid were both digested for 1h at 37°C using Acc65I and HindIII as it 
follows 
Reagent Volume 
Amplicon/pGL3 vector 27 µl 
FD Acc65I 2 µl 
FD HindIII 2 µl 
10x FD Buffer  4 µl 
Nuclease-free water 5 µl 
Digested PCR amplicon and plasmid were resolved in a 1,5% agarose gel and purified as 
previously described in section 3.1.9. 
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Purified amplicons and plasmid were ligated as it follows for more than 2h at RT. 
Reagent Volume 
pGL3 (Acc65I + HindIII) 1 µl 
Flt1a/promoter (Acc65I + HindIII) 1 µl 
2x Rapid Ligation Buffer  5 µl 
T4 DNA ligase   1 µl 
Nuclease-free water 2 µl 
5µl of the ligation reaction were transformed in competent bacteria as described in 
section 3.4.4. Minipreps and maxipreps were prepared as in 3.4.5 and sequenced as in 
3.1.10. 
 
3.4.3 Site-directed mutagenesis  
Zebrafish flt1 promoter regions harboring mutated sites were generated according to 
the GENEART® Site-Directed Mutagenesis System from Invitrogen. 4 potential binding 
sites were mutated: a consensus CRE site (-196 -188), a CRE site with a variation (-105 -
97), half CRE binding site (-72 -67) and one TRE site (-42 -35). Specific primers with the 
desired modifications were designed according to the manufacturer´s instructions. 
More information about the mutagenesis strategy can be found in Table 2-5. 
In short, the target DNA (the previously generated 800bp dre-fl1-pGL3 vector) was 
methylated by a DNA methylase. The complementary primers harboring the mutated 
binding sites anneal to the targeted area and recombine. After degradation of 
methylated DNA, the resulting construct contains the desired modifications. Mutated 
versions of the construct were transformed into bacteria as described in 3.4.4 Minipreps 
and maxipreps were prepared as in 3.4.5 and sequenced as in 3.1.10. 
  
3.4.4 Bacterial transformation 
Bacterial transformation was used to propagate plasmid DNA. Depending on the plasmid 
size and the application, Top 10, DHL5 alpha or XL1blue E.coli competent bacteria were 
used. In short, a small amount of ligation product or plasmid (~200ng) was incubated 
with the bacteria for 20 minutes on ice. After this time, heat shock was performed: 
bacteria were incubated for 45 seconds at 42°C and then 2 minutes on ice. Between 250-
500µl of SOC medium was added and subsequently was incubated for at least 1h at 37°C 
with gentle shaking. A small volume of this preparation was then seeded onto agar 
plates (containing the appropriate antibiotic) for selection. Positive colonies were picked 
and grown into 5ml medium (for mini preps) or in 200ml (for maxi preps). Commercial 
pU18 plasmid and water were used as positive and negative controls respectively. 
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3.4.5 DNA isolation from plasmids: minipreps and maxipreps  
The plasmids were isolated from minipreps (5ml) or maxipreps(200ml). For small scale 
isolation, Nucleospin© Plasmid kit was used according to manufacturer´s instructions. 
For the large-scale purification, PureLink© HiPure Plasmid Maxiprep Kit was used 
according to manufacturer’s instructions. Both kits were based on the same principle. 
First the bacteria were sedimented from the medium by centrifugation. Then they were 
re-suspended in alkaline lysis buffer containing RNAse. The suspension was neutralized 
and clarified by centrifugation to remove proteins, cell debris and genomic DNA. Next, 
the upper soluble phase was purified on a column containing a silica resin that 
selectively binds RNA. After several washes with alcohol-based buffers, the plasmids 
were eluted in water. DNA quality and quantity were assessed with the nanodrop (3.1.3) 
and sequenced as explained on section 3.1.10. 
 
3.5 Cell culture methods 
3.5.1 Culture conditions and maintenance: Murine Embryonic Fibroblasts 
(MEFs), endothelioma cells, F9 and mouse embryonic stem cells (mESCs) 
Mouse Embryonic Fibroblasts Junb +/+ and Junb -/-and Endothelioma Junb-/- and Junb +/ - 
(Schorpp-Kistner et al., 1999; Licht et al., 2006) were cultured on Dulbecco´s Modified 
Eagle´s Medium (DMEM) with 10% Fetal Bovine Serum (FBS) medium at 37°C and 5% 
CO2 and passaged every 3-4 days. Cell-specific medium was changed every other day if 
not specified otherwise. For each passage, the cells were washed twice with 1x PBS and 
detached from the surface using Accutase© or 0,25% Trypsin. After a short incubation 
at 37°C, the cells were counted and seeded accordingly. Murine teratocarcinoma F9 cells 
were cultured in F12/DMEM based medium and passaged every other day. The medium 
was changed twice a day and they were treated with 0.025% trypsin prior passaging. 
mESCs were culture into gelatin-coated dishes, the medium was changed daily and they 
were passaged every other day. mAll the cells were cultured in sub-confluent conditions 
and checked regularly. All the cells were manipulated under sterile conditions. 
 
3.5.2 Differentiation of stem cells 
Mouse embryonic stem cells were differentiated into lymphatic endothelial cells 
according to the previously described instructions in human stem cells with several 
adaptations (Kusuma et al., 2013). Shortly, the cells were subjected to a three-step 
differentiation protocol. In the first step, the stem cells were cultured on 0,1% gelatin-
coated dishes with Knockout DMEM Medium (Gibco) supplemented with 10% stem cell-
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qualified Fetal Bovine Serum (Gibco), 1% Penicillin / Streptomycin, 2mM Glutamax (Life 
Technologies), 0,1mM β-mercaptoethanol (Sigma) and 1000 U/ml of murine Leukemia 
Inhibitory Factor (LIF) (Millipore). The cells were cultured in the presence of LIF to 
maintain their stemness property and under feeder-free conditions for three passages. 
Cells were passaged every other day to low density (30-50%) and medium was changed 
daily. Thereafter, the cells were succumbed to a mesodermal-derived spontaneous 
differentiation by culturing the cells in alpha-modified Minimum Essential Medium Eagle 
(alphaMEM) medium supplemented with 10% stem cell-qualified Fetal Bovine Serum, 
1% Penicillin / Streptomycin, 2mM Glutamax (Life Technologies), 0,1mM β-
mercaptoethanol (Sigma) yet in the absence of LIF. The cells were plated at a density of 
6 x 103 cells / cm2 in absence of LIF to promote spontaneous differentiation , passaged 
every other day and medium was changed daily. Upon spontaneous differentiation for 
6 consecutive days, the cells were subjected to the third step of lymphatic endothelial 
cell directed differentiation. For this last step, the cells were detached, counted and 
seeded to the density of 1,25 x 104 cells/cm2 in Endothelial Cell Medium kit 
supplemented with 100ng/µl of VEGF-C to and 10 µM SB431542, an TGF-β RI 
(Transforming Growth Factor beta Receptor I) inhibitor (Oka et al., 2008; Clavin et al., 
2008; Avraham et al., 2010). The cells were cultured in this medium for another 4 days 
and the medium was changed every other day. The cells were maintained at 37°C and 
5% CO2.  
 
3.5.3 Freezing and thawing of cells 
mESC were dissociated using 0,25% trypsin and separated into a one-cell suspension. 
They were counted using Cell counter Z2 (Beckmann Coulter) and frozen into 1 million 
cells/ml cryovials. The freezing medium consist of: 10% Fetal Bovine Serum,10% 
Dimethyl Sulfoxide (DMSO) and 80% culture medium. mESC freezing medium 
containing: 65% stem cells medium, 10% Dimethyl Sulfoxide (DMSO) and 15% stem cell 
qualified Fetal Bovine Serum. 
 
3.5.4 Mycoplasma check 
All cells were routinely tested for mycoplasma contamination using Mycoplasma PCR Kit 
(Minerva Biolabs) according to manufacturer´s instructions. 
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3.5.5 Transient transfection of cells 
For transfection experiments, the cells were seeded 24 hours prior the experiments. 
Transfection of plasmids into MEFs was performed using polyethylenimine (PEI) and 
plasmid in a 1:3 (Boussif et al., 1995) Plasmid DNA: PEI ratio and using FuGENE®HD 
transfection agent for F9 cells using 1:2.5 ratio following manufacturer’s instructions. In 
short, cells were washed with serum-free medium and added the plasmid: transfection 
reagent complex mixtures in a dropwise manner. Medium of the transfected cells was 
refreshed after 24 hours. Analyses and harvesting of the cells were performed 48 hours 
post-transfection. 
For the transfection of MEFs using PEI: 
Format # cells Optimem Plasmid (1µg/µl) PEI 
12-well dish 25.000 cells 100 µl 1 µl 3 µl 
 
For the transfections of F9 cells using FuGENE®HD 
Format # cells Serum-free DMEM Plasmid (1µg/µl) FuGENE®HD 
12-well dish 40.000 cells 100 µl 1µ 2.5 µl 
6-well dish 80.000 cells 200 µl 2 µl 5 µl 
10 cm dish 800.000 cells 500 µl 5 µl 12.5 µl 
 
3.6 Luciferase Reporter Assay 
25000 MEFs were plated in 12-well plates 24 hours prior the transfection. 3 independent 
transfections using PEI as transfection reagent were carried out in parallel as described 
in Section 4.3.1. For the luciferase experiment, all the experimental conditions were 
transfected with 1µg of promoter construct and normalized by co-transfection of 0.05 
ng/µl of RSV-Renilla construct. In addition, 5X TRE and mutated 5X TRE vectors were 
used as internal controls and transfected to assess the efficacy of the luciferase 
experiment. Transfection efficiency was assessed by transfecting GFPmax construct and 
controlling GFP expression by fluorescence microscopy. Only transfection rates of 80-
90% were considered acceptable to continue with the experiments. 48 hours after 
transfection, the medium was removed and washed twice with cold 1x PBS prior using 
Dual-Glo® Luciferase Assay System (Promega). In short, 150 µl of Passive Lysis Buffer was 
added to the surface of the wells and incubated for 20 minutes with gentle shaking. The 
protein containing buffer was collected and shortly centrifuged to precipitate cell 
membranes. 50 µl of the protein isolates were loaded into a white-bottom 96-well plate. 
For the luciferase Assay, a luminescence program was designed, and the 
bioluminescence was measured in a Clariostar multiplate reader equipped with injectors 
primed with the luciferase reagents.  
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In this program, the multiplate reader inject 100 µl of the Luciferase Reagent and 
measure the bioluminescence for 10 consecutive seconds. Subsequently, 100 µl of the 
Stop and Glow reagent was injected in the same well prior bioluminescence 
measurement.  
The data were normalized according to their transfection efficiency by calculating the 
ration between the sum of the luciferase and renilla signal among the three technical 
replicates. The ratios of the conditions with transfected promoter vectors were 
normalized to the condition of the transfected empty pGL3 vector that was set to 1. The 
statistical analysis was performed among three independent biological replicates. 
 
3.7 Animal experiments in zebrafish 
3.7.1 Maintenance and breeding 
Zebrafish husbandry and handling during the experimental procedures  were performed 
according to the guidelines of the Weizmann Institute Animal Care and Use Committee 
(Avraham-Davidi et al., 2012). 
All the zebrafish transgenic lines used in this study were previously described:  
Tg(fli1:EGFP)y1 (Lawson and Weinstein, 2002), Tg(fli1:gal4ubs3;uas:Kaederk8) (Herwig et 
al., 2011) and Tg(flt1_9a_cFos:GFP)wz2 (Nicenboim et al., 2015). d Tg(HuC/D:Gal4) 
(Faucherre and López-Schier, 2011)  
Zebrafish were raised and maintained as previously described in Westerfield, M The 
Zebrafish Book. A Guide for the Laboratory Use of Zebrafish (Danio rerio). In short, larvae 
and adult zebrafish were kept at 28°C in a 14h light/10h darkness cycle in an aquaculture 
system (Tecniplast). 
All the embryos used in this study were collected from natural spawning. For the natural 
breeding to take place, females and males were placed separately in false-bottom 
mating tanks in the evening. The next morning, the transparent divider was removed 
since the morning light is a natural stimulus to breed. 15-20 minutes after the removal 
of the separator, the fertilized eggs could be collected in egg water and be ready for 
injection or kept at 28°C till later stages. Around 4-6 hpf, the embryos were checked 
under the binocular and only viable eggs were selected for further experiments. Dead 
embryos were discarded. Depending on the purpose of the experiment, the embryos 
were raised in different water solutions: if the offspring needed to be raised till 
adulthood; the embryos were grown in zebrafish embryo medium containing methylene 
blue that inhibits mold growth in water. When the embryos were used for wholemount 
immunofluorescence of in situ hybridization, they were placed in 0,003% PTU (1-phenyl-
 
47 METHODS 
2-thiourea) to inhibit pigmentation. PTU is a chemical that blocks all the tyrosinase-
dependent steps during melanin synthesis.  
All the embryos used in the study were staged according to the somite number (Kimmel 
et al., 1995). 
 
3.7.2 Preparation of injection needles and plates 
The molds for injection wells were placed on top of petri dishes filled with 1% agarose 
in blue water and kept at 4°C till the injections. 
The needles were prepared from 1mm capillaries tubes with filament that were 
prepared using the needle puller to obtain an optimum shank. 
 
3.7.3 Injections 
For the injections, fine capillaries tubes, injection plates, micromanipulator and 
microinjector were used. First, the injection solution was loaded into the capillary and 
placed into the micromanipulator. The needle was broken using a gated pressure in the 
microinjector. The opening of the tip of the capillary was calibrated and the pressure 
time was modified accordingly till the injection volume was 1nl. The freshly collected 
embryos were arranged in the injection wells, oriented in a way that animal pole is 
opposite to the needle and injected at one-cell stage. 
The DNA constructs, Cas9 protein and transposase solutions were injected directly into 
the cell. RNA was injected into the yolk of the egg since it diffuses into the cell by 
cytoplasm streaming.  
 
3.7.4 Wholemount In situ Hybridization 
Probe synthesis 
Sense or antisense probes of junba or junbb (Ishida et al., 2010) were cloned into BSK 
plasmids, in vitro transcribed and DIG labelled using digoxigenin DIG RNA Labelling Kit 
(SP6/T7) according to manufacturer´s instructions. Newly transcribed RNA was then 
sedimented using 4M Lithium Chloride and cleaned by 70% alcohol washes at -20°C. RNA 
probes were loaded into an agarose gel for stability check and re-suspended in 
formamide-containing buffer. All probes were stored at -20°C. 
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Embryo preparation 
PTU-treated embryos staged at the age of interest were manually dechorionated and 
anaesthetized. They were placed on ice for 10 minutes and then fixed in cold 4% 
paraformaldehyde (PFA) in PBS-T overnight at 4°C with gently shaking. The day after, 
the embryos were quickly rinsed in PBS-T and dehydrated through a methanol/PBS-T 
gradient (25%, 50%, and 75%) for five minutes and stored in 100% methanol at -20°C. 
Probe Hybridization 
The wholemount protocol was based on the published protocol (Thisse et al., 2004). In 
short, the embryos were hydrated through a methanol gradient (75%, 50%, and 25%) 
and washed in PBS-T. The embryos were permeabilized with Proteinase K as follows. 
Stage Final Proteinase K Digestion time 
20 hpf 10 µg/µl 6 minutes 
24 hpf 10 µg/µl 6 minutes 
30 hpf 30 µg/µl 10 minutes 
 
The embryos were fixed again in 4% PFA and incubated in formamide-containing 
hybridization buffer for two hours. The probes were diluted accordingly in hybridization 
buffer and incubated at 68°C overnight. The embryos went through a series of washing 
steps at 68°C to remove the formamide (2x Saline sodium citrate Tween 20) SSCT-50% 
formamide, 2xSSC-T, 0,2x SSC-T) and incubated in blocking buffer with goat serum for 1 
hour at room temperature. 1:5000 sheep alpha-Digoxigenin Alkaline Phosphatase-
conjugated Fab fragments were then incubated with the embryos for 2 hours at room 
temperature with gentle shaking. Subsequently, the embryos were washed overnight. 
On the next day, later the embryos were shortly calibrated in staining solution before 
being developed in staining solution with NBT (4-Nitro Blue Tetrazolium)/BCIP(X-
Phosphate/5-Bromo-4-Chloro-3-indolyl-phosphate). The staining was controlled every 
half an hour and stopped according to the intensity of the staining. 
The embryos were washed and fixed and stored in glycerol until their imaging. Embryos 
were oriented in 1% methylcellulose and imaged using a binocular (Leica).  
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3.7.5 CRISPR design and mutant generation.  
Since zebrafish genes junba and junbb(junb-like) genes consist solely of one exon; the 
targeted area was designed to be at the beginning of the coding sequence using the 
CRISPR tool from the Zhang Lab (http://crispr.mit.edu/) and CHOP-CHOP design tool 
(http://chopchop.cbu.uib.no)(Labun et al., 2016). In addition, extra care was taken in 
order not to target highly conserved regions of other Jun family members and select 
CRISPR guide with less predicted off- targets effects. 
I designed individual oligos guide RNAs for each gene and oligos were annealed and 
ligated into pT7-gRNA plasmid (pT7-gRNA was a gift from Wenbiao Chen (Addgene 
plasmid # 46759, Jao et al., 2013). CRISPR gRNAs were in vitro transcribed using 
MEGAshortscript T7 kit AM1354 according to manufacturer's instruction and checked in 
an agarose gel for stability check. 
200 pg of guideRNAs were co-injected with Cas9 protein in one-cell stage embryo. A 
sample of the injected embryos was selected, and their genomic DNA was isolated prior 
PCR amplification using specific primers. Amplicons were separated into a high 
resolution 3% MetaPhor© agarose gel and injection was only considered successful 
when small differences in the amplicon size were observed as smear. Only then, the 
embryo batches were raised until adulthood. When the fish reached the age of 3 
months, and thus puberty, they were backcrossed to wildtype animals and their progeny 
was analyzed for germline transmission of the mutated junb allele. Single 24 hpf 
embryos were genotyped as described before. PCR amplicons were cloned into pGEMT 
plasmids and sequenced. Only fish carrying mutations resulting in a frameshift and 
premature STOP codon were selected as founders and were outcrossed to vascular 
reporter lines. 
 
3.7.6 junb-kalt4 reporter mutant 
A fragment of the junba sequence containing the CRISPR targeted area was amplified 
with specific primers and cloned into eGFPbait-E2A-KalTA4-pA donor vector addgene 
#61069 (Auer et al., 2014) by restriction enzyme free cloning. Successful insertion of the 
sequence was assessed by restriction enzyme digestion. 
This junba-Kalt4 construct was co-injected with Cas9 protein and junba gRNAs into one-
cell Tg(UAS:Kaede) zebrafish embryos. After Cas9 nuclease activity, concurrent cleavage 
of the genomic locus and the junba-Kalt4 plasmid occurred and the junba-Kalt4 donor 
plasmid was integrated into the genome by the homology-independent DNA repair 
machinery.  
 
 
50 METHODS 
3.7.7 Generation of overexpression vector 
junba and junbb coding frame was amplified from pGEMT vectors containing the junba 
and junbb sequences from zebrafish embryos. Specific primers were designed with 
flanking attB1 and attB2 sites. The amplicons were used in BP recombination with 
DONR221 plasmid. junba/junbb-DONR221 vectors were purified and sequenced. 
Previously designed constructs: 3’ attL4 UAS promoter attR1 vector, 5’ aatR2 E2A linker-
RFP attL3 vector and attL1 gene of interest attL2 DONR221 vector were LR recombined 
into a destination vector containing flanking Tol2 sites. This Tol2 sites allow the 
integration of the vector into the genome by the transposase action. 
Concurrent injection of 30µg the final construct UAS:GOI-E2A-RFP and 30µg transposase 
was injected into Tg(fli1:gal4ubs3) one-cell stage embryos. Efficacy of the construct 
injection was validated by fluorescence. 
 
3.7.8 Scoring and Morphological analyses of the embryos 
The quantification of the number of PACs, TD fragments and the analysis of the ectopic 
sprouts present in the embryos were performed analyzing the pictures of 3 dpf and 5 
dpf embryos. The embryos were raised in PTU and kept at 28ºC for their optimum 
development. Before the imaging, the embryos were shortly anaesthetized in 0.25% 
tricaine and immobilized and oriented in 6% methylcellulose. Confocal pictures of the 
trunk vasculature (the seven somites over the extension yolk) were taken for their 
analysis. 
PACs and TD fragments were considered complete when the structures could be easily 
identified and tracked between the somites. Absent PACs and TD fragments were 
considered when the lymphatic sprouts did not reach the horizontal myoseptum or 
when the structure looked incomplete respectively.  
The number of ectopic sprouts was quantified considering the dorsal part of the ISVs 
only. The sprouts were considered complete only when the sprout link to the 
neighboring somite was visible or disconnected when a space between the sprout tip 
cell and the neighboring ISV was observed. aISVs and vISVs were quantified tracking 
each ISVs to their origin. aISVs were considered when the ISVs were originated from the 
dorsal aorta and vISVs were considered when the ISVs was originated from the posterior 
cardinal vein.Blind quantification was performed in a single embryo basis prior 
genotyping of the analyzed embryos. 
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3.8 Imaging and imaging processing 
Zebrafish embryos submitted to WISH were imaged using a Leica M165 FC binocular. 
Zebrafish embryo confocal imaging was performed using a Zeiss LSM 710 and LSM 780 
upright confocal microscope with a W-Plan Apochromat 20x objective NA 1.0 and 
excited with a 488nm laser. In vivo time-lapse of the embryos was performed as 
previously described (Ben Shoham et al., 2012). A plastic chamber linked to a perfusion 
pump that regularly circulated temperature-controlled medium was placed in the stage 
of the microscope. In short, the dechorionated embryos were shortly anaesthetized in 
0.25% tricaine and oriented and immobilized in the plastic chamber containing 0.25% 
low melting agarose. Subsequently, the embryos were raised for 1 or 2 days in contact 
to a constant flow buffer containing tricaine and PTU and maintained at 28ºC to 
guarantee their proper development. Z-stacks of the embryo trunk were taken every 10 
minutes for 1-2 days.  
Fluorescence cell imaging of F9 cells was performed using a Nikon Eclipse Ti microscope 
and a 40x objective. Brightfield imaging of the mESCs was performed in an Olympus 1x51 
ZEISS ZEN microscope software and Fiji is Just Image J (FIJI) were used to analyze the 
time-lapse and the confocal pictures respectively. Z-projections based on the maximum 
intensity point were created for each confocal image. Brightness and contrast were 
modified accordingly and were performed equally in all the experimental groups. Grey 
LUT was modified when indicated in the text 
 
3.9 Statistical analysis 
The data were analyzed using unpaired two-tail Student test: ns (not significant) p>0.05, 
* p<0.05, ** p<0.01, *** p<0.001, ****p<0.0001. For in vitro cells, the analyses were 
performed among three biological replicates. For in vivo experiments, the sample 
number was selected considering previous experimental variability. 
For the in vivo data, the normal distribution and similar variance was assumed. For the 
analysis of fold change and relative gene expression, the data was normalized using a 
logarithmic transformation. For the luciferase reporter assay analysis, serial comparison 
of the mutant versions of the promoter respect the wildtype promoter was done with t-
test and Dunnett’s multiple comparison test. 
All startistical analysis was performed with Graph Pad software. All the data in graphs 
are displayed as mean ± SD. 
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4 RESULTS 
4.1 Role of JUNB in an in vitro LEC differentiation model. 
4.1.1 Optimization of a mESC differentiation protocol into LECs 
 4.1.2 JUNB activity is increased during "in vitro" LEC differentiation 
 4.1.3 Junb-/- mESC fail to form LEC-like cells 
 4.1.4 Junb-/- mESC fail to upregulate VEGFR2 during LEC differentiation 
 4.1.5 Surviving Junb-/-  mESCs form immature LEC-like cells. 
 4.2 Impact of Junb in lymphangiogenesis in Zebrafish 
 4.2.1 junba and junbb are differently expressed in zebrafish development. 
 4.2.2 CRISPR-Cas-mediated generation of junb mutants 
4.2.3 CRISPR-Cas junb mutants are fertile and reach adulthood. 
4.2.4 junb mutants partially phenocopy the morphants 
4.2.4.1 junb mutants display an allele-dependent loss of PACs 
4.2.4.2 junb mutants develop a normal thoracic duct 
4.2.5 junb mutants generate ectopic sprouts from 3 dfp until 5 dpf 
4.3 Outlook 
4.3.1 flt1 is a JUNB-direct target 
4.3.2 Generation of a gain of function mutant 
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4.1 Role of JUNB in an in vitro LEC differentiation model 
4.1.1 Optimization of a mESC differentiation protocol into Lymphatic 
Endothelial Cells 
Since both total and endothelial-specific Junb deletion results in embryonic lethality 
before lymphatic endothelial specification takes place (Schorpp-Kistner et al., 1999; 
Licht et al., 2006); an in vitro system of mESCs differentiation into LECs was implemented 
to investigate the role of JUNB in LEC specification. 
In vitro LEC differentiation has not been as widely attempted in the community as the 
differentiation of stem cells into other cell lineages. However, several teams have 
succeeded using different strategies such as the generation of embryoid bodies (Liersch 
et al., 2006; Kreuger et al., 2006) and the co-cultures of the stem cells with feeder-cells 
(Kusuma et al., 2013; Nicenboim et al., 2015). Unfortunately, neither of the published 
approaches were optimal for my aim: the variety of cells within the embryoid bodies 
hampers the study of specific cells throughout the process. Besides, the high basal JUNB 
expression levels in the feeder cells complicates the monitoring of the JUNB induction 
kinetics during LEC differentiation.  
Therefore, since maintaining mESCs under feeder-free conditions does not affect their 
proliferation or differentiation potential (Tamm et al., 2013), I aimed to develop a 
feeder-free LEC differentiation protocol.  
Similarly to other described methods, this in vitro protocol targets the lymphatic 
differentiation via a mesoderm differentiation step recapitulating the in vivo process. In 
short, the presented protocol consists of three steps: i) expansion of stem cells under 
undifferentiated conditions, ii) spontaneous differentiation towards mesoderm and 
angioblast formation and iii) LEC-directed differentiation (Figure 4-1) 
In the first step, the mESCs were cultured under stem cells conditions for 3 passages. 
During this period, the cells were maintained at low confluency to avoid cell-cell contact 
and further differentiation in the presence of Leukemia Inhibiting Factor (LIF). Thus, 
mESCs were passaged every other day and LIF-containing medium was changed daily. 
After this first period, the cells were deprived from LIF for 6 consecutive days to trigger 
a spontaneous differentiation towards mesoderm. The cell density was adapted in 
comparison with other reports so the culture could be passaged every other day and 
medium was daily refreshed.  
Finally, the last part of the protocol aimed for a lymphatic endothelial specific 
differentiation step with a combination of stimuli from different protocols.  
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Figure 4-1: Feeder-free mESC differentiation protocol into Lymphatic Endothelial Cells.  
Schematic representation of the feeder-free LEC differentiation protocol. mESCs were expanded for six 
days in the presence of LIF prior differentiation towards mesodermal vascular precursors. Vascular 
progenitors were subjected to a growth factor and inhibitors cocktail to trigger a LEC-specific 
differentiation. 
Kreuger et al., (2006) described that solely addition of either VEGF-A or VEGF-C lead to 
the formation of a LYVE1+ cells, although a combination of these two stimuli resulted in 
a synergistic effect. In addition, Vittet et al., (2012) showed that TGFβ1 reduced the 
expression of key lymphatic transcriptional regulators Nr2f2 (Coup-TfII) and Sox18 in a 
stem cell model. This effect could be chemically reverted by adding an inhibitor of the 
TGFβ1 signaling, SB421356, to the medium. Thus, in order to  potentiate the LEC 
differentiation, the cells were kept in culture in endothelial-specific medium 
supplemented with a cocktail of growth factors, 100ng/ml of VEGF-C and 10µM of 
SB421356 every 48 hours. 
Visual control of the cells by phase-contrast microscopy revealed that the cells adapted 
well to the surface of the dishes throughout the experiment. During the first expansion 
step, the cells grew as organized colonies feeder-free on the gelatin-coated dishes. Later 
on and in the absence of LIF, the cells at the edges of the colonies began to differentiate 
and by the fourth day, they lost their 3D structure and remained as a monolayer 
morphologically resembling to mesenchymal stem cells. After the addition of the stimuli 
for the endothelial cell-directed differentiation, most cells displayed a more cobblestone 
morphology, more endothelial-like appearance and endothelial cell islands were 
observed (Figure 4-2 A). 
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It has been reported that a population of mesodermal cells spontaneously expresses 
VEGFR2 after 4 days without LIF (Hirashima et al., 2003). These VEGFR2+ cells are 
considered to be the vascular progenitors or angioblasts that are stimulated by 
mesenchymal signals. The presence of these VEGFR2+ cells is then a key step to 
guarantee that the cells will be stimulated during the endothelial cell-specific 
differentiation.   
In order to analyze the purity of the VEGFR2+ population, cells deprived of LIF for four 
days (SD 4-LIF) were stained for VEGFR2 and analyzed by flow cytometry. Around 60% 
of the analyzed cells exhibited a high expression of VEGFR2 indicating the high efficiency 
of the protocol and excluding the necessity of an additional purification step as 
suggested in other protocols (Figure 4-2 B).  
 
 
Figure 4-2: Validation of a feeder-free three-step mESCs differentiation protocol into LECs.  
A) Representative phase-contrast pictures of the mESCs throughout the differentiation process: mESCs 
expansion, day 4 of the spontaneous differentiation (SD 4-LIF) and endpoint of the LEC differentiation. 
Black arrowheads point to the mESCs colonies and dashed lines mark the EC island.Scale bar 200 µm upper 
panel and 100 µm lower panel B) Flow cytometry density plot showing a shift in the VEGFR2+ population 
at the expansion step and after 4 days in the absence of LIF. Histograms depict the increase in the VEGFR2+ 
population at the mESC expansion step and at the fourth day of the spontaneous differentiation step (SD 
4-LIF). 
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To further prove that the protocol successfully led to cells of the lymphatic lineage, the 
expression of several markers from undifferentiated and differentiated LECs were 
investigated throughout the process. As expected, a gradual decrease of the markers 
indicative for undifferentiated ES cells (Oct3/4, Sox2, Nanog and c-Myc) was detected 
during the spontaneous differentiation and their expression was minimal at the 
endpoint of the experiment (Takahashi and Yamanaka, 2006) (Figure 4-3A). In addition, 
expression of early LECs markers such as Nr2f2 (Coup-tfII), Sox18 and Prox1 were 
detected prior to the known late markers Lyve1, Vegfr3 and Podoplanin. Prox1 levels 
significantly rose during the spontaneous differentiation (SD 4-LIF) and were 
significantly maintained (15x fold higher compared to the undifferentiated mESCs) at 
the LEC endpoint step. As expected, Lyve1 and Podoplanin expression levels significantly 
peaked (40x fold and 7x fold respectively) at the endpoint of the experiment (Figure 4-
3 B). 
 
Figure 4-3: Expression switch from stem cells to lymphatic markers during the “in vitro” LEC 
differentiation.  
A) Relative expression of stem cells markers : Sox2, Oct3/4 and Nanog and  B) LEC markers: Prox1, Lyve1 
and Podoplanin at three different steps of the differentiation protocol: end of mESCs expansion, day 4 of 
the spontaneous differentiation (SD 4-LIF) and LEC endpoint. mRNA levels of the genes of interest were 
analyzed by qRT-PCR and normalized to the expression of Rplp0. Fold change is shown relative to their 
expression at the expansion step which was set to 1.The lines and error bars refer to mean ± SD of three 
independent experiments N=3. Statistical analysis was performed using unpaired two-tailed t-Student 
test. ns (not significant) p>0.05, * p<0.05, ** p<0.01, *** p<0.001, ****p<0.0001. 
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In summary, differentiation of feeder-free mESCs into LEC was possible and the applied 
cell densities and chosen stimuli and concentrations were appropriate to achieve LEC-
like cells that express LEC-specific markers. 
 
4.1.2 Junb levels are increased during in vitro LEC differentiation 
In order to assess whether JUNB is important for LEC differentiation, its induction levels 
were monitored at different stages of the process. For this purpose, total RNA and whole 
cell protein were isolated and subjected to gene expression and protein analyses, 
respectively. 
Both Junb transcript and protein levels were significantly upregulated during the 
differentiation process although they presented different intensity and induction 
kinetics. Junb transcripts continuously increased throughout the entire process in a 
moderate manner (around 2x fold during the spontaneous differentiation and 3x fold in 
the endpoint). JUNB protein, was first undetectable in undifferentiated cells and then 
displayed a sudden and strong induction upon deprivation of LIF for 4 days during the 
spontaneous differentiation (SD 4-LIF). These high protein levels were maintained 
throughout the spontaneous differentiation process. In the last step, JUNB levels 
diminished although the phosphorylated isoform was still detectable (Figure 4-4). 
 
Figure 4-4: JUNB is induced during in vitro LEC differentiation at the transcript and protein level.  
A) Relative Junb expression in mESCs differentiated to LECs determined by qRT-PCR. Junb mRNA levels 
were normalized to Rplp0 expression and depicted as fold change relative to the starting point at which 
Junb expression was set to one. The lines and error bars refer to mean ± SD of three independent 
experiments N=3. Statistical analysis was performed using unpaired two-tailed t-Student test. p-value * 
p<0.05. B) Representative western blot of JUNB levels in mESCs submitted to in vitro LEC differentiation: 
mESC expansion, spontaneous differentiation (SD 2-LIf), (SD 4-LIF) and (SD 6-LIF) and LEC endpoint. 
Cyclophilin A (PPIA) was used as control for equal quality and loading of protein extracts. 
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These results are consistent with the starting hypothesis of JUNB controlling LEC 
formation. The protein data suggest that JUNB is even playing a role at earlier time 
points since JUNB is induced during the spontaneous differentiation (SD 4-LIF) when the 
vascular progenitors express VEGFR2. 
 
4.1.3 Junb-/- mESCs fail to form LEC-like cells 
 
Next, I asked whether the presence of Junb is essential for the generation of the vascular 
progenitors in the first place and ultimately on fully differentiated LEC cells. In order to 
assess this, parallel studies were performed on Junb+/+ and Junb-/- mESCs (Schorpp-
Kistner et al., 1999; Schmidt et al., 2007) 
Morphological inspection of the cells by phase-contrast microscopy revealed that 
Junb+/+ and Junb-/- mESCs were visually indistinguishable in the non-differentiated status 
until the spontaneous differentiation (SD 4-LIF) (Figure 4-5). 
 
 
Figure 4-5: Junb+/+  and  Junb-/- mESCs behaved similarly during the first steps of LEC differentiation.  
 
A) Genotyping of the mESCs by PCR amplification of the Junb locus. Neomycin/Hygromycin cassettes 
insertion in the Junb-/- cells are detected. B) Representative phase-contrast microscopy pictures showing 
no morphological differences between the two cell types at several stages of the differentiation: 
undifferentiated mESC expansion and day 4 of the spontaneous differentiation (SD 4-LIF). Lower panels 
are magnifications of the middle panels. Scale bar 200 µm upper and middle panel and 100 µm lower 
panel 
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Since JUNB is known to control the cell cycle in different phases by activating p16 and 
and CyclinA and repressing CyclinD1 (Passegué and Wagner, 2000; Andrecht et al., 2002; 
Bakiri et al., 2000) a closer look into the proliferation rate was given. For that, the cell 
number was measured every 2 days and doubling time was calculated. No difference in 
the doubling time in the analyzed cells from the undifferentiation step up to day 4 of the  
spontaneous differentiation (SD 4-LIF) was appreciated. 
These data were in line with other publications which showed that loss of Junb did not 
affect the overall turnover of the population (Passegué et al., 2001).  
Surprisingly, there was a very striking difference between the cells at day 6 of the 
spontaneous differentiation (SD 6-LIF). At that time, Junb-/- cells succumbed to a major 
cell crisis manifested by a very abrupt drop of cell numbers (Figure 4-6 A). 
 
 
Figure 4-6: Junb -/- mESCs exhibited increased apoptosis rate during LEC differentiation.  
 
A) Cell doubling time of Junb +/+ and Junb -/- mESCs during early LEC differentiation. Each point represent 
the mean±SD of biological triplicates. B) Quantification of the apoptotic cells at day 6 of the spontaneous 
differentiation (SD 6-LIF) and at the endpoint of the LEC differentiation. Bars represent mean±SD of 
biological triplicates. Asterisks mark statistical significance p<0.05 unpaired student t-test ** p<0.01 and  
****p<0.0001 C) Flow cytometry histograms of Annexin V+ populations in differentiating Junb+/+ and   
Junb-/-  cells respectively. In all cases, black dots and graphs refer to Junb+/+ and red dots and graphs refer 
to Junb-/- cells. 
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To further investigate this loss in Junb-/- cells, the presence of apoptotic/Annexin V+ cells 
was analyzed by flow cytometry.  
Serial comparison of Annexin V+ populations between Junb+/+ and Junb-/- cells showed 
no difference in the apoptosis rate during the expansion of the undifferentiated cells. 
However, there was a significant increase in the apoptotic cell population at the day 6 
of the spontaneous differentiation (SD 6-LIF). This difference was more pronounced 
when the surviving Junb-/- cells were submitted to the LEC directed differentiation step 
and analyzed at the end point of the differentiation (Figure 4-6B C). 
These data suggest that Junb induction at day 4 of spontaneous differentiation is rather 
necessary for cell survival than for cell proliferation. 
 
4.1.4 Junb-/- mESC fail to upregulate VEGFR2 during LEC differentiation 
Since Junb-/- mESCs showed an increased apoptosis rate during LEC differentiation; a 
closer look on the main survival signaling pathways in endothelial cells was taken. In 
endothelial cells, the survival cascade is mediated by PI3K/AKT phosphorylation via 
stimulation of Neuropilin, Fibroblast Growth Factor Receptors or Vascular Endothelial 
Growth Factor Receptors (Gerber et al., 1998).  
Since the growth factors VEGF-A and VEGF-C were used as specific stimuli used in the 
differentiation protocol, the focus was directed towards their respective tyrosine kinase 
receptors. VEGF-A is a ligand of VEGFR1 and VEGFR2 and VEGF-C is able to bind and 
activate both VEGFR2 and VEGFR3. While VEGFR1 and VEGFR2 are key regulators for 
vasculogenesis as well as blood endothelial differentiation, VEGFR3 is critical for 
lymphatic endothelial differentiation (Shibuya, 2011; Alitalo et al., 2005). 
Thus, the focus was on these receptors and I aimed to investigate whether there is any 
imbalance in the expression levels of these receptors during the differentiation process. 
Therefore, Vegfr1 and Vegfr2 RNA and protein levels were assessed by qRT-PCR and 
western blot respectively.  
In Junb+/+ mESCs, VEGFR1 and VEGFR2 were detected as expected from literature and 
my previous optimization experiments, thus, confirming the correct course of the 
differentiation process. Importantly, in Junb-/- mESCs the expression of both receptors 
was found to be impaired when compared to the wildtype cells. Vegfr1 transcript levels 
in both Junb+/+- and Junb-/- cells were similar at the SD 4-LIF phase. However, VEGFR1 
protein levels were already reduced in the expansion phase but still induced upon 
spontaneous differentiation, yet to a slightly lesser extent when compared to wildtype 
cells. 
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Intriguingly, Vegfr2 was not induced upon differentiation on both RNA and protein levels 
in Junb-/- cells. Vegfr2 transcript levels were significantly reduced (4x) in Junb-/- cells. At 
the protein level, no induction of VEGFR2 was observed at the spontaneous 
differentiation step suggesting that Junb-/- mESCs are impaired to generate VEGFR2+ 
vascular progenitors during spontaneous differentiation (Figure 4-7).  
 
Figure 4-7: Expression of both VEGFR1 and VEGFR2 is affected in Junb-/- mESCs during spontaneous 
differentiation. 
A) Vegfr1/Vegfr2 transcript levels were assessed by qRT-PCR  and normalized to the expression of Rplp0. 
Expression levels were normalized to those of Rplp0 and wildtype levels at the expansion time point were 
set to 1. Black and red dots refer to Junb+/+ cells and Junb-/- cells respectively. The lines and error bars mark 
the mean± SD of biological triplicates N=3. B) Representative western blot for VEGFR1,VEGFR2 and JUNB 
during LEC differentiation. Cyclophilin was used as loading control for equal quality and quantity of loaded 
proteins.C) Quantification of the protein levels in the western blots among biological triplicates at the 
spontaneous differentiation step (SD 4-LIF). Bars and error lines mark the mean± SD. Asterisks mark 
statistical significance by unpaired student t-test: ns (not significant), * p<0.05 and  ** p<0.01. 
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In order to assess whether the impairment in Vegfr1 and Vegfr2 expression could be due 
to the loss of the transcriptional regulator function of JUNB, I first aimed to recapitulate 
these results in a distinct cell type, namely murine endothelioma cells. These cells are 
fully differentiated immortalized endothelial cells in which either one or two alleles of 
Junb were deleted (END72 Junb+/- and END70 Junb-/-). They were previously generated 
in the lab from the Junb embryos isolated at midgestation and subsequently 
immortalized by retroviral transduction of PymT (Licht et al., 2006).  
These cells displayed similar expression of endothelial surface markers CD31 and CD105  
regardless of their genotype and have been used for validation of other JUNB targets in 
the past (Licht et al., 2006) (Figure 4-8).  
 
Figure 4-8: Transformed murine endothelioma cells lacking one or two Junb alleles display similar 
expression of endothelial markers CD105 and CD31. 
A) Genotype of the endothelioma cells ( END 72 Junb+/- and END 70 Junb-/-) used in this study by PCR 
amplification of the Junb locus. Neo cassette insertion in the Junb +/- was detected. B) Flow cytometry 
histograms for CD105 and CD31 endothelial markers in comparison with unstained control. 
Total RNA and protein isolates from these cells were obtained and analyzed for Vegfr1 
and Vegfr2 expression. 
Indeed, endothelioma cells lacking Junb expressed lower levels of both receptors at the 
transcript and protein level. Similarly to the observations in mESCs, both Vegfr1 and 
Vegfr2 transcripts levels were significantly reduced in Junb-/- endothelioma cells in 
comparison to Junb+/- cells. At the protein level, the results confirmed the mESCs data: 
while a mild although significant VEGFR1 decrease was observed, VEGFR2 protein levels 
were diminished by more than 50% in Junb-deficient endothelioma cells (Figure 4-9).  
Taken together, these data strongly suggest that Vegfr1 and Vegfr2 are JUNB-regulated.  
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Figure 4-9: Diminished VEGFR1 and VEGFR2 expression in Junb -/- endothelioma cells.  
A) Relative expression of Vegfr1 and B) Vegfr2 transcript levels assessed by qRT-PCR and normalized to 
Rplp0. Fold change is depicted relative to expression levels in murine endothelioma END Junb+/- cells which 
were set to 1. C) Representative western blot for VEGFR1,VEGFR2 and JUNB in endothelioma cells. 
Cyclophilin A was used as control for equal quality and loading of protein extracts. D) Quantification of 
protein levels from western blots of biological triplicates N=3. Bars and error lines mark the mean±SD. 
Asterisks mark statistical significance by unpaired Student t-test. * p<0.05, ** p<0.01 and *** p<0.001. 
Black dots and  black-pattern columns refer to Junb+/- cells and red dots and columns refer to Junb-/- 
endothelioma cells. 
 
 
 
 
 
 
 
 
66 MATERIALS 
4.1.5 Surviving Junb-/- mESCs form immature LEC-like cells 
The small percentage (around 30%) of Junb-/- mESCs that survived up to the sixth day of 
the spontaneous differentiation (SD 6-LIF) was subjected to the final step of the 
differentiation. In the presence of endothelial growth factors and VEGF-C as stimulus, 
most of the Junb-/- mESCs survived until the LEC endpoint.  
In order to investigate whether the surviving cells properly differentiated into mature 
LECs, gene expression analysis for the key lymphatic markers was performed. Expression 
of  Prox1, Lyve1 and  Podoplanin revealed no differences as their transcript levels 
increased throughout the differentiation process at similar rates in Junb -/- and Junb+/+ 
mESCs (Figure 4-10).  
 
Figure 4-10: Junb+/+ and Junb-/- LEC-like cells express comparable levels of lymphatic markers transcripts. 
A) Relative expression of Prox1, Lyve1 and Podoplanin transcript levels assessed by qRT-PCR and 
normalized to Rplp0. Fold change of expression at the LEC endpoint relative to the mESCs expansion 
timepoint which was set to 1 is depicted. Lines and error bars mark the mean±SD among three biological 
triplicates (N=3). Statistical analysis was performed using unpaired two-tailed t-Student test: ns (not 
significant). Black dots and red dots refer to Junb+/- cells and Junb-/-  cells respectively. 
In addition, the  reduced transcript and proteins levels of the vascular receptors Vegfr1 
and Vegfr2 observed in the Junb -/- cells during the spontaneous differentiation (SD 4-
LIF), were no longer observed. In fact, the addition of the lymphatic stimuli in Junb-/- 
vascular progenitors restored the expression of these receptors to levels similar to those 
of the Junb+/+ cells (Figure 4-11 A-B). 
Considering that a significant increment in apoptosis was observed in Junb-/- cells at both 
spontaneous differentiation and LEC endpoint but the decrease on VEGFR1 and VEGFR2 
was detected only in the former one; I wondered whether the expression levels of other 
receptor were impaired. At this later stage of the differentiation, the cells have turned 
into LEC-like cells and the main signaling is via VEGFR3 activation. Thus, I analyzed the 
expression of receptor Vegfr3 and its ligand Vegf-C. 
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It was found out that in the Junb-/- cells, Vegfr3 and Vegf-c transcript levels were 
significantly decreased. This lack of Vegfr3 in Junb-/- cells is in line with the defects on 
survival pathway observed previously (Figure 4-11 C-D). 
Taken together, these data suggest that the minority of the surviving Junb-/-   cells 
differentiated into more immature and less-responsive to VEGF-C lymphatic cells   
 
Figure 4-11: Surviving Junb-/- cells generate immature LEC-like cells in the presence of endothelial 
stimuli.  
A) Representative western blot of the VEGFR1 and VEGFR2 upregulation throughout the differentiation 
process (mESC expansion and endpoint) in the presence of endothelial stimuli in Junb+/+ and Junb-/- mESCs. 
Cyclophilin A was used as control for equal quality and loading of protein extracts. B) Transcript levels  of 
Vegfr1 and Vegfr2 were restored upon lymphatic stimulation. mRNA levels were normalized to Rplp0 
levels and depicted as fold change. C) Schematic representation of the obtained LEC-like cells at the 
endpoint. D) Transcript levels  of Vegfr3 and Vegfr-C were significantly reduced in the surviving LEC-like 
cells. mRNA levels were normalized to Rplp0 levels and depicted as fold change. Lines refer to mean±SD 
among biological triplicates (N=3). Asterisks mark statistical significance by unpaired Student t-test. ns 
(not significant), * p<0.05 and ** p<0.01. 
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4.2 Impact of Junb in lymphangiogenesis in Zebrafish 
Our previous studies in zebrafish embryos with transiently suppressed junb (Kiesow et 
al., 2015) as well as the in vitro mESC differentiation data strongly suggested that JUNB 
is critically implicated in the developmental process of lymphangiogenesis. To further 
investigate the function of Junb in lymphangiogenesis in vivo , I used the zebrafish model 
to i) track the junb expression dynamics during embryo development, ii) generate novel 
loss-of-function mutants and iii) characterize lymphatic vessel development at the 
embryo stage in the absence of Junb. 
4.2.1 junba and junbb are differently expressed during early zebrafish 
development. 
In zebrafish, a whole-genome duplication took place during the evolution of teleost 
ancestors (before the divergence of zebrafish, pufferfish and medaka lineages) (Amores 
et al., 1998; Meyer and Málaga-Trillo, 1999; Meyer and Schartl, 1999). As a result of this, 
there exist two Junb paralogues in zebrafish− the junba (junb) and junbb (junb-like) 
genes−(Figure 4-12A). 
junba and junbb are located on different chromosomes (chromosome 1 and 3, 
respectively) but they share about 71% identity in their gene sequence. Multiple 
sequence alignment shows that, besides several other areas, the 5’ segment of both 
genes is especially highly conserved with regard to the murine and human Junb gene. At 
the protein level, they comprise domains similar to mouse and human protein: a JNK-
binding domain, a bZIP domain for DNA binding and leucine zipper for dimerization. 
(Figure 4-12 B-C). 
In order to determine which of the two paralogues is relevant for lymphatic 
development, I aimed to track the expression pattern of these genes during early 
zebrafish development by qRT-PCR and Whole mount In Situ Hybridization (WISH).  
For qRT-PCR analyses, RNA from whole wildtype embryo was isolated at specific time 
points of development : the 5-somites stage (early timepoint prior to vasculogenesis), 
16 hpf (start of LEC specification at the PCV), 24 hpf (formation of first main vessels), 30 
hpf (formation of ISVs and lymphatics sprouts), 48 hpf (first rise of PACs) and 72 hpf 
(completion of PACs) (Padberg et al., 2017). 
It was observed that junba and junbb displayed different expression patterns and 
kinetics. While junba levels were quite low with maximal expression at very early 
timepoints, the 5-somite stage and the 20 hpf, and then gradually decreased with time. 
junbb levels has their peak at 20hpf (5x fold increase compared to 5-somites time point) 
and then stayed at a moderate level (2x fold change respect the starting point) until 72 
hpf (Figure 4-13A). 
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human           ATGTGCACTAAAATGGAACAGCCCTTCTACCACGACGACTCATACACAGCTACGGGATACGGCCGGGCCCCTGGTGGCCTC 
mouse           ATGTGCACGAAAATGGAACAGCCTTTCTATCACGACGACTCTTACGCAGCGGCGGGATACGGTCGGAGCCCTGGCAGCCTG            
junba           ATGTCAACAAAAATGGAGCAACCGTT---TTATGACGACTCGTTTCTTTCT---------GCTTATGGTCATCCAGACGCT 
junbb           ATGAGTACAAAAATGGAGCAGCCGTTTTACCACGACGACTCGTTTCTGTTG---------GGTTACGGTCACAACGACGCG 
 
human           TCTCTACACGACTACAAACTCCTGAAACCGAGCCTGGCGGTCAACCTGGCGGACCCCTACCGGAGTCTCAAAGCGCCTGGG  
mouse           TCTCTACACGACTACAAACTCCTGAAACCCACCTTGGCGCTCAACCTGGCGGATCCCTATCGGGGTCTCAAGGGTCCTGGG  
junba           GCCCTGCACGACTACAAGCTCCTAAAGCAGAACATGAGCGTGAGCTTCGCCGAACCCTACCGGAACCTCAAGACCCTCC--  
junbb           GCTCTACACGACTACAAACTCCAGAAACCGGGCATGAACTTGAACGTGACCGAGCCGCCCT------------ATCGGA-- 
                  
human           GCTCGCGGACCCGGCCCAGAGGGCGGCGGTGGCGGCAGCTACTTTTCTGGTCAGGGCTCGGACACCGGCGCGTCTCTCAAG  
mouse           GCGCGGGGTCCAGGCCCGGAGGGCAGTGGGGCAGGCAGCTACTTTTCGGGTCAGGGATCAGACACAGGCGCATCTCTGAAG 
junba           ----------------------------GCTCCGAAATCGACTTCTACACAGCGGCGACCGGAGACGTGGGCTCGCTGAAA  
junbb           ----------------------------GCCTCAAATCGGACCTCTATCAGGCGTCCAGCGCCGATGTGGGCTCACTCAAA  
                  
human           CTCGCCTCTTCGGAGCTGGAACGCCTGATTGTCCCCAACAGCAACGGCGTGATCACGACGACGCCTACACCCCCGGGACAG  
mouse           CTAGCCTCCACGGAACTGGAGCGCTTGATCGTCCCCAACAGCAACGGCGTGATCACGACGACGCCCACGCCTCCGGGACAG  
junba           CTCGCCTCTCCGGAGCTGGAGAGACTCATCATCCAGAACGGTAACGGCGTCATCACATCACCCACGCC-------------  
junbb           CTGGCCTCCCCGGAGCTGGAGAGGCTCATCATCCAGACGGGCAACGGCGTGCTGACGACCCCCACACC-------------  
                                        
human           TACTTTTACCCCCGCGGGGGTGGCAGCGGTGGAGGTGCAGGGGGCGCAGGGGGCGGCGTCACCGAGGAGCAGGAGGGCTTC  
mouse           TACTTTTACCCCCGTGGGGGTGGCAGCGGTGGAGGTACAG---------GGGGCGGCGTCACCGAGGAGCAGGAGGGCTTT  
junba           --------------------------------GGGGCAGTATTTGTACGGTCGGAGCATCACAGAGGAGCAAGAGGGCTTC 
junbb           --------------------------------GGGCCAGTACCTCTACGGTCGGGGGATCACCGACGAGCAGGAGGGCTTC  
 
human           GCCGACGGCTTTGTCAAAGCCCTGGACGATCTGCACAAGATGAACCACGTGACACCCCCCAACGTGTCCCTGGGCGCTACC  
mouse           GCGGACGGTTTTGTCAAAGCCCTGGACGACCTGCACAAGATGAACCACGTGACGCCCCCCAACGTGTCCCTGGGCGCCAGC  
junba           GCGGACGGATTCGTCAAAGCGCTGGACGAGCTCCACAAAATGAACCAAATGCCCCCGCCGAACGTGTCCATCGGAGCCCCC  
junbb           GCGGAGGGCTTCGTCAAGGCTCTGGATGAGCTCCACAAGATGAACCAGATGCCCCCGCCCAACGTGTCGATTGGAGCCGGC 
   
               
human           GGGGGGCCCCCGGCTGGGCCCGGGGGC---------GTCTACGCCGGCCCGGAGCCACCTCCCGTTTACACCAACCTCAGC  
mouse           GGGGGTCCCCAGGCCGGCCCAGGGGGC---------GTCTATGCTGGTCCGGAGCCGCCTCCCGTCTACACCAACCTCAGC  
junba           GGGGTGTCGAGTTGTTCGGTGGCGTCGTCAGTCTTCGGCGCCTCCTTACCGCCCGAGACTCCGGTGTACACCACCCTGAAC  
junbb           GGCGTGACGACGTGCTCGACAACTGCGTCCGTTTTCGGCTCCTCCCTGCAGTCGGAGCCTCCCATTTACACGACGCTGAAC  
                
human           AGCTACTCCCCAGCCTCTGCGTCCTCGGGAGGCGCCGGGGCTGCCGTCGGGACCGGGAGCTCG-------------TACCC  
mouse           AGTTACTCCCCAGCCTCTGCACCCTCTGGAGGCTCCGGGACCGCCGTCGGGACTGGGAGCTCA-------------TACCC  
junba           AGCTGCAATCCTAACACTAACCTCACACCTGCAGCCAACTACCCGACAGCCACCATCAGCTACCTGCCTCACCATCACCAC  
junbb           GCATACTGCCCAGCACCC------------------AGCCACCGTCCACCCACCATCAGCTACCTGCCGTCCCACATACAG  
 
human           GACGACCACCATCAGCTACCTCCCACACGCGCCGCCCTTCGCCGGTGGCCACCCGGCGCAGCTGGGCTTGGGCCGCGGCGC  
mouse           GACGGCCACCATCAGCTACCTCCCACATGCACCACCCTTTGCGGGCGGCCACCCGGCACAGCTGGGCTTGAGTCGCGGCGC  
junba           CACCAGCAGTACCACCACCATCA-CCACCAGCCCACGCCGCATCCTCATCACTTCCAGCACTCGCTCCATCCGCAGCGGCT  
junbb           CAGAGCCAGCACCCG------GA----------AACC---GCGCACGCGTTCCAGCACCCCGGCGTGCTCCCCCAGCGCTT  
 
human           CTCCACCTTCAAGGAGGAACCGCAGACCGTGCCGGAGGCGCGCAGCCGGGACGCCACGCCGCCGGTGTCCCCCATCAACAT 
mouse           TTCCGCCTTTAAAGAGGAACCGCAGACCGTACCGGAGGCACGCAGCCGCGACGCCACGCCGCCTGTGTCCCCCATCAACAT  
junba           CGTTACTCTGAAAGAGGAGCCACAGACCGTCCCCGACCTGCAGAGCAGCGATGGTTCTCCTCCCATGTCGCCCATCGACAT 
junbb           CTTGCCTTTAAAAGAGGAACCGCAGACTGTTCCCGACATGCATAGCAGCGACGGCTCGCCGCCCATGTCCCCGATCGACAT  
 
human           GGAAGACCAAGAGCGCATCAAAGTGGAGCGCAAGCGGCTGCGGAACCGGCTGGCGGCCACCAAGTGCCGGAAGCGGAAGCT  
mouse           GGAAGACCAGGAGCGCATCAAAGTGGAGCGAAAGCGGCTGCGGAACAGGCTGGCGGCCACCAAGTGCCGGAAGCGGAAGCT  
junba           GGAGGACCAGGAGCGCATCAAAGCGGAGCGCAAGAGGCTCCGGAACCGACTGGCGGCCACCAAGTGCCGGCGACGGAAGCT  
junbb           GGACTCGCAGGAACGCATCAAGGCGGAACGCAAGAGGCTCCGGAACCTACTGGCGGCCACCAAATGCCGAAGGCGCAAACT  
 
human           GGAGCGCATCGCGCGCCTGGAGGACAAGGTGAAGACGCTCAAGGCCGAGAACGCGGGGCTGTCGAGTACCGCCGGCCTCCT  
mouse           GGAGCGCATCGCGCGCCTGGAGGACAAGGTGAAGACACTCAAGGCTGAGAACGCGGGGCTGTCGAGTGCTGCCGGTCTCCT  
junba           GGAGCGCATCTCCCGGCTGGAGGACAAAGTGAAAGTGCTCAAGTCGGATAACGCCGGACTGTCCAGCACTGCGTCCCTGCT  
junbb           AGAACGCATCGCGCGGCTGGAGGAAAAGGTGAAGGTACTGAAGTCCGACAACGCCGGACTGTCCAACACAGCGTCTGTTCT 
  
              
human           CCGGGAGCAGGTGGCCCAGCTCAAACAGAAGGTCATGACCCACGTCAGCAACGGCTGTCAGCTGCTGCTTGGGGTCAAGGG  
mouse           ACGGGAGCAAGTGGCGCAGCTCAAGCAGAAGGTCATGACCCATGTCAGCAACGGCTGCCAGTTGCTGCTAGGGGTCAAGGG  
junba           GAGGGAGCAGGTAGCTCAGCTTAAGCAGAAGGTCATGACCCATGTGAGCAGCGGGTGCCAGCTGATGCTGACGCCCAAGAT  
junbb           GCGGGAACAGGTGGCGCAACTCAAGCAGAAGGTCCTGAGGCACATGAACAGCGGCTGTCAGCTCATGCTGACCAGTAAGAT  
                 
human           ACACGCCTTCTGA 
mouse           ACACGCCTTCTGA  
junba           CAAGTCGTTTTAG 
junbb           GGAGGCGTTTTAA  
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Figure 4-12: junba and junbb paralogues share sequence homology with their murine and human 
orthologues. 
A) Phylogenetic tree obtained from the alignment and comparison of human, murine and zebrafish junb 
coding sequences. This cladogram is a Neighbour -joining tree without distance corrections. B) Summary 
table comprising the location and size of the transcripts and proteins of the two Junb paralogues in 
zebrafish. C) Multiple nucleotide sequence alignment of human, murine and zebrafish junb sequences 
revealed high sequence conservation at the 5’ area. Red font marks the conserved nucleotides among the 
four sequences. Yellow shade marks the start and end of the coding sequence. 
Furthermore, wildtype zebrafish embryos isolated at the most relevant time points for 
LEC specification (20 hpf, 24 hpf and 30 hpf) were subjected to WISH using specific 
probes. Expression of these two genes in eyes, lenses and brain could be observed and 
was in line with previously described data (Thisse et al., 2004; Kiesow et al., 2015). 
However, a closer look into the truck area revealed a distinct expression pattern for the 
two paralogues.  
junba is expressed in the ventral part of the embryo around 20 hpf and 24 hpf. At this 
latter timepoint, it is quite ubiquitously distributed and it is seen in many other tissues 
as, for example, in the tip of the tail. At 30 hpf and in line with the expression data 
obtained from the qRT-PCR, nearly no or unspecific signal was detected.  junbb is also 
expressed in the ventral part of the trunk around 20hpf. From 20 hpf until 24 hpf a strong 
signal in the pronephric area that could correspond to the zebrafish blood island was 
observed (Figure 4-13 B). 
These data suggest distinct roles of junba and junbb during zebrafish development. 
While junba seems to play a role in the earliest steps of embryonic development, junbb 
rather seems to be required for later stages. The fact that both genes are expressed to 
some extent in the vein and around the time when lymphangiogenesis takes place, 
prompted me to address the impact of each gene on this process separately. 
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Figure 4-13: Differential expression of junba and junbb in time and space during zebrafish development.  
A) Relative expression of junba (left graph, green marks) and junbb (right graph, purple marks) during the 
first three days of development of zebrafish embryo: 5-somites, 20 hpf, 24 hpf, 30 hpf, 48 hpf and 72 hpf. 
mRNA levels were analyzed by qRT-PCR and normalized to the expression of beta-actin. Fold changes 
were depicted relative to the first time point (5 somites) which was set to 1. Lines and error bars mark 
mean±SD among biological triplicates. B) Representative brightfield images of wholemount embryos 
stained with junba (top panel) and junbb (bottom panel) specific antisense in situ probes at 20 hpf, 24 hpf 
and 30 hpf. 
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4.2.2 CRISPR-Cas-mediated generation of junb mutants 
In order to address the role of junba and junbb genes in lymphatic development 
individually, single zebrafish mutants were generated using the CRISPR-Cas9 technology. 
Since both junba and junbb consist only of one exon, CRISPR guideRNAs were in silico 
designed to target the first 200 bp of the exons using two softwares programs: CHOP-
CHOP (Labun et al., 2016) and CRISPR-design from the Zhang Lab. Only gRNAs that 
fulfilled the following criteria were considered: i) PAM location at the start of the exon 
ii) high mutagenesis potential and iii) low off-target prediction in coding areas. Selected 
gRNAs were cloned into pT7 plasmid and “in vitro” transcribed. 
To guarantee the mutagenesis success, two parallel strategies were followed. In the first 
one, I aimed for a non-homologous end joining repair that will randomly generate 
insertions or deletions at the targeted area. Moreover, an additional approach aiming a 
homology directed repair was included so a pre-designed donor DNA could be 
specifically inserted in the region of interest. Similarly to the described method of Auer 
et al., (2014), a DNA cassette harboring three stop codons in all possible reading frames 
was generated so it could be incorporated after Cas9 nuclease activity (Figure 4-14). 
 
Figure 4-14: Model of the two different approaches followed to generate junb mutant fish.  
A) Schematic representation of the two types of mutations generated by CRISPR-Cas9 technology in this 
study. Non-homologous end joining generated random insertion/deletions (indels) at the targeted area 
and homology directed repair incorporated the donor  STOP cassette at a designated area. 
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Concurrent injection of gRNA, Cas9 protein and STOP cassette oligo were performed 
into one-cell stage wildtype embryos. In order to check the efficacy of the mutagenesis, 
DNA from 24 hpf injected embryos was isolated and a PCR reaction was performed using 
specific primers flanking the targeted region. PCRs were then resolved on a 3% 
metaphor high resolution agarose gel to detect variations in the amplicon size. gRNAs 
were only used if indels were noticed as smear on the gels. Providing that the 
mutagenesis was successful, the injected embryos were grown until adulthood. 
In order to address whether the generated mutations were transmitted via the germline, 
the adults from the previously injected embryos were crossed to wildtype fish in single 
pairs and their progeny (24 hpf embryos) was studied as described above. A germline 
transmission of the mutation was assumed when a clear band different from the 
wildtype amplicon size was observed on the high resolution gel. To characterize the 
mutation in detail, PCR amplicons were cloned into pGEMT vectors and sequenced. Only 
fish carrying mutations resulting in premature STOP codons or frameshifts were further 
propagated.  
Table 4-1. Collection of all the mutants sequenced during the study. Grey shaded cells mark the mutants 
selected for further studies. 
 
For junba, a 5bp insertion mutant resulting in a frameshift and premature STOP codon 
was selected (Figure 4-15A). For junbb, a 14bp deletion mutant with a frameshift in the 
reading frame was identified. Additionally, junbb mutants harboring the STOP cassette 
insertion were considered for further studies (Figure 4-15B). 
Founders (F0) that successfully transmitted the mutations to their progeny were further 
crossed with zebrafish vascular and lymphatic reporter lines and their offspring was 
raised until adulthood (F1). Fin biopsies of the F1 adult fish were genotyped and only 
heterozygous animals were kept. Further outcrosses of heterozygous fish with wildtype 
fish were performed to get rid of possible off target mutations (Figure 4-15C). 
In summary, junba/junbb zebrafish mutants were successfully generated. 
 
74 MATERIALS 
 
Figure 4-15: Generation of junb mutant zebrafish applying the CRISPR-Cas9 technology. 
A) Comparison of the DNA and protein sequence of the generated 5bp insertion junba mutant and B) 
STOP cassette insertion and 14 bp deletion junbb mutants. Bold letters mark the CRISPR target area, green 
letters mark the PAM sequence, red letters indicate the mutated base pairs and residues and yellow shade 
mark the inserted STOP codons. C) Schematic representation of the generation and selection of a new 
mutant zebrafish line. Each cycle (from embryo to fertile adult fish) lasted 3 months. 
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4.2.3 junb mutants are fertile and reach adulthood. 
Next, I aimed to characterize the newly-generated mutants. For that purpose, 
heterozygous fish were crossed to generate a heterogeneous offspring in which all the 
possible genotypes were represented. Henceforth junba5i and junbbSTOP mutants are 
referred as junba and junbb mutants respectively. 
A first global analysis of the genotype distribution among the mutants was done in a 
blind selection of 24 hpf embryos. Single embryo DNA isolation and subsequent PCR 
analysis was performed to assess whether the distribution of the mutant alleles followed 
a Mendelian ratio (Figure 4-16 A-B). 
 
Figure 4-16: Differential Mendelian ratio between junba and junbb mutants. 
A) Genotype of single 24 hpf zebrafish embryos by amplification of the junba  (left) and junbb (right) locus. 
Mutated and wildtype amplicons are marked with black arrows. B) Mendelian ratio distribution for junba 
(n=98 embryos, N=3) and junbb (n=120, N=3) offspring. C) junba mutant allele distribution into the 
germline of junba males and females (n=48, N=3). 
junbb homozygous and heterozygous mutants were identified by genotyping and were 
found at the expected Mendelian ratio of 1 wildtype: 2 heterozygous mutants: 1 
homozygous mutant. Surprisingly, no junba homozygous mutants were identified in the 
tested 24 hpf samples (~100 embryos). Mendelian ratio of the identified junba  
heterozygous mutant embryos displayed a 2 heterozygous mutants: 1 wildtype ratio 
distinctive of the recessive lethal genes.(Figure 4-16 C)  
In order to rule out the possibility that junba Mendelian ratio was due to an impairment 
of the mutant allele distribution, single junba+/-  fish were crossed with wildtype fish and 
their offspring was analyzed. Both junba+/- females and males were found to transmit 
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junba mutated allele equally and junba +/-  offspring was identified at the expected ratios 
excluding a problem during junba mutant egg and sperm formation. (Figure 4-16D). 
Considering that junba+/- parents can transmit the allele and that junba transcript levels 
peaked at early time points (Figure 4-13A), I wondered whether junba-/- fish may form 
but die before the 24 hfp.  
In order to confirm the importance of junba in early zebrafish development, a mutant 
reporter line following the strategy of the Gal4: Upstream Activator Sequence (UAS) 
system was generated. Gal4 is a transcriptional activator that binds UAS sequence in 
trans (Kakidani and Ptashne, 1988; Webster et al., 1988). This system allows the 
expression of any reporter gene under the control of UAS sequence anywhere where 
Gal4 is active. Thus, I aimed to generate a construct with junba sequence cloned in-
frame with KalT4 sequence, a less toxic variant of Gal4 activator (Figure 4-17A). 
This junba-Kalt4 construct was co-injected with Cas9 protein and junba gRNAs into one-
cell Tg(UAS:Kaede) zebrafish embryos. After Cas9 nuclease activity, concurrent cleavage 
of the genomic locus and the junba-Kalt4 plasmid occurred and the junba-Kalt4 donor 
plasmid was integrated into the genome by the homology-independent DNA repair 
machinery (Figure 4-17B). 
This generated transgenic zebrafish line drives Kalt4 expression under the endogenous 
junba promoter so whenever junba promoter is active, KALT4 is simultaneously 
transcribed. KALT4 will then transactivate UAS-driven Kaede expression resulting in 
green fluorescence. junba-expressing tissues can then be easily identified by confocal 
fluorescence microscopy. 
The insertion success of this construct was very low (only 5% of the injected embryos 
exhibited mosaic expression of KAEDE) but this data is in line with the previous reports 
(Auer et al., 2014). Mosaic fishes that reached adulthood and were fertile were checked 
for germline transmission and identified as founders. 
Microscopic analyses of this line Tg(UAS:Kaede, junba-Kalt4) revealed a high expression 
of junba in the vegetal pole of the fertilized egg. At later stages (4 dpf), expression  of 
junba  was rather low and was restricted mainly to the eyes, the yolk and cardinal vein 
(Figure 4-17C).  
Taken together, the early expression pattern of junba suggests an important role for its 
protein during the first steps of embryo formation. 
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Figure 4-17. Generation of Tg (UAS:Kaede, junba-Kalt4) reporter line 
A) Schematic representation of the cloning performed to insert a fragment of the junba locus (containing 
the CRISPR targeted area) into a junba-E2A-Kalt4 donor vector. B) Schematic representation of the 
injection mixture and the CRISPR-mediated recombination. C) Representative brightfield and fluorescence 
images of an injected 6 dpf mosaic larva. D) Representative brightfield and fluorescence images of 5-
somites and 4 dfp Tg(UAS:kaede, junba-Kalt4) embryos exhibiting tissue-specific junba expression. 
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4.2.4 junb mutants partially phenocopy the morphants 
4.2.4.1 junb mutants display an allele-dependent loss of PACs 
In order to investigate whether junb mutants also display defects on the formation of 
early lymphatic structures similar to the previously published morphants (Kiesow et al., 
2015), the formation of PACs was assessed. For that purpose, the mutants were raised 
in the pan-endothelial Tg(fli:EGFP)y1 background in which all endothelial cells plus some 
neuronal cells in the head and in the trunk are labelled with EGFP. Next, crossing of 
heterozygous fish was performed to obtain a heterogeneous population of embryos 
with all the possible genotypes and were grown in PTU-containing medium to avoid 
pigmentation.  
A random sample of this population was selected and analyzed by confocal microscopy. 
The characterization of the lymphatic development was done blindly on a single embryo 
basis. Each embryo was shortly anaesthetized with 0.25% tricaine solution, quickly 
oriented and immobilized in 6% methylcellulose prior visualization. After its observation, 
each embryo was carefully washed, placed back in PTU-containing medium and kept in 
the incubator until 5dpf for further analyses.  
Thus, the presence of PACs throughout on the 7 somites over the yolk extension were 
quantified. Each hemisegment was analyzed independently and classified as: 
“complete” when the PACs were present or “absent” when there were no PACs or the 
PACs sprout from the vein did not reach the horizontal myoseptum. 
The analysis of PACs formation in junba and junbb mutants showed that ,similarly to the 
morphants, there was a significant allele-dependent loss of PACs.  
Solely loss of one junbb allele resulted in a significant decrease in the number of PACs 
formed at 72 hpf (4,389 ± 0,24 versus wildtype siblings 5,433 ± 0,1774). This effect was 
more evident in the junbb-/- embryos since at the same time point they only displayed 
PACs in half of the measured segments in comparison to their wildtype siblings (3,03 ± 
0,2153 versus 5,433 ± 0,1774).  
Similarly, loss of one junba allele also caused a reduction in the formation of the PACs 
with regard to their respective wildtype siblings (4,105 ± 0,1988 versus 5,88 ± 0,09748). 
 
In order to assess whether loss of both junba and junbb could lead to a total loss of PACs, 
junbb-/- junba+/- mutants were generated and analyzed. Surprisingly, although a 
significant reduction in the PACs formation was observed, a synergistic effect in the loss 
of PACs was not observed. Although junbb-/- junba+/- embryos displayed less PACs that 
junba+/- alone (4,105 ± 0,1988 versus 3,542 ± 0,2948), the observed phenotype was not 
as striking as in the junbb-/- embryos (3,03 ± 0,2153)(Figure 4-18 A-B). 
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These data suggest that both junba and junbb could affect the formation of parachordal 
cells presumably by participating in the same pathway. 
In order to rule out that the defect in the formation of the PACs could be due to a failure 
during the arterial and venous sprouting, a quantitative analysis of the identity of 
Intersegmental Vessels (ISVs) was carried out. Primary sprouts derive from the dorsal 
aorta (DA) and give rise to arteries and secondary sprouts stem from the posterior 
cardinal vein (PCV) and give rise to the veins. Normal ISVs networks comprises 50%:50% 
arterial:venous ISVs (Bussmann et al., 2010). Therefore, an imbalance on the A:V ratio 
suggests a defect in the PCV sprouting.  
Thus, the same previously analyzed embryos were carefully examined for the ISVs 
identity. Calculation of the arterial:venous ratio revealed no significant differences 
among the analyzed mutants compared to the wildtype siblings (aISVs:vISVs junbb+/+ 
47:53%; junbb+/- 47:53%; junbb-/- 44:55%; junba+/- 48:52% and junbb-/- junba+/- 49:51%), 
yet all of them displayed a slight shift towards vISVs (Figure 4-18 C). 
In order to exclude a defect in the blood circulation, the embryos were monitored for 
heart development, heart beat and workflow which were undistinguishable from or 
similar to wildtype embryos. 
These data rule out the possibility of an intrinsic PCV sprouting defect or a cardiovascular 
secondary effect.  
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Figure 4-18: junb mutants display an allele-dependent decrease in PACs formation at 72 hpf. 
A) Representative confocal images of the trunk region of Tg( fli:EGFP)y1 junb mutant zebrafish embryos in 
which the PACs from junba and junbb mutants and their respective wildtype siblings were quantified. 
Dorsal is up and posterior to the left. White asterisks mark the absence of a hemisegment. ISVs 
(Intersegmental Vessels), PACs (Parachordal Cells), DA (Dorsal Aorta) and PCV (Posterior Cardinal Vein). 
Scale bar 30 µm. B) Quantification of the present PACs at 72 hpf  (count of 7 hemisegments in n>25, N=3). 
Each dot marks an independent embryo. The lines and error bars refer to mean ± SD. Statistical analysis 
was performed using unpaired two-tailed t-Student test. ns (not significant) p>0.05, ** p<0.01 and  **** 
p<0.0001 .C) Quantification of the arterial/venous ratio in junba and junbb mutants and their respective 
siblings (count of 7 hemisegments in n>25, N=3). 
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4.2.4.2 junb mutants develop a normal thoracic duct 
The parachordal cells are the building blocks of the trunk lymphatics: once formed, they 
migrate ventrally and dorsally to form the thoracic duct (TD; anatomically located 
between the DA and the PCV) and the dorsal longitudinal lymphatic vessel (DLLV) and 
the intersegmental lymphatic vessel (ISLV) respectively (Yaniv et al., 2006; Küchler et al., 
2006; Hogan et al., 2009a). 
In order to investigate whether the failure in the formation of the PACs also provoked 
the generation of a defective thoracic duct;  5 dpf embryos were analyzed similarly as 
described before. Thereafter, each embryo’s DNA was isolated and genotyped and PACs 
and TD counts were associated with each embryo.  
The presence of the thoracic duct in the 7 somites over the yolk extension were 
quantified. Each hemisegment was independently classified as “complete” or “absent”. 
Solely loss of either 1 or 2 junbb alleles did not affect the formation of the thoracic duct 
and all the analyzed embryos displayed a complete TD (junbb -/- 6,389 ± 0,2003 and 
junbb+/- 6,526 ± 0,1404 versus junbb wildtype siblings 6,762 ± 0,09524) (Figure 4-19 A/C). 
The presence of one mutated junba allele was not sufficient to affect TD development 
as most of the analyzed embryos exhibited a complete TD (junba+/- 6,838 ± 0,06143 
versus junba wiltype sibling 6,892 ± 0,05175).  
Yet, when one junba and junbb alleles were lost (junbb-/- junba+/- mutants) a significant 
decrease in the TD was observed. Some fragments were discontinuous or were missing 
in comparison with single junba+/- or wiltype sibling (junbb-/- junba+/- 6,071 ± 0,286 versus 
junba+/- 6,838 ± 0,06143 or junba wiltype sibling 6,892 ± 0,05175), yet the majority of 
the segments displayed a complete TD (Figure 4-19 B/C). 
 
The fact that loss of either junb paralogue exhibited defects on PACs formation and the 
junbb-/- junba+/- showed a subtle impairment in TD formation, proposes a role for both  
junba and junbb in lymphangiogenesis.  
These data suggest that the loss of junba and junbb is more detrimental for lymphatic 
vascular development in the early developmental steps while in the later steps the loss 
might be compensated. 
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Figure 4-19: junb mutants are able to form a complete thoracic duct by 5 dpf. 
A) Representative confocal images of the trunk of Tg(fli:EGFP)y1 junbb and B) junba mutant fish. Lower 
panels are magnifications of the white squared regions of the upper panels.Scale bar 30 µm. The thoracic 
duct is marked by white dashed lines. Dorsal is up and anterior to the left. C) Quantification of the 
presence of TD fragments at 5 dpf (count of 7 hemisegments in n>20 embryos, N=3) Each square marks 
an independent embryo. The lines and error bars refer to mean ± SD. Statistical analysis was performed 
using unpaired two-tailed t-Student test. ns (not significant) p>0.05, ** p<0.01. 
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Defects on the formation or malfunction of the lymphatic system are normally 
associated with the presence of edema, tissue swelling caused by an accumulation of 
fluid, normally observed in the back of the head, the heart or the yolk of developing 
embryos. 
In order to determine whether the loss of some TD fragments is sufficient to trigger a 
systematic lymphatic failure, junb mutants were grown and 6 dpf larvae were 
characterized for the presence of edema. Morphological analysis of the growing larvae 
revealed no edema presence among the mutants. In addition, mutants were found to 
be undistinguishable with regard to their size and phenotype (Figure 4-20). 
The fact that the junb mutants are displaying almost a complete and functional TD may 
explain lack of edema and their ability to reach adulthood. 
 
Figure 4-20. junb mutants display no signs of edema or lymphatic malfunction at 6 dpf. 
Representative brightfield images of 6 dpf junb mutant zebrafish larvae exhibiting no features 
of lymphatic failure or edema in the head or trunk. Dorsal is up and anterior to the left 
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4.2.5 junb mutants generate ectopic sprouts from 3 dfp until 5 dpf. 
Aside from the previously described failure in the formation of the PACs at 72 hpf, junb 
mutants exhibited normal development of vascular structures such as: dorsal aorta (DA), 
posterior cardinal vein (PCV), intersegmental vessels (ISVs) and dorsal longitudinal 
anastomotic vein (DLAV). Unexpectedly, several junb mutants displayed dorsal vascular 
hyperbranching at the level of the neural tube.   
In order to characterize this novel phenotype, junb embryos were grown in PTU and 
analyzed by confocal microscopy as described before. 
The presence and the development of the ectopic sprouts on the 7 somites over the yolk 
extension was analyzed from 72 hpf until 5 dpf. 
The analysis of the number of ectopic sprouts revealed a significant difference in the 
junbb mutants at 72 hpf and a significant difference in both junba and junbb mutants  at 
5 dpf in comparison to their respective wildtype siblings. 
 
At 72 hpf, solely loss of one junbb allele provoked the generation of ectopic sprouts 
(0,4063 ± 0,098 versus wildtype siblings 0 ± 0). This effect was more evident in the   
junbb-/- embryos since at the same developmental stage they display even more sprouts 
in comparison to their wildtypes siblings (0.625 ± 0,2069 versus 0 ± 0).  
In addition, even though few sprouts were documented in some junba+/- mutants, there 
was no statistical difference between  junba+/- or junbb-/- junba+/- mutants and junba+/+ 
fishes (Figure 4-21 A-C). 
 
At 5 dpf, a significant increase in the number of ectopic sprouts was observed in junbb+/- 
and junbb-/- mutants when compared to junbb+/+ embryos (0,75 ± 0,168 and 0,5833 ± 
0,1797 versus 0 ± 0 respectively). Unexpectedly,  the loss of both junbb alleles did not 
aggravated the phenotype. 
Also, junba+/- mutants exhibited more ectopic sprouts than the wildtype siblings (1,1 ± 
0,3317 versus 0,02128 ± 0,02128). junbb-/-junba+/- embryos also developed more 
branches (0,7917 ± 0,2691 versus 0,02128 ± 0,02128) but there was not significant 
difference between the loss of one single junba or junbb allele and the loss of both junbb 
and one junba allele (Figure 4-21 A’ B’ and D). 
 
Taken together, these data uncovered a putative new role of junb in controlling proper 
blood vessel sprouting in zebrafish embryos. 
 
85 RESULTS 
 
 
 
 
 
86 MATERIALS 
Figure 4-21: junba and junbb mutants exhibit dorsal vessel branching at 72 hpf until 5 dpf. 
A) Representative confocal images of the trunk vasculature of junbb mutants at 72hpf and 5 dpf. B) 
Representative confocal images of the trunk vasculature of junba mutants at 72hpf and  5 dpf. Left panels 
are original images of the mutants in Tg(fli:EGFP)y1 background and right panels are colored in grey for 
better visualization of the sprouts. Yellow squares mark the area where the sprouts were found and 
quantified. White arrowheads mark the ectopic sprouts. Blue and red lines refer to arterial ISVs and 
venous ISVs respectively.Scale bar 30 µm. C) Quantification of the number of sprouts found along 7 
somites of 72hpf embryos and D) 5dpf embryos (n>20 embryos, N=3). Each dot marks an independent 
embryo. The lines and error bars refer to mean ± SD. Statistical analysis was performed using unpaired 
two-tailed t-Student test. ns (not significant) p>0.05, ** p<0.01. *** p<0.001, ****p<0.0001 
During the recording of the presence of ectopic sprouts, it was observed that their 
length and presence was dynamic. In order to track the development of the sprouts and 
analyze their origin and fate, single embryos were subjected to in vivo time lapse imaging 
with confocal microscopy. 
For all the analyzed mutants, two behaviors were detected: while some sprouts 
developed continuously throughout the recording period (~24 hours); some other 
sprouts stopped growing and retracted until they were no longer visible at 5 dpf (Figure 
4-22).  
 
Figure 4-22: Retraction and sprout growth was tracked in the junb mutants. 
A) Representative selected segments of confocal projections of the time lapse imaging of a spout 
retracting with time. B) Representative selected segments of confocal projections of the video imaging of 
a sprout growing with time. Original color  was modified to grey for better visualization. Red arrowheads 
mark the tip of the sprout in each time. Lower panels are schematic representations of the processes 
observed above. 
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It was observed that more of half of the documented cases, the sprouts were more 
prone to grow rather than regress once they were formed (67,86 % in  junbb+/-, 50% in 
junbb-/-, 78,26 % junba+/- and 79,17 % in junbb-/- junba+/-. The duration of this ectopic 
sprouting varied from embryo to embryo. 
Although most of the sprouts were found to grow, the majority of them never connected 
with the next ISVs as observed in the 88 %, 78.9 %, 86.2 % and 95.4 % of the junbb+/-, 
junbb-/-, junba+/- and junbb-/-junba+/- sprouts, respectively (Table 4-2).  
Similar phenotypes has been described in the literature: while arterial sprouts have 
linked liked to the loss of dll4 (Leslie et al., 2007)and flt1 (Krueger et al., 2011);sprouts 
stemming from venous ISVs have been related to a neuronal-specific loss of sFlt1 (Wild 
et al., 2017). 
To address whether the junb mutants were generating ectopic sprouts from arterial or 
venous ISVs, a careful examination of the origin and fate of the sprouts was performed. 
It was observed that around 90% of the sprouts were originated from venous ISVs and 
were migrating toward arterial ISVs (70%). Additional data can be found in Table 4-2.  
Table 4-2. Origin and development of the ectopic sprouts at 5 dpf. 
Embryo 
genotype 
Number 
of 
sprouts 
Origin of the sprouts End of the sprouts Connection with the ISV 
Arterial ISV Venous ISV Arterial 
ISVs 
Venous 
ISV 
Connected Not 
connected 
junbb +/- 25         12 % 88 % 72 % 28 % 12 % 88 % 
junbb -/- 20 5,26 % 94,74 % 89,47 % 10,53 % 21,05 % 78,95 % 
junba +/- 29 3,45 % 96,56 % 72,41 % 27,59 % 13,79 % 86,21 % 
junbb -/- 
junba +/- 
22 15 % 85 % 66,67 % 33,33 % 4,55 % 95,45 % 
 
These data was consistent through all the analyzed mutants and are reminiscent of the 
phenotype observed in zebrafishes with neuronal loss of sFlt1 or Vegfa overexpression 
(Wild et al., 2017) 
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4.3 Outlook  
4.3.1 flt1 is a JUNB-direct target 
Since both junba and junbb mutants displayed features previously associated with flt1 
loss and Junba and Junbb protein homology is up to 70%; I wondered, whether both 
proteins  are able to could be transactivate Flt1 expression. 
Since the main domains required for transcriptional transactivation are conserved in 
Junba and Junbb, I evaluated their ability to physically bind to CRE and TRE sequences, 
well-known JUNB/AP-1 binding sites in the flt1 promoter as it has been previously 
observed in our lab for murine and human JUNB (Sator-Schmitt and Schorpp-Kistner, 
unpublished). Since the zebrafish promoter shared no conserved sequence areas with 
the mammalian promoters, a large fragment of the promoter region until the first intron 
(-10000 bp - +3000 bp) of flt1 was investigated for the presence of AP-1 and CRE putative 
sites. Although many CREs sites were identified throughout the promoter, not many 
TREs sites were found to in the proximal promoter region. Yet, a proximal region of the 
flt1 promoter of 800 bp was narrowed down as a promising segment since it harbored 
a cluster of three putative CREs: a consensus CRE site(-196/-188); a putative CRE site           
(-105/-97) and half CRE site (-72/-67) and one consensus TRE (-42/-35) binding site                    
(Figure 4-23 A). 
In order to validate whether Junba and Junbb can transactivate the zebrafish flt1 
promoter, this 800 bp sequence was cloned in front of a luciferase reporter gene (into a 
pGL3 vector) for further analysis. Since the DNA binding domain is conserved among 
zebrafish and mammalian JUNB, an in vitro system of Junb+/+ mouse embryonic 
fibroblasts was used. These cells were transfected with flt1 promoter vector for 48 hours 
prior luciferase measurement. Co-transfection of renilla vector was used for the 
normalization of data. 
A statistically significant increase (3x fold) of the luciferase light units compared with the 
empty pGL3 vector was observed, indicating that flt1 promoter can be activated in 
Junb+/+ cells (Figure 4-23 B). 
Next, I wondered which one of the binding sites was necessary for flt1 transcription. In 
order to address this question, site-directed mutagenesis targeting each of the binding 
sites was performed. At least 3 to 6 nucleotides were modified to assure that the binding 
activity was lost. Then, vectors containing single mutated versions of the promoter were 
produced and subjected to the luciferase studies as described above. Comparison of the 
luciferase/renilla ratio revealed that only the single mutation of the TRE site at position 
(-42/-35) led to impaired luciferase expression (Figure 4-23C).  
Since the signal is reduced by half (2x fold decrease) but still somehow detected, AP-1 is 
important but not indispensable for flt1 activation.  
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Figure 4-23:  flt1 transactivation is TRE-dependent 
A) Illustration of the 800 bp promoter area used in the luciferase assays with the respective putative CRE1, 
CRE2, CRE3 and TRE sites. B) Luciferase/Renilla ratio graph of the 800bp dre-flt1 promoter vector 
transactivation study in Junb +/+ cells. C) Illustration of the site-directed mutagenesis strategy for each of 
the binding sites. Bold underlined font marks the binding site, red font marks the mutated nucleotides. D) 
Graph depicting the Luciferase/Renilla ratio of the mutated versions of the zebrafish flt1 promoter in Junb 
+/+ cells. Data was normalized to empty pGL3 vector signal which was set to 1. The bars and error lines 
refer to mean ± SD (N=3). Statistical analysis was performed using unpaired two-tailed t-Student test. ns 
(not significant) p>0.05, ** p<0.01 and ****p<0.0001. 
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4.3.2 Generation of a gain of function mutant 
In order to demonstrate that the zebrafish ectopic sprouting in the mutants is due to 
Junb loss, a tissue-specific overexpression construct was generated using the Gateway 
Multisite Cloning strategy.  
For that purpose, a vector with junba and junbb coding sequence, a 3’ UAS promoter 
vector and a 5’ E2A linker and RFP sequence vector were recombined into a destination 
vector containing  flanking Tol2 sites, the UAS:junb-E2A-RFP vector. This Tol2 sites will 
allow the integration of the vector into the genome by the transposase action.  
In order to determine whether this reporter construct could indeed drive the 
overexpression of junb, UAS:junb-E2A-RFP vector  was co-transfected with a p16:Gal4 
vector into F9 cells, a murine testicular teratoma line devoid of most of the AP1 
members. 
 
Figure 4-24: Overexpressing vectors drive zebrafish junb expression in F9 cells. 
A) Representative fluorescence microscopy images of F9 cells untransfected or transfected with 
overexpressing uas:junb-E2A-RPF vector + p16:Gal4.Scale bar 50 µm B) Representative western blot of 
RFP signal in transfected cells. Cyclophilin A was used as control for equal quality and loading of protein 
extracts. C) Relative expression of  junba in untransfected and transfected cells was analyzed by RT-PCR. 
mRNA levels were normalized to Rplp0 levels and depicted as fold change. The lines and error bars refer 
to mean ± SD of three independent experiments (N=3). Statistical analysis was performed using unpaired 
two-tailed t-Student test ****p<0.0001. 
Due to the lack of antibodies that specifically recognize the zebrafish proteins, RFP 
expression was initially examined. Fluorescence microscopy and western blot analyses 
revealed a substantial RFP signal in the transfected cells compared to the untransfected 
cells indicating that the UAS:junb-E2A-RFP construct was successfully expressed. In 
addition, total RNA from transfected and untransfected cells was isolated and junb 
expression levels were assessed. Zebrafish junb transcript was found to be massively 
expressed (15000x fold increase) compared with the untransfected cells.  
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These data are proof of principle that the newly-generated construct is expressed in 
vitro system and could be used for in vivo studies (Figure 4-24).  
Next, I aimed to generate a new zebrafish line. Thus, the overexpression vector and 
transposase mRNA were injected into once-cell embryos of the endothelial Tg(fli:UAS) 
or neuronal Tg(HuC/D:UAS) background. Since transient overexpression was not enough 
to assure a successful insertion in the targeted cells, embryos were raised until 
adulthood. In the future, these new lines will be crossed with the previously described 
junba and junbb mutants and the presence and development of ectopic sprouts will be 
assessed. In these settings, either junb mutants with rescued endothelial or neuronal 
expression are hypothesized to correct the vessel hyperbranching revealing the source 
of Junb-driven Flt1 (Figure 4-25).  
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Figure 4-25: Generation of a tissue-specific overexpression junb line 
A) Schematic illustration of the generated overexpression vector and its integration on the 
zebrafish genome upon transposase activity. B) Schematic illustration of the zebrafish crossings 
that need to be performed to obtain embryos with solely expression of junb in the endothelial 
or neuronal tissues. Red marks the tissues where the overexpression construct is active. 
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5 DISCUSSION AND FUTURE PERSPECTIVES 
5.1 JUNB is induced during in vitro differentiation of mESCs into LECs 
5.2 JUNB-dependent control of VEGFRs during LEC differentiation and its effect on  
survival and  differentiation potential 
5.3 Junb loss does not affect LEC specification  
5.4 junb mutants partially phenocopy the morphants 
5.4.1 Loss of junb provokes a defect on the formation of the lymphatic system 
5.4.2 Unlike morphants, junb mutants do not display any cardiovascular defects  
5.4.3 Development of ectopic sprouts in junba and junbb mutant zebrafishes 
5.4.4 Differences between the murine Junb-/- and the zebrafish mutant embryos. 
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5.1 JUNB is induced during in vitro differentiation of mESCs into LECs. 
Many studies have demonstrated that JUNB functions as a context-dependent 
transcription factor of its target genes (Passegué and Wagner, 2000; Andrecht et al., 
2002; Bakiri et al., 2000). In general, the transactivating function of JUNB has been 
mostly related with vascular development and tissue homeostasis control (Schorpp-
Kistner et al., 1999; Licht et al., 2006; Schmidt et al., 2007; Licht et al., 2010) and the 
repressor functions have been associated to the inflammatory response (Florin et al., 
2006; Pflegerl et al., 2009). 
In addition, as many other AP-1 members, JUNB has been linked to cell differentiation 
regulating myogenic (Chalaux et al., 1998), erythroid (Jacobs-Helber et al., 2002), 
osteoclast (Kenner et al., 2004), myeloid (Passegué et al., 2001) as well as Th2 and Th17 
cell differentiation (Li et al., 1999; Yamazaki et al., 2017). Importantly, Obier et al., (2016) 
described the induction of several AP-1 members during in vitro differentiation of stem 
cells towards hemogenic endothelium. 
The goal of the present study was to identify whether JUNB was necessary for the 
lymphatic differentiation process and identify the processes affected by its regulatory 
functions. Herein, I present a novel role of JUNB in mammalian lymphatic endothelial 
cell differentiation. 
Remarkably, an increase of JUNB at the RNA and protein level was observed throughout 
the in vitro LEC differentiation process. Whereas the prolonged increase of Junb mRNA 
was quite moderate; an enormous increase of JUNB was detected at the fourth day of 
the spontaneous differentiation (angioblast formation) and was maintained until the 
end of the LEC differentiation process. These results highlight the activation of the gene 
regulator JUNB during the reprogramming of cells towards the vascular and specifically 
lymphatic endothelial fate. 
Considering that the differentiation of stem cells into LECs induces a whole new 
transcriptional program in the cells, it makes sense that if JUNB regulator function is 
needed, Junb is induced.  
Interestingly, the transcript levels did not drop even after several days of continuous 
stimulation. However, at the protein level, both the phosphorylated and non-
phosphorylated variants were detected from the fourth day of the spontaneous 
differentiation until the endpoint of the process. At this latter stage, only the 
phosphorylated form was observed suggesting that JUNB regulatory function might be 
more relevant in differentiating cells than in fully differentiated and mature LECs.  
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Many other factors need to be considered to explain JUNB induction pattern in LEC 
differentiation such as its transactivation, mRNA half live, translation efficiency and 
protein degradation dynamics. The amount of mRNAs in the cells does not correlate with 
the translation rate since many of the mRNAs can remain as untranslated or free 
messenger ribonucleotides rather than bound to active polysomes (Hershey et al., 
2012). Thus, it could be that Junb is not only transcriptionally but also post-
transcriptionally regulated during LEC differentiation. Schmid et al., (2013) described 
post-transcriptional and translational control of JUNB in activated human endothelial 
cells upon thrombin stimulation and uncovered two regulatory mechanisms: i) an 
increase in the polysome-associated Junb mRNA fraction and  ii) an association of the 5’ 
cap of the Junb mRNA with the eukaryotic initiation factor 4e (eIF4E). The post-
transcriptional regulation of JUNB is thought to be stimulus-dependent but the amount 
of protein detected suggests that JUNB turnover is highly dynamic at the latter step of 
the differentiation. A post-transcriptional control of the transcripts similar to the one 
described (Schmid et al., 2013) would indeed facilitate the generation of proteins in a 
more rapid and precise way during the cell reprogramming. 
In addition, post-translational modifications like phosphorylation (Li et al., 1999) and 
SUMOylation (Garaude et al., 2008) have been reported  to regulate the transcriptional 
activity of JUNB. The high amount of the phosphorylated form during the last parts of 
the differentiation protocol could be part of the JUNB turnover via accelerated 
phosphorylation-dependent proteasomal degradation. This turnover has been 
described in other settings were JUNB breakdown is carefully controlled such as in the 
cell cycle (Farràs et al., 2008)  
Importantly, since JUNB has been described as a TGFβ1 direct target in the JUNB-SMAD 
signaling (Gervasi et al., 2012), one could not exclude the possibility that the reduced 
levels of JUNB in the last differentiation step could simply be an effect of the SB431256 
inhibition present in the LEC differentiation medium.  
In order to investigate the role of JUNB in LEC differentiation, I adapted the most suitable 
in vitro system up to date and included some modifications to optimize the outcome. 
Yet, the system faced some technical limitations.  
Firstly, the conclusions of this study are based on the transdifferentiation of LECs from 
pre-existing angioblasts so they can only be extrapolated to those cases where a venous 
structure is previously present. This system aimed to mimic the in vivo formation of the 
first lymphatic structures from the cardinal vein as seen in mammals (Srinivasan et al., 
2007a; Yang et al., 2012) and zebrafish (Nicenboim et al., 2015; Koltowska et al., 2015).  
Recently, cell tracing experiments have demonstrated that, in mice, some organ-specific 
lymphatics originate from non-venous structures: the mesenteric lymphatic vessels 
derive from cKit hemogenic-endothelium cells (Stanczuk et al., 2015); the dermal 
lymphatics arise  de novo during a lymphvasculogenesis process in which LECs cluster 
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together to assemble the lymphatic networks (Martinez-Corral et al., 2015) and a 
population of heart lymphatics derive from non-venous structures (Klotz et al., 2015). 
Due to technical reasons, these alternative origins were not considered during the study 
although it would be interesting to revisit them in the future. 
Secondly, the conclusions were gained from an  in vitro system and they will need further 
validation in a in vivo mammalian system. The study of organ-specific 
lymphangiogenesis is also not possible in the  Junb-/- embryos−which prematurely die at 
E9.5−  because the first lymphatics form at E9.5, mesenteric lymphatics from E12-E14 
and skin lymphatics develop over the E12-E18 (Oliver and Srinivasan, 2010). Therefore, 
future experiments should include the generation of a conditional Junb knock out mouse 
in which ablation of Junb is specific for lymphatic endothelial cells. This tissue-specific 
deletion of Junb approach could be achieved by using transgenic mice in which the Cre-
recombinase is under the control of specific promoters such us Sox18, Prox1 or Vegfr3.  
At the time of this study, the characterization of Prox1-Cre Junb>/> mice was terminated 
and revealed no morphological or functional abnormalities in adult lymphatic 
vasculature in comparison with wildtype mice. The inducible system Prox1-CreERT2 
(Srinivasan et al., 2007b) where the Cre-recombinase is active in the lymphatic cells upon 
tamoxifen treatment was also tested. Both approaches mating either Prox1-Cre or 
Prox1-CreERT2 to Junb >/> mice failed because but Junb was not sufficiently deleted  in 
either adult or embryonic LECs (Sila Appak-Baskoy and Schorpp-Kistner, unpublished). 
Alternatively, a combination of in utero injections of a lentiviral construct coding for 
short hairpin Junb RNA in tissue-specific Cre transgenic mice, may be used in the future  
to achieve a cell specific downregulation of Junb similarly to the experiments performed 
in Yoshitomi et al., (2017). 
Additionally, now that the JUNB induction pattern has been traced down to the majority 
of mesodermal cells during the angioblast formation; it would be interesting to 
investigate lymphangiogenesis in embryoid bodies or 3D-cultures (Fang and Eglen, 2017) 
so a deeper look into the vessel assembly, orientation and functionality could be 
performed.  
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5.2. JUNB-dependent control of VEGFRs during LEC differentiation and its 
effect in survival and differentiation potential. 
Parallel studies in Junb+/+ and Junb-/- mESCs revealed a JUNB-dependent expression of 
VEGFRs through the LEC differentiation process. After four days of spontaneous 
differentiation, the mesoderm-derived cells upregulated VEGFR2 to form the vascular 
precursors as previously described (Hirashima et al., 2003). At this specific step during 
the angioblast formation, Junb-/- cells displayed a small and huge defect on VEGFR1 and 
VEGFR2 induction respectively.  
The loss of these vascular receptors did not affect the cell doubling rates but was linked 
to an increased apoptotic rate in Junb-/- mESCs. 
It is known that depending on the cell cycle phase, JUNB can either promote or block 
the cell cycle by regulating the expression of p16INK4a (Passegué and Wagner, 2000), 
CyclinD1 (Bakiri et al., 2000) and CyclinA (Andrecht et al., 2002). Yet, no difference in the 
cell doubling rate was detected in the early steps of differentiation (from the expansion 
of mESCs until the formation of angioblasts in the spontaneous differentiation) between 
the analyzed Junb+/+ and Junb-/- mESCs. This result was in line with previous reports in 
Junb-/- MEFs (Andrecht et al., 2002) and in Junb-/- EC cells (Passegué and Wagner, 2000). 
A possible explanation is that unlike other cell types, embryonic cells lack D-type cyclins 
expression, making them unsusceptible to JUNB-dependent p16INK4a variations during 
the cell cycle (Savatier et al., 1996)  
The accumulation of p16INK4a in MEFs was also linked to the presence of premature 
senescence features in Junb expressing MEFs (Passegué and Wagner, 2000). In addition, 
other AP-1 members have also been associated with apoptosis (Angel and Karin, 1991). 
In embryonic stem cells, apoptosis is normally initiated after three days of LIF-starvation 
(Duval et al., 2006). During that period of time, some of the cells promote a 
transcriptional swift allowing them to adapt and survive.  
In the present study, I showed an increase in the apoptotic activity of Junb-/- cells during 
the spontaneous differentiation and LEC endpoint. This increment on the cell death was 
accompanied with reduced levels of VEGFR1 and VEGFR2 at the angioblast stage and 
Vegfr3 at the LEC-like stage suggesting that the cells most likely did not receive survival 
signals.  
On one side, VEGF via its receptors VEGFR1 and VEGFR2 phosphorylation triggers 
downstream PI3 kinase activity and subsequent AKT activation which leads to survival 
response (Gerber et al., 1998). On the other side, VEGFR2 and VEGFR3 phosphorylation 
and  PI3K -mediated survival signaling have also been described for angioblasts and LECs. 
In addition, phosphorylation of the human 1175-PY of VEGFR2 and the VEGFR2-PLCγ axis 
is essential for the specification of VEGFR2+ angioblasts (Sase et al., 2009). 
 
99 DISCUSSION 
Taken together, my in vitro data strongly suggest that Junb-/- mESCs died during LEC 
differentiation due to i) a defect on the formation of VEGFR2+ angioblasts and ii) an 
impaired survival signaling of the angioblasts via VEGFR1/VEGFR2 signaling. 
Furthermore, surviving Junb-/- LEC-like cells were found to express lymphatics markers 
such as Prox1, Lyve1 and Podoplanin at comparable levels as Junb+/+ LEC-like cells. 
Importantly, Vegfr3 and Vegf-C expression in Junb-/- LEC-like cells was quite diminished 
when compared with the wildtype cells suggesting that surviving Junb-/- angioblasts 
formed more immature structures.  
Considering the increased levels of apoptotic cells and the low expression levels of both 
Vegf-C and Vegfr3 in Junb-/- LEC-like cells, one might argue about the viability of these 
cells at later stages. Since VEGF-C-induced VEGFR3 activation controls LEC proliferation, 
survival and migration (Oliver and Srinivasan, 2010) and that PROX1-VEGFR3 positive 
feedback loop together with VEGF-C are essential for the maintenance of LEC identity in 
LEC progenitors and mature LECs (Srinivasan et al., 2014); survival of Junb-/- LEC-like cells 
is highly impaired if these signals are not properly compensated.   
In the present study, I showed a JUNB-dependent decrease of VEGFR2 levels during the 
angioblast formation step. However, this decrease of VEGFR2 expression in the Junb-/- 
cells was no longer detectable if the surviving Junb-/- cells were subjected to LEC-directed 
differentiation.The reduced number of Junb-/- LEC-like cells that survived during the 
differentiation process expressed comparable levels of VEGFR2 at the RNA and protein 
level suggesting that compensation of VEGFR2 levels was necessary for survival.  
Unlike VEGFR1, VEGFR2 signaling is still very relevant for LECs signaling. Since VEGFR2 is 
the main transducer of VEGF-A, the observed increased of the receptor in the last step 
of the differentiation could be explained by the ectopic addition of VEGF-A and other 
growth factors in the media. In fact, it has been described that the binding of VEGF-A to 
VEGFR2 initiates the uptake of VEGFR2 and stimulates the trafficking of newly 
synthetized VEGFR2 from the Golgi to the plasmatic membrane (Koch and Claesson-
Welsh, 2012).  
However, VEGFR3 expression is detrimental for LEC development and functionality and 
VEGFR2 upregulation alone could never maintain the VEGF-C-driven signaling. The 
upregulation of VEGFR2 levels and downstream signaling as a result of the loss of 
VEGFR3 has only been observed in blood endothelial cells (Heinolainen et al., 2017). In 
fact, LECs submitted to VEGFR3 deletion displayed unaltered VEGFR2 levels (Zhang et 
al., 2018). In addition, although VEGF-C also binds VEGFR2, VEGF-C-derived VEGFR2 
signaling in lymphangiogenesis has only been described to promote vessel enlargement 
and very limited sprouting (Wirzenius et al., 2007). Therefore, LEC-like cells expressing 
low levels of Vegfr3 would be severely impaired to function as proper lymphatic 
endothelial cell. 
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My data suggests that JUNB regulates the expression of Vegfr1, Vegfr2 and Vegfr3 at 
different steps of the differentiation potential. However, whether JUNB is directly 
controlling the transactivation of these genes or indirectly controlling specific regulators 
remains unclear. 
As it has been described that Junb physically binds to Vegf promoter (Schmidt et al., 
2007); one may speculate that Vegfr1, Vegfr2 and Vegfr3 are direct JUNB targets. 
Unpublished data from our lab (Sator-Schmitt and Schorpp-Kistner, unpublished) 
identified several JUNB binding areas within the murine Vegfr1 promoter using 
Electrophoretic Mobility Shift Assay (EMSA) and luciferase transactivation assays. In 
addition, in silico analysis of the human Vegfr2 and Vegfr3 promoters also identified 
several putative AP-1 binding sites. Hence, it would be interesting to perform similar 
promoter studies to investigate whether Vegfr2 and Vegfr3 are also JUNB direct targets 
In conclusion, these results underscore the importance of JUNB regulating key vascular 
receptors during  the in vitro differentiation of mESCs into LECs. 
 
Figure 5-1. Schematic model of the in vitro LEC differentiation 
Left panel: Model of LEC differentiation in Junb+/+ mESCs in which mesodermal VEGFR2+ vascular 
progenitors were formed prior differentiation into VEGFR2+ VEGFR3+ LEC-like cells. Right panel: Loss of 
Junb in mESCs lead to a mixed population during the spontaneous differentiation. The vast majority of the 
cells (VEGFR2-)failed to expressed VEGFR2-  and as a result of this, they initiated the apoptotic cascade 
and die. The remaining VEGFR2+ cells survived to the later LEC-like stage although lacking VEGFR3 
expression. 
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5.3 Junb loss does not affect LEC specification  
It is proven that blocking or eliminating regulators of early steps of lymphangiogenesis 
−LEC competence and LEC specification− will lead to the total absence of LECs. However, 
defects on regulators of later steps of the process such as LEC determination would not 
affect the formation of LECs itself rather than provoke other defects in LEC vasculature 
like valve malformation, aberrant patterning or reduced number of vessels. 
PROX1 is sufficient and necessary to trigger the LEC fate in vivo an in vitro (Hong et al., 
2002; Petrova et al., 2002; Wigle and Oliver, 1999; Wigle et al., 2002). This transcription 
factor was detected and monitored throughout the LEC differentiation and although a 
difference in the protein formation and stabilization was indeed observed at the very 
early stages; this variation was not perceptible at the later stage where both Junb+/+ and 
Junb-/- LEC-like cells expressed similar RNA and protein levels. 
It is conceivable that in a setting where cells are lacking Junb-/- expression, Vegf-C and 
Vegfr3 receptor expression are reduced. A failure in the expression of the ligand and 
receptor is linked to defects on the formation of the first lymphatic structures, the lymph 
sacs and further lymphovenous separation as well as reduced LEC maturation and LEC 
sprouting.  
The data presented in this study revealed an essential role of JUNB in angioblast 
formation. These results are in line with previous studies in mice (Schorpp-Kistner et al., 
1999) in which Junb-deficient embryos displayed strong defects in vasculogenesis. 
Additionally, a previous investigation revealed that VEGFR2+ embryonic cells subjected 
to complete AP-1 inhibition, reduced the transcript levels of a cluster of genes related 
to angiogenesis, vessel development and morphogenesis (Obier et al., 2016). 
Taking all the data together, this study provides robust evidence for JUNB control of 
angioblast formation via regulation of Vegfr1 and Vegfr2. Furthermore, JUNB does not 
seem to act as a lymphatic cell fate factor itself but rather modulate fate cell decision in 
later steps for the maintenance of the fate in a quiescent state. 
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5.4 junb mutants partially phenocopy the morphants 
5.4.1 Loss of junb provokes a defect on the formation of the lymphatic 
system. 
Previous studies of junba and junbb were performed using morpholinos, oligos of 
analogue DNA that bind to the complementary sequence of the target gene blocking 
translation (Kiesow et al., 2015). In the present study, I generated novel mutants for 
ablated junba and junbb using CRISPR-Cas9 technology. One mutant for each gene 
harboring mutations that caused a premature end of the frameshift were selected and 
raised in the pan-endothelial Tg(fli:EGFP)y1 background to fine trace the development of 
the vasculature. 
Kiesow et al., (2015) showed that silencing of either junba or junbb or of a combination 
of both  by injection of antisense morpholinos led to a defect in the formation of the 
parachordal cells and subsequent thoracic duct formation. Like the morphants, the 
mutants also displayed a reduced number of complete PACs by 3 dpf. In the morphants, 
both downregulation of junba or junbb provoked a defect on PACs formation displaying 
only 60% of their total PACs at 72 hpf. This feature was shared with the junba and junb 
heterozygous mutants since they also displayed similar values of formed PACs at 72hpf. 
junbb-/- mutants displayed even less formed PACs since only half of the hemisegments 
were completed by 72 hpf. Contrary to the morphants, the analysis of the junbb-/- junba 
+/-  mutants did not reveal any synergistic effect. 
In contrast to the morphants, the failure of the TD formation was not observed in the 
mutants. Whilst only 20% of the TD was formed upon simultaneous junba and junbb 
downregulation or CRISPR-gRNAs injection; single mutation of junba or junbb or 
combined loss of junba and junbb showed very little or no effect on TD formation. In 
fact, most of the analyzed mutants displayed a complete thoracic duct. Only some of the 
junbb-/-junba+/- mutants exhibited a very mild defect on the TD with some missing 
fragments throughout the trunk at 5 dpf. Once again, the concomitant loss of both junba 
and junbb did not evoke a stronger lymphatic malformation. This lack of synergistic 
phenotype in comparison with single gene manipulation has also been observed for 
other lymphatic regulators like Prox1a and Prox1b whose simultaneous downregulation 
did not generate a stronger lymphatic defect in either morphants (Giacco et al., 2010) 
or mutants (van Impel et al., 2014). 
The presented data differ from those from Kiesow et al., (2015) who described the 
maintenance of the morphant phenotype in injected embryos with CRISPR-gRNAs. 
However, the characterization of the lymphatic vasculature was performed in a batch of 
mosaic injected embryos rather than in a clean mutant line with a characterized 
mutation. The analysis of mosaic embryos, in which only a cluster of cells may be 
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mutated and not sufficient to trigger a compensatory mechanism, could explain the 
similarity to the morphant phenotype. 
In addition, in both morphants and mutants, a general sprouting defect from the PCV 
could be discarded since in both cases the arterial: venous ratio aISVs:vISVs was quite 
similar. Yet, in both cases a shift towards the venous compartment formation was 
detected (Kiesow et al., 2015). The presence of arterial ISVs is required for the proper 
lymphatic patterning (Bussmann et al., 2010). The lymphatic cells located at the 
horizontal myoseptum migrate dorsally and ventrally to form the lymphatic vessels (TD, 
ISLVs and DLLV) and they migrate exclusively along the arterial ISVs. Thus, a reduced 
number of arteries is linked to defective LEC migration and explains the failure in the 
formation of the TD , ISLV and DLLV in the trunk.  
The reason why the loss of PACs is not accompanied by the loss of TD remains unclear. 
Parallel control of wildtype siblings and analysis of the formation of other anatomical 
structures ruled out the possibility of a developmental delay in the mutants at 72 hpf. A 
possible explanation is that even though there are only few PACs at 72 hpf, they are 
sufficient to migrate ventrally and form part of the TD. Another possibility is that the 
effect of junba and junbb loss is only important at the early stages of PACs formation but 
no later.  
In any case, the results in this study are reminiscent of the discordance in the 
phenotypes between gene knockdowns and gene mutations in zebrafish (Rossi et al., 
2015). These discrepant phenotypes have been described for many genes (Kok et al., 
2015) and for most of the key lymphatic regulators in zebrafish (Semo et al., 2016) as is 
summarized in Table 5-1.  
The inactivation of a gene induces a compensation program that regulates a whole new 
set of genes at the transcriptomic and proteomic level. However, these modifications 
cannot be observed in transient down-regulation approaches.  
The presence of damaged DNA and mutant mRNA among others are considered to be 
the main triggers of the transcriptional response (El-Brolosy and Stainier, 2017). During 
gene manipulation of junba and junbb using the CRISPR-Cas9 system, a double break in 
the DNA was generated and the DNA repair machinery was activated. As a result of these 
processes, a lot of DNA damage was created. DNA damage is normally accompanied by 
a chromatin reorganization which may affect the neighboring and compensating genes. 
In addition, the mutants generate mutant RNA which is degraded by the RNA 
surveillance pathways like the nonsense mediated-decay (NMD) pathway (Lykke-
Andersen and Jensen, 2015). In contrast to translation-blocking morpholino injection, 
where the morpholino binds and stabilize the transcript, the presence of fragmentated 
or degraded RNA was linked to milder phenotypes due to its ability to trigger genetic 
compensation (Schuermann et al., 2015). 
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New developments and tools are constantly appearing for the study of vascular biology 
in zebrafish. In the future, it would be interesting to generate junba and junbb tissue-
specific mutants (Wild et al., 2017) or heat-inducible mutants (Shoji and Sato-Maeda, 
2008) in order to address the role of these transcription factors in specific cell types or 
at specific time points.  
 
Table 5-1 Comparison of morphants and mutants phenotypes of lymphatic regulators 
Gene Morphant phenotype Knock Out phenotype 
prox1 Loss of PACs and TD and edema (Yaniv et 
al., 2006) 
Reduced number of PACs and TD segments  
and edema around the eyes and gut in  
prox1ai278 mutant(van Impel et al., 2014); 
Loss of PACs and TD in maternal zygotic 
mutants MZprox1ai278 (Koltowska et al., 
2015) 
prox1b Loss of TD and cardiac edema (Giacco et al., 
2010)No phenotype (Tao et al., 2011) 
No phenotype in prox1bhu3510 mutant (Tao 
et al., 2011);  
No phenotype in prox1bSA0035 mutant (van 
Impel et al., 2014) 
sox 18 Loss of PACs and TD (Cermenati et al., 2013) No phenotype in sox18hu10320 mutant (van 
Impel et al., 2014) 
coupTFII 
(Nr2f2) 
Loss of PACs and TD (Aranguren et al., 2011) No phenotype in coup-TFIIhu10330 mutant 
(van Impel et al., 2014) 
vegfr3 Loss of TD (Hogan et al., 2009b); 
Defect on lymphatic branchial arches and 
Ventral Aorta lymphangioblast (Okuda et 
al., 2012) 
Loss of TD in expando Flt4hu4602 (Hogan et 
al., 2009b) 
Loss of PACs and TD in Flt4hu4602 (Le Guen et 
al., 2014)  
lyve 1 No phenotype (Flores et al., 2010) 
 
ccbe1 Loss of PACs (Le Guen et al., 2014) 
Loss of Facial lymphatic sprout and Ventral 
Aorta Lymphangioblast (Okuda et al., 2012) 
Loss of PACs and TD  ccbe1hu3613 mutants (Le 
Guen et al., 2014) 
vefg-c Loss of PACs (Cermenati et al., 2013) Loss of TD in vegfchu5055 (Le Guen et al., 
2014) 
junba/ 
junbb 
Loss of PACs and TD (Kiesow et al., 2015) Loss of PACs but present TD (Gutierrez-
Miranda et al, Unpublished) 
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In zebrafish, the duplication of genes caused the partition and generation of new 
functions as well as regulating their activation (Conant and Wolfe, 2008; Hahn, 2009). 
Since individual loss of junba or junbb provoked similar lymphatic defects; one may 
suggest that these two genes share some of their targets. In line with that, it is 
conceivable that the single mutant phenotype may be compensated.  
An exhaustive research on junba and junbb regulation is still needed since very little is 
known. In the present study I show that in wildtypes, these two genes showed two 
different pattern and expression kinetics during the early zebrafish development. This 
differential expression in development could be due to i) different inducers ii) different 
temporal induction pattern or iii) differential epigenetic control. It is known that 
promoter methylation blocks downstream expression in mammals and plants (Weber et 
al., 2007; Zemach et al., 2010). In zebrafish, it has been described that for many 
duplicated genes, whilst the promoter of one gene is methylated and inactive, the other 
duplicated gene promoter is hypomethylated  and active at the same time (Zhong et al., 
2016). Therefore, further studies should be performed to understand junba and junbb 
chromatin dynamics in gene regulation. 
Despite the fact that the role of junba and junbb in PACs formation was addressed,  the 
role of these genes in zebrafish angioblast formation remains uncertain. Time lapse 
imaging of the mutants at early time points was performed to observe the development 
of the first venous and lymphatics sprouts from the PVC. However, technical difficulties 
and the limited movie footage did not allow to draw a clear conclusion. One could claim 
that there should not be a big difference in the angioblast population since the 
formation of lymphatic structures is not completely impaired. However, since the in vitro 
data obtained in this study showed a dramatic decrease of the angioblast population, 
further experiments should be performed. It would be important to repeat the time-
lapse experiments in mutants raised in another zebrafish background like the transgenic 
Tg(flt1_9a_cFos:GFP), a line generated and used by Nicenboim et al.,(2015) because 
apart from the arterial expression of Flt1, it could label the angioblast population within 
the PCV. The quantification of the ventral angioblasts in the PCV and the quantification 
of the committed Prox1+ dorsal cells in the PCV (Koltowska et al., 2015) may help to 
clarify whether junba and junbb play a role in the early steps of zebrafish 
lymphangiogenesis. 
In addition, the mutants could also be crossed into a Tg(fli1:gal4ubs3;UAS:Kaederk8) line 
(Herwig et al., 2011) to perform photo-switching of the ventral PCV similarly to the 
experiments performed by Nicenboim et al., (2015). KAEDE is a green fluorescent 
protein that will shift to a red fluorescent protein upon UV exposure. Thus, applying UV 
light to the ventral side of the PCV, would turn the expression of Kaede from green to 
red fluorescence allowing a fine tracing of the angioblast differentiation through time. 
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Besides, phosphorylation of Junb proteins has been described as key events of wound 
healing and fin regeneration of larval and adult zebrafishes (Ishida et al., 2010). Whether 
junba and junbb are necessary for vascular regeneration are important questions that 
should be addressed in the future.  
 
5.4.2 Unlike morphants, mutants do not display any cardiovascular 
defects  
In addition to the lymphatic phenotype, two other vascular-related phenotypes were 
observed in the junb morphants and were absent in the mutants.  
In Meder et al., (2010), the reduction of junba an junbb levels by morpholino-mediated 
knockdown resulted in cardiac edema and abnormal blood circulation at 3 dpf. These 
features were caused by aberrations in the Z-disc structure of the myofilaments 
affecting the heart and skeletal muscle development. In (Kiesow et al., 2015), this 
cardiac defect was not present in individual junba and junbb morphants as well as 
double junba/junbb morphants which displayed normal heart development and 
continuous blood flow. Intriguingly, some junbb morphants developed hemorrhages in 
the aortic branch and the carotid artery branches at 48hpf and 72 hpf.  
The difference between these studies relies on the design of the targeted morpholinos 
and their doses. While (Meder et al., 2010) used 4 ng of junba morpholino that could 
not completely target the junbb sequence; (Kiesow et al., 2015) used two different sets 
of morpholinos per gene and their doses were finely adapted to 2 ng. With this 
approach, a detectable downregulation of the transcripts was achievable without 
jeopardizing normal embryonal development. 
The junba and junbb mutants presented on this study were devoid of any cardiovascular 
defects. Although (Meder et al., 2010) described hypo-contractile and dilated ventricles 
in the morphants, junb mutants developed normal heart cavities and their heart beat 
was similar to their wildtype siblings. In addition, all the mutants lacked any sign of 
internal bleeding in the heart and in the trunk area.  
As previously mentioned, a combination of the off-target effects or the toxicity of the 
down-regulation and the dosage compensation might explain the differences between 
these morphants and the mutant’s phenotypes. 
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5.4.3 Development of ectopic sprouts in junba and junbb mutant 
zebrafishes 
Both junba and junbb mutants exhibited normal blood circulation and the formation of 
the main blood vessels such as PCV, DA and DLAV remained unaltered. However, small 
ectopic sprouts in the dorsal part of the ISVs were detected in the trunk of embryos from 
the 3 dpf until 5 dpf. Most of these sprouts were generally sprouting from a venous ISVs 
towards aortic ISVs and appeared to be mostly disconnected to their neighboring 
vessels. 
Sprouting angiogenesis is important for the formation of the vascular network and 
requires the specification of endothelial cells into tip or stalk cells. The tip cells are 
located at the edge and generate filopodia to migrate towards a gradient of cues. The 
stalk cells on the other side, follow the tip cells. Some of the receptors involved in this 
cell differentiation are the vascular endothelial Growth Factor Receptors (VEGFR1, 
VEGFR2 and VEGFR3) and the Notch-Delta like 4 (Dll4) (Phng and Gerhardt, 2009; Roca 
and Adams, 2007). 
The development of hyperbranching in the dorsal areas has been associated with the 
loss of two tip cell markers: VEGFR1 (Krueger et al., 2011) and DLL4 (Leslie et al., 2007). 
In mammals and in zebrafish, VEGFR1 (also known as Flt1) encodes for a membrane-
bound receptor and smaller soluble form that contains the VEGF binding domain (Sela 
et al., 2008; Krueger et al., 2011). While membrane-bound VEGFR1 binds its ligands and 
controls downstream signaling via its tyrosine kinase domain; the soluble VEGFR1 binds 
VEGF-A controlling its availability in the surrounding tissues (Ambati et al., 2006; 
Gerhardt et al., 2003). In mice, Vegfr1 expression is observed in the blood islands and 
extra-embryonic tissues (Fong et al., 1995) and Vegfr1-/- embryos die prematurely (E8.5) 
due to aberrant vascular formation. In zebrafish, vegfr1 expression is mostly found in 
endothelial cells of arterial origin such as dorsal aorta and arterial intersegmental vessels 
and in some spinal cord neurons. Studies with vegfr1 morpholino knockdown revealed 
that Vegfr1 regulates arterial branching and tip cell formation in zebrafish embryos 
(Krueger et al., 2011).  
DLL4 is a key player of the Notch signaling and is linked to the proliferation and branching 
control in endothelial cells. In zebrafish, it is also expressed in the endothelial cells of 
the dorsal aorta and in the intersegmental vessels and in a small cluster of neural cells. 
Morpholino-mediated knock-down also revealed the formation of aberrant sprouts at 
the neural tube level (Leslie et al., 2007). 
In these both reports, the loss of these tip cell markers ended in the formation of aortic 
ectopic sprouts that generated connections with adjacent vessels.  
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Recently, neuronal sVEGFR1 has been proposed to be the main regulator of neural tube 
vascularization in both mice (Himmels et al., 2017) and zebrafish (Wild et al., 2017). In 
this later study, vegfr1 mutants also exhibited ectopic sprouts in the dorsal area of the 
ISVs at the neural tube level. They proposed that the neural tissue controls 
vascularization by expressing the pro-angiogenic molecule Vegfaa and scavenger, 
sVegfr1. Thus, an increase of the angiogenic molecule or a decrease of the anti-
angiogenic receptor results in a similar outcome: an increased availability of Vegfaa in 
the tissue. This Vegfaa increase is detected by the responsive endothelial cells triggering 
the hyperbranching of the vein endothelial cells (Wild et al., 2017) 
Remarkably, the junba and junbb mutants displayed venous sprouts at the neural tube 
level similarly to the phenotype described in (Wild et al., 2017). However, the number 
of sprouts present in the junb mutants was much lower in comparison with the 
description of the vegfr1 mutant. 
There is very little information about the function of JUNB in the neurovascular plexus. 
A recent report described JUNB as a regulator of neurovascular alignment in mouse 
embryos (Yoshitomi et al., 2017). In zebrafish, the immunolabeling of motorneurons in 
junba and junbb morphants revealed no differences in the development of the neural 
tube (Kiesow et al., 2015), although the differences in the expression within the neural 
tissue were not addressed. The collected data suggest that the loss of junba and junbb 
might affect to some extent the expression of sVegfr1 in the neuronal tube. Thus, it 
would be interesting to cross the generated mutants to other reporter lines indicative 
for the neural tube such as Tg(Xla.Tubb:DsRed)zf148 (Wild et al., 2017) to analyze whether 
i) the neural tube develops normally and ii) isolated cells from the junba and junbb 
mutants express lower levels of vegfr1 in comparison with wildtype neural tube cells. 
For these purposes, the mutants should be crossed to a transgenic neuronal reporter 
line and subjected to cell sorting prior to transcriptomic analysis. The generation of the 
mutants in the double transgenic background is quite time-consuming, as zebrafishes 
have the generation time of four months. Thus, due to the lack of appropriate 
experimental tools , I unfortunately was not able to measure vegfr1 levels in the neural 
tube of the presently analyzed Junb mutant embryos.  
In light of the previous in vitro data regarding JUNB-dependent VEGFR1 expression and 
the similarity of the phenotypes of junb and vegfr1 mutants, a closer look into the Vegfr1 
promoter was undertaken.  
In the human Vegfr1 promoter, the cAMP response element binding protein/ Activating 
Transcription Factor (CREB/ATF) and the ets motifs were identified to be essential for 
Vegfr1 transcription (Morishita et al., 1995; Wakiya et al., 1996). 
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In addition, the unpublished data on the murine Vegfr1 promoter revealed JUNB-
dependent transcription via direct binding to TRE and CRE sites (Sator-Schmitt and 
Schorpp-Kistner, unpublished). As the AP-1 transcription Factor JUNB has been 
described to bind TRE as well as CRE binding sites within the promoter of many target 
genes; a study on the zebrafish promoter was initiated.  
The zebrafish promoter shares very little conserved regions with the human and murine 
Vegfr1 promoter as well as with other vertebrates. Hence, the zebrafish promoter was 
investigated to identify areas enriched on the TRE and CRE binding sites. An 800 bp 
region of the promoter was selected and cloned and directed mutations were 
performed to individually destroy each of the putative binding sites. Subsequently, the 
wildtype zebrafish promoter and the respective mutated versions were transfected in a 
murine cell type and subjected to luciferase reporter assays. The transactivation studies 
revealed that the luciferase activity decreased in half when the TRE (-42/-35) site was 
mutated suggesting that this specific TRE site may be actively involved in vegfr1 
transcription. Contrary to TRE site,the manipulation of the CRE putative binding sites 
had no effect on vegfr1 transactivation. 
This last in vitro experiment had some limitations due to the murine nature of the cells. 
Although there are some commercially available zebrafish cell lines, almost none of 
them are used in the community. In a first approach, I used the teratocarcinoma cell line 
F9 because of its low levels of AP-1 members and tried to overexpress both the zebrafish 
vegfr1 promoter construct and either junba or junbb or a combination of both. However, 
neither of the zebrafish proteins could be successfully expressed in this system. At least 
two constructs with different promoters were used for the construction of the vectors 
containing the zebrafish variants with similar results. In addition, there are not 
commercially available antibodies to detect specifically the zebrafish Junba and Junbb 
proteins so I could never validate whether the zebrafish proteins were properly formed 
in the murine cells. Therefore, since I could not assess the individual effect of the 
zebrafish genes, I decided to analyze whether murine JUNB (which shares most of the 
carboxyl terminal part with the zebrafish proteins including the DNA binding domain) 
could recognize and bind any of the TRE and CRE candidate sites. Thus, I used wildtype 
MEFs to perform the transactivation studies with the wildtype promoter and the mutant 
variants. The results obtained from the luciferase reporter assay suggested that similarly 
to the human and murine promoter, the zebrafish vegfr1 transactivation is TRE-
dependent. 
Still, these results should be taken with caution since I cannot rule out the possibility 
that in the murine cells, the transactivation of the dre-vegfr1 promoter is performed by 
a combination of transcription factors that might not be necessarily present in the 
zebrafish cells. In order to prove the direct binding of Junba or Junbb to the zebrafish, 
CHIP-seq experiments should be performed in isolated neurons. 
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Nevertheless, the data collected from the characterization of the mutants and the 
luciferase reporter together with the mESC differentiation data and the unpublished 
reporter studies clearly point to Vegfr1 as a putative JUNB-direct target. 
If true, Vegfr1 would be another example of conserved JUNB targets. Cbfb, for example, 
was also proven to be directly regulated in mouse (Licht et al., 2006) and downstream 
of Junb in zebrafish (Meder et al., 2010). 
 
5.4.4 Differences between the murine Junb-/- and the zebrafish mutant 
embryos. 
Over all, the zebrafish mutants exhibited a less severe phenotype than the described 
Junb-/- mouse embryos which is lethal at E9.5 (Schorpp-Kistner et al., 1999). junbb 
mutants are viable until adulthood and although junba seems to be recessive embryonic 
lethal similar as murine Junb, the specific stage of development in which they are lost 
could not be identified during the duration of this study. In a first approach, a time-point 
among the first four hours of development was considered since only during this period 
of time embryo lethality was observed. However, due to the low number of cells at those 
stages and the rapid DNA degradation, no clear junba-/- embryos could be identified. 
Therefore, until the presence of junba-/- embryos can be detected at specific 
developmental stages, one cannot exclude that they might still be formed in a very 
reduced ratio.  
Still, there are many differences between the phenotypes in the two species: On one 
hand, the phenotype observed in the mouse was a result of impaired vasculogenesis. 
The embryos displayed defects in the vascularization of the embryo and extra-
embryonic tissues. As a result of this improper feto-maternal circulation of oxygen and 
nutrients, the murine Junb-/- embryos were grossly retarded in development and were 
much smaller compared to the wiltype mice. Except for junba, the junbb phenotype 
observed in the zebrafish was not as dramatic as there was not effect on vasculogenesis. 
In fact, the vascular defects comprised the formation of PACs and ectopic sprouts 
towards the neural tube. In addition, the junba and junbb mutants as well as junbb-/- 
junba+/- developed normally and were indistinguishable from the wildtype embryos at 
least until the larval stage.  
These differences might be explained by the i) ex utero fertilization of zebrafish embryos 
and the ii) passive transport of oxygen. The zebrafish embryo development takes place 
externally following fertilization and lacks the placentation step for which JUNB has been 
described to be absolutely essential in mammals (Schorpp-Kistner et al., 1999). Also, the 
zebrafish profits from passively diffused oxygen even in the absence of a proper 
cardiovascular system for the first days of development (Stainier et al., 1996). JUNB has 
also been described to regulate Vegf-a and Hmox-1 upon hypoxia induction in mice 
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(Schmidt et al., 2007; Textor et al., 2006; Hock et al., 2007). The fact that the oxygen 
supply is guaranteed during the first steps of development in zebrafish might also 
explain the differential relevance of JUNB regulatory functions in the development of 
their vascular systems.  
In both cases, the vascular phenotype has been linked to the loss of Vegfr1.  On one 
hand, the mouse Junb-/- embryos displayed an allele-dependent reduction in the 
expression of Vegfr1 in the yolk sac. On the other hand, the zebrafish mutants displayed 
a phenotype similar to the one described for the loss of soluble vegfr1 in the neural tube 
and a JUNB-dependent activation of the zebrafish promoter was detected. 
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Final conclusions  
 
In summary, the present thesis unraveled evidence of JUNB regulating different steps of 
lymphangiogenesis in murine cells and zebrafish. 
For the first time, JUNB induction was detected and traced during lymphatic endothelial 
cell differentiation in a mammalian cell system. The data disclosed in this study provide 
robust evidence on the JUNB induction and JUNB-dependent regulation of vascular 
endothelial growth factors receptors during the in vitro angioblast formation and 
differentiation process. JUNB-dependent VEGFR2 expression was essential for the 
activation of the survival cascade in angioblasts and LEC like cells. In addition, the data 
suggest that JUNB is not directly controlling the lymphatic fate regulators but it is 
needed at later stages of the differentiation for proper lymphatic cell maturation. 
In addition, novel zebrafish mutants were generated using CRISPR-Cas9 technology. 
Morphological characterization of the development of the lymphatic system validated 
previous results highlighting the importance of junba and junbb in the formation of the 
first lymphatic structures in zebrafish, the parachordal cells. Additionally, novel 
transgenic lines were generated to investigate crucial steps of vascular development 
that were not possible before due to the embryonic lethality of the Junb-deficient mice.  
Moreover, the characterization of the mutants revealed the presence of ectopic sprouts 
around the neural tube opening new questions about the role of Junb in 
neurovascularization. Due to the similarity of a previous report relating the presence of 
ectopic sprouts with the loss of soluble  Vegfr1, the zebrafish vegfr1 promoter was 
further investigated. 
Taken together, this study pinpoints JUNB as one of the key regulators in vascular 
biology. Further studies on the transcriptomic variations upon Junb loss together with 
chromatin immunoprecipitation studies would provide a deeper understanding of the 
downstream effectors of JUNB signaling in vascular development. 
The establishment of the LEC differentiation protocol as well as the generation of novel 
Junb zebrafish mutants generated during this study are important tools that may used 
to address the remaining questions such us the validation of vegfr1 and vegfr2 as direct 
Junb targets and the role of Junb in adult and tissue-specific lymphangiogenesis. 
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Figure 5-2. Schematic model of the lymphangiogenesis steps that are affected upon Junb loss.  
Upper panel. Schematic illustration of the lymphangiogenesis steps affected upon Junb loss during in vitro 
LEC differentiation and in zebrafish embryos. Lower panel: Detailed description of the putative JUNB 
targets and processes altered upon Junb loss. mESC in vitro differentiation studies revealed a big defect 
on the angioblast formation and survival due to a big defect in Vegfr2 expression and subtle defect in 
Vegfr1 expression. In addition, Junb-/- cells displayed reduced levels of Vegfr3 during the determination 
step. In vivo studies of the zebrafish mutants did not reveal any defect on angioblast formation but a 
defect on the formation of the parachordal cells which are the primitive lymphatic structures similar to 
the lymph sacs in mammals. 
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